naltrexone has been researched along with Alcoholism in 932 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (1.07) | 18.7374 |
| 1990's | 120 (12.88) | 18.2507 |
| 2000's | 328 (35.19) | 29.6817 |
| 2010's | 362 (38.84) | 24.3611 |
| 2020's | 112 (12.02) | 2.80 |
| Authors | Studies |
|---|---|
| Azar, MR; Berzetei-Gurske, I; Cashman, JR; Ghirmai, S; Polgar, WE | 1 |
| Azar, MR; Cashman, JR; Ghirmai, S | 1 |
| Chen, J; Garment, A; Gold, H; Goldfeld, K; Kermack, A; Laska, E; Lee, JD; Malone, M; McDonald, R; Obi, R; Rotrosen, J; Schatz, D; Tofighi, B; Vittitow, A | 1 |
| Kalin, NH | 1 |
| Springer, SA | 1 |
| Amaral, RA; Castaldelli-Maia, JM; de Antonio, J; de Berardis, D; de Oliveira, ABP; de Toledo Gonçalves, F; Firigato, I; Gattás, GJF; Gonçalves, PD; Malbergier, A; Negrão, AB; Ventriglio, A | 1 |
| Brasch, J; Chaimowitz, G; MacKillop, J; Minhas, M; Olagunju, AT; Slavin-Stewart, C; Turna, J | 1 |
| Worley, J | 1 |
| Altice, FL; Bachireddy, C; Ding, R; Duerr, AC; Galvez de Leon, SJ; Gonzales, P; Grieco, A; Lama, J; Ulrich, A | 1 |
| Carpenter, RW; Emery, NN; Meisel, SN; Miranda, R | 1 |
| Askgaard, G; Nielsen, AS; Thiele, M | 1 |
| Kranzler, HR; Mann, K; Nakovics, H; Roos, CR; Votaw, VR; Witkiewitz, K | 1 |
| Corbin, WR; DeMartini, KS; Fucito, LM; Kranzler, HR; Leeman, RF; MacKinnon, DP; O'Malley, SS; Waddell, JT | 1 |
| Burnette, EM; Gillis, AJ; Grodin, EN; Hurley, B; Meredith, LR; Miotto, K; Nieto, SJ; Ray, LA | 1 |
| Cheong, JC; Kim, JY; Kim, SY; Shin, DW; Suh, S | 1 |
| Habu, H; Hashimoto, N; Kishi, Y; Matsuo, K; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Yamada, N | 1 |
| Carter, I; DeWitt, C; Forsgren, E; McCollough, M; Philippine, T; Taira, BR | 1 |
| Bach, P; Kiefer, F; Klose, C; Koopmann, A; Krisam, J; Lenz, B; Limprecht, R; Pourbaix, M; Ries, M; Stenger, M; Thomas, BC; Vollstaedt-Klein, S; Zimmermann, S | 1 |
| Gerhardt, S; Grundinger, N; Karl, D; Kiefer, F; Mann, K; Vollstädt-Klein, S | 1 |
| Fomin, V; Goodman, RP; Luther, J; Patel, SJ; Schaefer, E; Shay, JES; Vannier, AGL | 1 |
| Addolorato, G; Antonelli, M; Sestito, L; Tarli, C | 1 |
| Gueorguieva, R; O'Malley, SS; Phan, H; Wallach, JD; Witkiewitz, K; Wu, R | 1 |
| de Laat, B; Huang, Y; Krishnan-Sarin, S; Morris, ED; Nabulsi, N; O'Malley, SS | 1 |
| Burnham, EL; Chockalingam, L; Jolley, SE | 1 |
| Abraham, AJ; Harris, SJ; Yarbrough, CR | 1 |
| Ayyala, D; Bottyan, T; Dodge, JL; Gonzalez, JL; Han, H; Pimienta, M; Stager, K; Stolz, A; Terrault, NA; Tien, C; Yoo, J | 1 |
| Ali, A; Arenander, J; Batki, S; Coffin, P; Ikeda, J; Jain, J; Matheson, T; McLaughlin, M; Santos, GM; Vittinghoff, E; Walker, J | 1 |
| Balasanova, AA; Daniel, K; Tigh, J | 1 |
| Mason, BJ | 5 |
| Coralic, Z; Montoy, JCC; Murphy, CE; Ramirez, B; Raven, MC; Wang, RC | 1 |
| Bain, PA; Busch, AB; Huskamp, HA; Hyland, CJ; McDowell, MJ | 1 |
| Cornell, A; Loh, R; Taub, J; Terasaki, D; Thurstone, C | 1 |
| Gomes, T; Konstantelos, N; Lecce, P; McCormack, D; Tadrous, M; Tourchian, N | 1 |
| Ciraldo, K; DeFries, T; Gasper, J; Martin, M; Seraydarian, M | 1 |
| Enders, CK; Nieto, SJ; O'Malley, SS; Ray, LA; Witkiewitz, K | 1 |
| Lambeth, PS; Margolis, EB; Moulton, MG; O'Meara, MJ | 1 |
| Chuan-Ya, L; Ruei-Yuan, H | 1 |
| Agabio, R; Minozzi, S; Rösner, S; Saulle, R | 1 |
| Cosgrove, KP; de Laat, B; Hoye, J; Key, J; Krishnan-Sarin, S; Morris, ED; Papademetris, X | 1 |
| Andale, T; Aruasa, WK; Gakinya, B; Jaguga, F; Kerema, J; Kinyanjui, D; Kirwa, P; Kwobah, C; Kwobah, EK; Manji, I; Mwangi, F; Songok, J; Temet, E; Werunga, K | 1 |
| Falker, C; Garcia-Tsao, G; Kaplan, DE; Mahmud, N; Rabiee, A; Taddei, T | 1 |
| Al Hamdan, F; Böttcher, M; Grählert, X; Klut, IM; O'Connor, S; Plawecki, MH; Sauer, C; Smolka, MN; Sommer, WH; Spreer, M; Zimmermann, US | 1 |
| Ipsarides, J | 1 |
| Alto, M; Giusto, A; Greene, MC; Johnson, RM; Kane, J; Lovero, K; McClendon, J; Nicholson, T; Stockton, M; Tol, WA; Wainberg, ML | 1 |
| Bagley, SM; Chadi, N; Earlywine, JJ; Hadland, SE; Leslie, DL; Rodean, J; Zima, BT | 1 |
| Conigrave, JH; Conigrave, KM; Lee, KSK; Purcell-Khodr, G; Vnuk, J | 1 |
| Brogden, NK; Tobin, KV | 1 |
| Kranzler, HR | 4 |
| Byrd, ND; Gowin, JL; Kirk-Provencher, KT; Penner, AE; Ramchandani, VA; Rosenblatt, SL; Sloan, ME; Stangl, BL; Swan, JE | 1 |
| Drexler, K; Hsu, M; Malhotra, A; Tang, YL | 1 |
| Bobashev, G; Coffey, CP; Edlund, MD; Jonas, DE; Kennedy, SM; Kuznacic, K; McPheeters, M; O'Connor, EA; Riley, S; Voisin, C | 1 |
| de Laat, B; Gao, H; Goldberg, A; Huang, Y; Kapinos, M; Krishnan-Sarin, S; Morris, ED; Nabulsi, N; Najafzadeh, S; O'Malley, SS; Ropchan, J; Shi, J; Tetrault, JM; Zheng, MQ | 1 |
| Kranzler, HR; Mann, K; Roos, CR; Witkiewitz, K | 1 |
| Kreek, MJ; Zhou, Y | 2 |
| Duprez, R; Hammas, K; Ioannidis, JPA; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Hartwell, KJ; Korte, JE; McRae-Clark, AL; Walker, JR | 1 |
| Falk, DE; Fertig, J; Leggio, L; Litten, RZ; Ryan, ML | 2 |
| Braillon, A; Naudet, F; Palpacuer, C | 1 |
| Hobelmann, JG; Huhn, AS; Oyler, GA; Ramirez, A; Strain, EC | 1 |
| Brach, BS; Luderer, M; Meulien, D; Mueller, S; Schou, MB; Zhang, D | 1 |
| Bumb, JM; Dinter, C; Hermann, D; Karl, D; Kiefer, F; Koopmann, A; Mann, K; Otto, A; Vollstädt-Klein, S | 1 |
| Chandler, C; Cook, JE; Patterson, S; Platt, DM; Rüedi-Bettschen, D; Taylor, I | 1 |
| Akgün, K; Bryant, K; Crystal, S; Edelman, EJ; Fiellin, DA; Fiellin, LE; Gaither, JR; Gordon, AJ; Goulet, JL; Justice, AC; Korthuis, PT; Kraemer, KL; Marshall, BDL; McGinnis, KA; Oldfield, BJ; Williams, EC | 1 |
| Caballeria, E; Gual, A; López-Pelayo, H; Mann, K; Van den Brink, W; Zuluaga, P | 1 |
| Hayashi, T; Higuchi, S; Miyata, H | 1 |
| Hulme, J; Sheikh, H; Wiercigroch, D | 1 |
| Anton, RF; Arias, AJ; Feinn, R; Gelernter, J; Gueorguieva, R; Hartwell, EE; Hoffman, M; Kranzler, HR; Krystal, J; Morris, PE; Oslin, D; Petrakis, I; Schacht, JP | 1 |
| Dermody, SS; Hendershot, CS; Kennedy, JL; Stoner, SA; Wardell, JD; Zaso, MJ | 1 |
| Farrer, LA; Henderson, DC; Kranzler, HR; Lin, Y; Xu, H; Zhang, H | 1 |
| Anton, RF; Falk, DE; Hasin, DS; Heather, N; Kranzler, HR; Litten, RZ; Mann, KF; O'Malley, SS; Witkiewitz, K | 1 |
| Kuerbis, AN; Levak, S; Morgenstern, J | 1 |
| Tadori, Y | 1 |
| Altice, FL; Ding, R; Duerr, A; Gonzales, P; Grieco, A; Ignacio, RB; Lama, JR; Pinto-Santini, D; White, E | 1 |
| Brunette, MF; Citrome, L; Correll, CU; DiPetrillo, L; Green, AI; Jiang, Y; McDonnell, D; O'Malley, SS; Silverman, BL; Simmons, A | 1 |
| Farhadian, M; Farhadian, N; Farnia, V; Moradi, S; Rezaeian, S; Shahlaei, M; Zamanian, MH | 1 |
| Adhikari, S; Chapagai, M; Dhungana, S; Ojha, SP; Pant, SB; Tulachan, P | 1 |
| Agrawal, A; McCutcheon, VV | 1 |
| Graziani, R; Venturini, S | 1 |
| Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Nakamura, I; Takahashi, M; Tsuneyoshi, K | 1 |
| Ohgi, Y | 1 |
| Fairbanks, J; Karpyak, VM; Kolla, BP; Loukianova, LL; Schneekloth, TD; Sinha, S; Umbreit, A | 1 |
| Camarini, R; Dartora, VFMC; Lopes, LB; Matos, JKR; Rae, M; Santos, RA | 1 |
| Bromley, E; Hurley, B; McCreary, M; Ober, AJ; Tarn, DM; Watkins, KE | 1 |
| de Laat, B; Froehlich, JC; Huang, Y; Krishnan-Sarin, S; Morris, ED; Nabulsi, N; O'Malley, SS | 1 |
| Kenny, PJ; O'Brien, CP; Pierce, RC; Swinford-Jackson, SE; Unterwald, EM; Vanderschuren, LJMJ | 1 |
| Rösner, S; Soyka, M | 3 |
| Anton, RF; Book, SW; Glen, WB; Hoffman, M; Latham, PK; Randall, PK; Schacht, JP; Voronin, KE | 1 |
| Hong, TK; Huh, SY; Kim, SG | 1 |
| Muvvala, SB; O'Malley, SS; Rosenheck, R | 1 |
| Lohoff, FW | 1 |
| Kale, PP; Marathe, PA; Pooja, SG; Raut, AA; Raut, SB; Rege, NN; Satam, SD; Shetty, YC | 1 |
| Haass-Koffler, CL; Kenna, GA; Lee, MR; Leggio, L; Li, X; Long, VM; Piacentino, D; Swift, RM | 1 |
| Grodin, EN; Ho, D; Ray, LA; Towns, B | 1 |
| Avanceña, ALV; Hutton, DW; Mellinger, JL; Miller, N; Uttal, SE | 1 |
| Heikkinen, M; Lähteenvuo, M; Mittendorfer-Rutz, E; Taipale, H; Tanskanen, A; Tiihonen, J | 1 |
| Tamaki, K | 1 |
| Balasanova, AA; Patel, AK | 1 |
| Berquist, MD; Fantegrossi, WE | 1 |
| Bold, KW; Corbin, WR; DeMartini, KS; Fucito, LM; Kranzler, HR; Leeman, RF; Mann, K; O'Malley, SS; Roos, CR; Witkiewitz, K | 1 |
| Bhat, NR; Bierut, LJ; Borodovsky, JT; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 1 |
| Bendiks, S; Blokhina, E; Bryant, K; Cheng, DM; Gnatienko, N; Krupitsky, E; Samet, JH; Tsui, JI; Verbitskaya, E; Vetrova, M | 1 |
| Kertesz, SG | 1 |
| Clifasefi, SL; Collins, SE; Duncan, MH; Hoffmann, GE; Mayberry, N; Merrill, JO; Ries, RK; Saxon, AJ; Taylor, EM | 1 |
| Greenland, M; Kelty, E; Preen, D; Terplan, M | 1 |
| Bach, P; Bumb, JM; Dinter, C; Hermann, D; Karl, D; Kiefer, F; Koopmann, A; Mann, K; Vollstädt-Klein, S | 1 |
| Bach, P; Hermann, D; Hoffmann, S; Kiefer, F; Mann, K; Pompili, E; Sommer, WH; Vollstädt-Klein, S; Weil, G | 1 |
| Andersohn, F; Aubin, HJ; Blin, P; Dureau-Pournin, C; Falissard, B; Micon, S; Paille, F; Pénichon, M; Rigaud, A; Truchi, C | 1 |
| Ahamad, K; Bach, P; Mong, J | 2 |
| Montoy, JC; Murphy, CE; Raven, M; Wang, RC; Whittaker, E | 1 |
| Heyser, CJ; Mason, BJ | 1 |
| Bujarski, S; Du, H; Green, R; Grodin, EN; Nieto, SJ; Ray, LA; Roche, DJO | 1 |
| Burnette, EM; Green, R; Grodin, EN; Lim, AC; Miotto, K; Ray, LA | 1 |
| Andersohn, F; Borchert, K; Braun, S; Chick, J; Guillo, S; Haas, JS; Kuppan, K; Lemming, OM; Reines, EH; Toussi, M; Tubach, F | 1 |
| Bierut, LJ; Grucza, RA; Hartz, SM; Mintz, CM; Presnall, NJ; Sahrmann, JM; Xu, KY | 1 |
| Harries, B; Harries, J; Motluk, L; Szelest, I | 1 |
| Anton, R; Batzler, A; Biernacka, JM; Colby, C; Coombes, BJ; Frank, J; Geske, JR; Goldman, D; Ho, AM; Ho, MF; Hodgkinson, C; Karpyak, VM; Kiefer, F; Mann, K; O'Malley, SS; Pozsonyiova, S; Rietschel, M; Skime, M; Weinshilboum, R; Zillich, L | 1 |
| Anderson, ES; Chamberlin, M; D'Onofrio, G; Hawk, K; Herring, AA; McCormack, R; Ullal, M; Zuluaga, M | 1 |
| Anton, RF; Chen, BH; Hoffman, M; Schacht, JP | 1 |
| English, K; Gu, LY; Madden, EF; Mensah, NA; Qeadan, F; Venner, KL | 1 |
| Gibaja, V; Gillet, P; Labroca, P; Lemarié, J; Martini, H; Paille, F; Petitpain, N; Yéléhé-Okouma, M | 1 |
| Franchitto, N; Jullian, B; Pelissier, F; Rolland, B; Salles, J | 1 |
| Gajbhiye, SV; Petare, A; Potey, AV; Salve, B; Tripathi, RK | 1 |
| Anton, RF; Book, SW; Latham, PK; Myrick, H; Randall, PK; Schacht, JP; Voronin, KE | 1 |
| Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, AD; Timko, C; Wong, JJ | 1 |
| Gomes, T; Martins, D; Singh, S; Spithoff, S; Turner, S | 1 |
| Hallgren, KA; Heather, N; Kirouac, M; Maisto, SA; Montes, KS; Pearson, MR; Roos, CR; Wilson, AD; Witkiewitz, K | 1 |
| Chokron Garneau, H; Glasner, S; Rawson, R; Ray, LA; Venegas, A | 1 |
| De Filippis, S; De Persis, S; De Risio, L; di Giannantonio, M; Di Nicola, M; Janiri, L; Maremmani, AGI; Maremmani, I; Martinotti, G; Pettorruso, M | 1 |
| Brown, R; Busch, AC; Denduluri, M; Deyo, B; Gassman, M; Glass, J; Gugnani, SP; Hetzel, S; Krahn, D | 1 |
| Brumback, B; Bryant, K; Cohen, M; Cook, RL; Hu, X; Karki, M; Mai, D; Rathore, M; Thoma, K; Weber, KM; Young, M | 1 |
| Barr, SC; de Arellano, MA; López, CM; Reid-Quiñones, K | 1 |
| Lee, JC; Takayesu, AG | 1 |
| Holtyn, AF; Kaminski, BJ; Weerts, EM | 1 |
| Bernstein, SL; D'Onofrio, G | 1 |
| Carton, L; Gaboriau, L; Lescut, C; Rolland, B | 1 |
| Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C | 1 |
| Bonnet, U; Dembski, N; Niederhofer, A; Niederhofer, E; Nyhuis, PW; Scherbaum, N; Schifano, F; Specka, M; Tenbergen, M | 1 |
| Barrio, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L | 2 |
| Brumback, B; Chen, X; Cook, RL; Hahn, JA; Miguez, MJ; Wang, Y; Zhou, Z | 1 |
| Aballéa, S; Daeppen, JB; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Heinz, A; Hoffmann, S; Leménager, T; Mann, K; Nakovics, H; Roos, CR; Witkiewitz, K | 1 |
| Edelman, EJ; Marshall, BDL; Williams, EC | 1 |
| Adinoff, BH; Lin, A; Naglich, AC; Wakhlu, S | 1 |
| Donoghue, K | 1 |
| Garbutt, JC; Jonas, DE; Liles, A; Moore, C; Starke, B; Stepanek, KV; Stephens, JR | 1 |
| Blanchard, A; Gray, JC; Miranda, R; Treloar Padovano, H; Wemm, SE | 1 |
| Anton, RF; Book, SW; Hoffman, M; Latham, PK; Randall, PK; Schacht, JP; Voronin, KE | 1 |
| Bernoussi, A; Braillon, A; Taiebi, F | 1 |
| Altice, FL; Azar, MM; Barbour, R; Di Paola, A; Springer, SA | 1 |
| Ahmad, SU; Kumar, J; Mohamed, IN; Pakri Mohamed, RM | 1 |
| Hunter, SB; McCullough, CM; Ober, AJ; Osilla, K; Setodji, CM; Watkins, KE | 1 |
| Ingram, E; Leong, SH; Maisto, SA; McKay, JR; Oslin, DW; Possemato, K; Rotenberg, JR | 1 |
| Du, Y; Ehrich, E; O'Malley, SS; Silverman, BL; Todtenkopf, MS | 1 |
| Barrio Giménez, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L | 1 |
| Hughes, JR; Klemperer, EM; Naud, S | 1 |
| Binswanger, IA; Fazel, S; Hellner, C; Larsson, H; Molero, Y; Zetterqvist, J | 1 |
| Brown, ST; Bryant, KJ; Edelman, EJ; Fiellin, DA; Fiellin, LE; Hansen, N; Holt, SR; Justice, AC; Kyriakides, TC; Moore, BA; Virata, M | 1 |
| Erikson, CM; Walker, BM; Wei, G | 1 |
| Chan Osilla, K; Hunter, SB; Lamp, K; Lind, M; McCullough, C; Ober, A; Setodji, C; Watkins, KE | 1 |
| Chang, G; Crawford, M; Enggasser, JL; Goodwin, K; Pitts, M; Schein, AZ | 1 |
| Baillie, A; Haber, PS; Kranzler, HR; Luquin, N; Morley, KC; Shanahan, M; Teesson, M; Trent, R | 1 |
| Dermody, SS; Hendershot, CS; Stoner, SA; Wardell, JD | 1 |
| Corbin, WR; DeMartini, KS; Foster, DW; Fucito, LM; Kranzler, HR; Leeman, RF; O'Malley, SS; Romano, D | 1 |
| Kranzler, HR; Soyka, M | 1 |
| Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M | 1 |
| Bekier, NK; Brünen, S; Hiemke, C; Jahn, H; Kiefer, F; Korf, F; Wiedemann, K | 1 |
| Martin-Fardon, R; Matzeu, A; Terenius, L | 1 |
| Coenen, MJH; Kievit, W; Schellekens, A; Schene, AH; Sluiter, RL; Teichert, M; van der Wilt, GJ | 1 |
| Bullmore, ET; Deakin, B; Elliott, R; Ersche, KD; Flechais, R; Lingford Hughes, A; McGonigle, J; Murphy, A; Nestor, LJ; Nutt, DJ; Orban, C; Paterson, LM; Rabiner, I; Reed, L; Robbins, TW; Sahakian, BJ; Smith, D; Suckling, J; Taylor, E | 1 |
| Grahan, B | 1 |
| Brix Schou, M; Brotons, C; Castera, P; Großkopf, J; Meulien, D; Steiniger Brach, B; Stewart, E; Zhang, D | 1 |
| Lim, AC; Ray, LA; Roche, DJO | 1 |
| Krystal, JH; Petrakis, IL; Yoon, G | 2 |
| Bujarski, S; Green, R; Lim, AC; Ray, LA; Venegas, A | 1 |
| Harris, AHS; Matson, TE; Williams, EC | 1 |
| Bach, P; Canals, S; Dursun, SM; Greenshaw, AJ; Hermann, D; Hoffmann, S; Kiefer, F; Kirsch, P; Mann, K; Moratal, D; Perez-Ramirez, U; Pompili, E; Sommer, WH; Vollstädt-Klein, S; Weil, G | 1 |
| Bell, RL; Bredhold, KE; Cheong, MC; Engleman, EA; Katner, SN; Neal-Beliveau, BS; Steagall, KB | 1 |
| Blasey, C; Heifets, BD; Rodriguez, CI; Schatzberg, AF; Sudheimer, K; Williams, NR | 1 |
| Warren, D | 1 |
| Umhau, JC | 1 |
| Anton, RF; Falk, DE; Fertig, J; Hasin, DS; Johnson, B; Kranzler, HR; Litten, RZ; Mann, KF; Meulien, D; O'Malley, SS; Ryan, M; Slater, M; Witkiewitz, K | 1 |
| Alho, H; Castrén, S; Mäkelä, N | 1 |
| Bentzley, BS; Heifets, BD; Schatzberg, AF; Williams, NR | 1 |
| Agibalova, TV; Akhmetzyanov, II; Gurevich, GL; Khaeva, RF; Nedobylskiy, OV; Orlova, AV; Udachina, GL | 1 |
| Beaglehole, B; Boden, JM; Foulds, J; Mulder, RT | 1 |
| Ahonen, K; Luvisi, J; Sethi, R | 1 |
| Acion, L; Arndt, S; Jorge, RE; Li, R; Liu, X; McGavin, JK; Shorter, DI | 1 |
| Bonnet, U; Holzbach, R; Kirchof, U; Scherbaum, N; Stammen, G | 1 |
| Bujarski, S; Green, R; Magill, M; Ray, LA; Roche, DJO | 1 |
| Bujarski, S; Courtney, KE; Ghahremani, DG; Green, R; Grodin, EN; Hartwell, EE; Hutchison, K; Lim, AC; Miotto, K; Ray, LA | 1 |
| Holzbach, R; Kirchhof, U; Scherbaum, N; Stammen, G | 1 |
| Hayashi, T; Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Sørensen, P; Takahashi, M; Tsuneyoshi, K | 1 |
| Blanco, J; Paine Hughes, L; Quiñones-Lombraña, A; Shyhalla, K; Stewart, SH; Swiatek, D; Walitzer, KS | 1 |
| Iheanacho, T; Issa, M; Marienfeld, C; Rosenheck, R | 1 |
| Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Wu, R | 1 |
| Castaño-Duque, CH; Dávalos, A; Dorado-Bouix, L; García-Esperón, C; Gomis-Cortina, M; Hervás-García, JV; Jiménez-González, M; López-Cancio Martinez, E; Millán-Torné, M; Pérez de la Ossa-Herrero, N | 1 |
| Connery, HS; Fitzmaurice, GM; Greenfield, SF; Livchits, V; Nelson, AK; Shields, A; Shin, S; Yanov, S; Yanova, G | 1 |
| Swift, RM | 3 |
| Gual, A; He, Y; Mann, K; Torup, L; van den Brink, W | 1 |
| Anton, RF; Baker, NL; Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ; Randall, PK | 1 |
| Conn, N; Lindsey, KP; Lowen, SB; Lukas, SE; Mallya, G; Palmer, C; Penetar, DM; Rodolico, J; Tartarini, W | 1 |
| Bourgault, C; Friedmann, PD; Lonergan, S; Mello, D; O'Toole, TP | 1 |
| O'Connor, PG; O'Malley, SS | 1 |
| Krishnan-Sarin, S; Krystal, JH; O'Malley, S | 1 |
| Pagar, KP; Vavia, PR | 1 |
| Ahern, J; Kaskutas, LA; Lendle, S; Subbaraman, MS; van der Laan, M | 1 |
| Jarosz, J; Krumpl, G; Miernik, K; Wąchal, M; Walczak, J | 1 |
| Berrettini, W | 2 |
| Douaihy, AB; Kelly, TM; Sullivan, C | 1 |
| Gillett, K; Harshberger, E; Valdez, GR | 1 |
| Aubin, HJ; Daeppen, JB | 1 |
| Anastasov, OV; Connery, H; Greenfield, S; Heney, JH; Lastimoso, CS; Livchits, V; McGrady, L; Nelson, AK; Novoseltseva, OI; Patrick, N; Petrova, LY; Shields, A; Shin, SS; Stepanova, YP | 1 |
| Franck, J; Jayaram-Lindström, N | 1 |
| Froehlich, JC; Hausauer, BJ; Rasmussen, DD | 1 |
| Agibalova, TV; Gurevich, GL; Kuznetsov, AG; Petrov, AD; Rychkova, OV; Val'chuk, DS | 1 |
| Falk, D; Fertig, J; Litten, RZ; Ryan, M | 1 |
| Castle, IJ; Chen, CM; Falk, D; Fertig, J; Litten, RZ; Ryan, M; Yi, HY | 1 |
| Gianoli, MO; McCarthy, E; Petrakis, I; Ralevski, E | 1 |
| Mills, K | 1 |
| Bux, DA; Foa, EB; Imms, P; McLean, CP; O'Brien, CP; Oslin, D; Riggs, DS; Suvak, MK; Volpicelli, J; Yusko, DA | 1 |
| Keating, GM | 1 |
| Anton, RF | 7 |
| Ingram, E; Lantinga, LJ; Lynch, KG; Maisto, SA; McKay, JR; Oslin, DW; Possemato, K; Wierzbicki, M | 1 |
| Soyka, M | 4 |
| Alho, H; Julkunen, J; Lahti, J; Vuoristo-Myllys, S | 1 |
| Enoch, MA | 1 |
| Najavits, LM | 1 |
| Foa, EB; McLean, CP; Yusko, D | 1 |
| Altice, FL; Di Paola, A; Herme, M; Springer, SA | 1 |
| Heinz, A; Müller, CA | 1 |
| Alho, H; Kalska, H; Lahti, J; Lipsanen, J; Vuoristo-Myllys, S | 1 |
| Maremmani, I; Pacini, M; Pani, PP; Trogu, E | 1 |
| Spence, D | 1 |
| Batel, P; Chick, J; Gual, A; Kiefer, F; Sinclair, J; Sørensen, P | 1 |
| Braillon, A | 2 |
| McNulty, SJ; Williams, P | 1 |
| Anton, RF; Falk, DE; Johnson, BA; Kranzler, HR; Litten, RZ | 1 |
| Firoz, K; Manoj Kumar, G; Nidheesh Sankar, V; Raghuram, TM; Rajmohan, V | 1 |
| Bobashev, GV; Garbutt, JC; Greenblatt, AM; Jordan, HS; Kampov-Polevoy, A; Morgan, LC; West, SL | 1 |
| Gual, A; Mann, K; Sørensen, P; Torup, L; van den Brink, W | 1 |
| Altice, FL; Di Paola, A; Herme, M; Lincoln, T; Skiest, DJ; Springer, SA; Vagenas, P | 1 |
| Coen, K; Funk, D; Lê, AD; Lo, S | 1 |
| Ginsburg, BC; Lamb, RJ | 1 |
| Bhaw-Luximon, A; Goonoo, N; Hulse, GK; Jhugroo, A; Jhurry, D; Ujoodha, R | 1 |
| Aubin, HJ; Gual, A; Mann, K; van den Brink, W | 1 |
| Balguerie, K; Coune, F; Jeanblanc, J; Jeanblanc, V; Legastelois, R; Naassila, M | 1 |
| Collins, SE; Duncan, MH; Jackson, TR; Malone, DK; Ries, RK; Saxon, AJ; Smart, BF | 1 |
| Clifasefi, SL; Collins, SE; Duncan, MH; Jackson, TR; Joesch, J; Malone, DK; Merrill, JO; Ries, RK; Saxon, AJ; Smart, BF | 1 |
| Jeong, HJ; Jung, WY; Kim, JH; Kim, SG; Lee, JS; Yang, YH | 1 |
| Chalk, M; Fu, R; Gastfriend, DR; Hartung, DM; McCarty, D; Wiest, K | 1 |
| Bruguera, P; Gual, A; López-Pelayo, H | 1 |
| DeSantis, SM; Zhu, H | 1 |
| Brody, A; Courtney, KE; Ghahremani, DG; London, ED; Miotto, K; Ray, LA | 1 |
| Liang, J; Olsen, RW | 1 |
| Chen, AC; Covault, J; Davis, CM; Kahler, CW; Kranzler, HR; Kuerbis, AN; Morgenstern, J | 1 |
| Braciszewski, JM; Falk, D; Kranzler, HR; O'Malley, SS; Stout, RL; Subbaraman, MS | 1 |
| Gregg, M; Martinez, L; Samaritan, G | 1 |
| Barbosa, C; Brodtkorb, TH; Daeppen, JB; François, C; Knight, C; Laramée, P; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Aballéa, S; Bineau, S; Chalem, Y; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Oetzel, S | 1 |
| Wise, J | 1 |
| Anton, RF; Book, SW; Schacht, JP | 1 |
| Corbin, WR; Fucito, LM; Leeman, RF; O'Malley, SS; Toll, BA; Zalewski, S | 1 |
| Borro, P; Leone, S; Testino, G | 1 |
| Fauth-Bühler, M; Heinz, A; Hermann, D; Hoffmann, S; Kiefer, F; Leménager, T; Mann, K; Reinhard, I; Smolka, MN; Vollstädt-Klein, S; Zimmermann, US | 1 |
| Foa, EB; McLean, CP; Su, YJ | 2 |
| Nubukpo, P | 1 |
| Bendimerad, P; Blecha, L | 1 |
| Stafford, N | 1 |
| Adamson, SJ; Boden, JM; Douglas Sellman, J; Foulds, JA; Joyce, PR; Mulder, RT | 1 |
| Blaine, SK; Diamond, KA; George, DT; Heilig, M; Momenan, R; Phillips, MJ; Ramchandani, VA; Schwandt, ML; Spagnolo, PA; Usala, JM; Zhang, L | 1 |
| Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ | 1 |
| Brown, SA; Kivlahan, DR; Longabaugh, R; Witkiewitz, K; Worley, MJ | 1 |
| Gual, A; Jensen, TJ; Mann, K; Strang, J; Sørensen, P; van den Brink, W | 1 |
| Donoghue, K; Drummond, C; Elzerbi, C; Pilling, S; Saunders, R; Whittington, C | 1 |
| Adamson, SJ; Berks, J; Cape, G; Deering, D; Dunn, A; Foulds, JA; Frampton, CM; Nixon, L; Sellman, JD | 1 |
| Collins, SE; Dean, PE; Grazioli, VS; Greenleaf, SM; Haelsig, L; Hatsukami, AS; Herndon, P; Hoffman, GE; Jones, CB; Koker, MJ; Taylor, EM; Torres, NI; Zhu, MD | 1 |
| Adamson, SJ; Foulds, JA; Kennedy, MA; Mulder, RT; Sellman, JD; Ton, K | 1 |
| Corbin, WR; DeMartini, KS; Fucito, LM; Gueorguieva, R; Ikomi, J; Kranzler, HR; Leeman, RF; O'Malley, SS; Romano, DM; Sher, KJ; Toll, BA; Wu, R | 1 |
| Hester, RK | 1 |
| Saitz, R | 2 |
| Berrettini, W; Gordon, AJ; Leong, SH; Lynch, KG; O'Brien, CP; Oslin, DW; Rukstalis, M | 1 |
| Lieb, M; Soyka, M | 1 |
| Altice, FL; Brown, SE; Clark, JL; Duerr, AC; Gonzales, P; Konda, KA; Lama, JR; Sanchez, J; Vagenas, P | 1 |
| Aubin, HJ; Bladström, A; Chick, J; François, C; Nutt, DJ; Reimer, J; Torup, L | 1 |
| Morgan, MY; Pandor, A; Rawdin, A; Rice, P; Stevens, JW; Stevenson, M; Thompson, J | 1 |
| Johnson, RA; Kole, JW; Lukens, JM; Sisti, DA | 1 |
| Kittilsen, L | 1 |
| Favrod-Coune, T | 1 |
| Donnerstag, N; Lüthi, A; Mehlig, A; Raetz Bravo, A; Schneider, T; Taegtmeyer, A | 1 |
| Aubin, HJ; Chalem, Y; François, C; Luquiens, A; Rahhali, N; Sørensen, P | 1 |
| Kissler, JL; Walker, BM | 1 |
| Bullmore, ET; Maltby, K; Miller, SR; Mugnaini, M; Nathan, P; Ripley, TL; Sanchez-Roige, S; Stephens, DN; Wille, DR | 1 |
| Froehlich, JC; Kincaid, CL; Rasmussen, DD | 1 |
| Baroni, S; Dell'Osso, L; Marazziti, D; Mucci, F; Mungai, F; Piccinni, A; Presta, S | 1 |
| Agabio, R; Franconi, F; Gessa, GL; Pani, PP; Preti, A | 1 |
| Laramée, P; Rahhali, N; Rehm, J; Roerecke, M; Sørensen, P | 1 |
| Gofman, AG; Ponizovskiy, PA | 1 |
| Lu, X; Lynch, KG; Murphy, S; Oslin, DW | 1 |
| Bruhn, C | 1 |
| Serecigni, JG | 1 |
| Asnaani, A; Foa, EB; McLean, CP; Powers, MB; Rosenfield, D; Zandberg, LJ | 1 |
| Dahmke, H; Kullak-Ublick, GA; Kupferschmidt, H; Weiler, S | 1 |
| Areberg, J; Faerch, KU; Kyhl, LE; Larsen, F; Li, S; Soegaard, B | 1 |
| Adamson, SJ; Boden, JM; Foulds, JA; Mulder, RT; Newton-Howes, G; Sellman, JD | 1 |
| Sivolap, YP | 1 |
| Sudakin, D | 1 |
| Brett, J; Conigrave, K; Doyle, M; Ivers, R; Lawrence, L | 1 |
| Diana, M; Fois, GR | 1 |
| Bellissant, E; Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C; Reymann, JM | 1 |
| Martelli, A; Mattioli, F; Milano, G; Natta, WM; Zavan, V | 1 |
| Mayor, S | 1 |
| Anton, RF; Fitzmaurice, GM; Griffin, ML; McHugh, RK; Weiss, RD | 1 |
| Houck, J; Longabaugh, R; Miller, WR; Moyers, TB; Rice, SL | 1 |
| Fontenelle, LF; Piquet-Pessôa, M | 1 |
| Bell, M; Brodtkorb, TH; Irving, A; Laramée, P | 1 |
| Friede, M; Schnitker, J; Soyka, M | 2 |
| Addolorato, G; Bernardi, M; Caputo, F; D'Amore, A; Domenicali, M; Maremmani, AG; Maremmani, I; Zoli, G | 1 |
| Bell, M; Brodtkorb, TH; Irving, AH; Laramée, P | 1 |
| Alpert, E; Asnaani, A; Foa, EB; Kaczkurkin, AN | 1 |
| Alpert, E; Foa, EB; McLean, CP; Rosenfield, D; Zandberg, LJ | 1 |
| Dudek, M; Herr, DR; Hytönen, HR; Hyytiä, P; Korpi, ER; Linden, AM; Paasikoski, N; Vashchinkina, E | 1 |
| Allen, JP; Crawford, EF; Kudler, H | 1 |
| Klein, JW | 1 |
| Braillon, A; Granger, B; Naudet, F | 1 |
| Angus, K; de Andrade, M; Elders, A; Fitzgerald, N; Heather, N; McCambridge, J; Raistrick, D | 1 |
| Canals, S; Ciccocioppo, R; Cosa, A; Hyytiä, P; Moratal, D; Moreno, A; Pacheco-Torres, J; Sommer, WH | 1 |
| Aballéa, S; Chalem, Y; Cristeau, O; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Cicin-Šain, L; Kovak-Mufić, A; Marušić, S; Matošić, A; Vidrih, B | 1 |
| Naudet, F | 1 |
| Baillie, A; Haber, PS; Logge, W; Morley, KC; Pearson, SA | 2 |
| Blow, FC; Helstrom, AW; Kranzler, HR; Leong, S; Oslin, D; Slaymaker, V | 1 |
| Hendershot, CS; Rehm, J; Samokhvalov, AV; Wardell, JD | 1 |
| Salisbury-Afshar, E | 1 |
| Dilley, JE; Filosa, NJ; Fischer, SM; Froehlich, JC; Nicholson, ER; Rademacher, LC; Smith, TN | 1 |
| Aballéa, S; Brodtkorb, TH; Cristeau, O; Laramée, P; Millier, A; Montgomery, S; Rahhali, N; Rehm, J; Steeves, S; Toumi, M | 1 |
| Mann, K; Roos, CR; Witkiewitz, K | 1 |
| Batra, A; Hansson, AC; Hermann, D; Hirth, N; Hoffmann, S; Kiefer, F; la Fougère, C; Mann, K; Noori, HR; Reimold, M; Reischl, G; Smolka, MN; Sommer, WH; Spanagel, R | 1 |
| Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Griffin, N; Guo, S; Hu, X; Shan, F; Wang, X; Yi, Z; Zhang, X | 1 |
| Bullmore, ET; Deakin, B; Elliott, R; Ersche, KD; Flechais, R; Lingford-Hughes, A; McGonigle, J; Murphy, A; Nestor, LJ; Nutt, DJ; Orban, C; Paterson, LM; Rabiner, I; Reed, L; Robbins, TW; Sahakian, B; Smith, D; Suckling, J; Tait, R; Taylor, E | 1 |
| Gallop, RJ; Garbutt, JC; Kalka-Juhl, LS; Kampov-Polevoy, AB | 1 |
| Gual, A; Mann, K; Swift, R; Sørensen, P; Torup, L; van den Brink, W; Walker, B | 1 |
| Metrik, J; Patterson, D; Subbaraman, MS; Swift, R | 1 |
| Braillon, A; Fitzgerald, N; Naudet, F | 1 |
| Verma, R | 1 |
| Asnaani, A; Chazin, D; Foa, EB; Yu, J; Zandberg, LJ; Zang, Y | 1 |
| Almirall, D; Ertefaie, A; Lu, XL; Lynch, KG; McKay, JR; Nahum-Shani, I; Oslin, DW | 1 |
| Ahamad, K; Arenas, V; Ha, D; Korthuis, PT; Kunkel, LE; Lindblad, R; Lum, PJ; Mandler, RN; McCarty, D; Oden, NL; Sorensen, JL; Vergara-Rodriguez, P; Wood, E | 1 |
| Brewer, C; Skinner, M; Streel, E | 1 |
| Carmona, C; Elices, M; Gasol, M; Gasol, X; Martín-Blanco, A; Pascual, JC; Patrizi, B; Soler, J | 1 |
| Bolstridge, M; Boyce, M; Breuning Sluth, L; Flechais, RSA; Lingford-Hughes, A; McGonigle, J; Meulien, D; Mick, I; Newbould, RD; Nutt, D; Quelch, DR; Rabiner, E; Ramos, AC; Steiniger-Brach, B; van den Berg, F; von der Goltz, C; Wall, MB; Østergaard Nilausen, D | 1 |
| Goh, ET; Morgan, MY | 1 |
| Manolopoulos, VG; Ragia, G | 1 |
| Le Foll, B; Samokhvalov, AV | 1 |
| Baek, K; Bullmore, ET; Deakin, B; Elliott, R; Ersche, KD; Flechais, R; Lingford-Hughes, AR; McGonigle, J; Morris, LS; Murphy, A; Nestor, LJ; Nutt, DJ; Orban, C; Passetti, F; Paterson, LM; Rabiner, I; Reed, L; Robbins, TW; Sahakian, BJ; Smith, D; Suckling, J; Tait, R; Taylor, EM; Voon, V | 1 |
| Ben, K; Crowley, RS; Kreek, MJ; Prisinzano, TE; Zhou, Y | 1 |
| Correia, M; Deakin, JF; Elliott, R; Ersche, KD; Flechais, RS; Lingford-Hughes, AR; McGonigle, J; Murphy, A; Nutt, DJ; Orban, C; Passamonti, L; Paterson, LM; Reed, LJ; Riccelli, R; Robbins, TW; Sahakian, BJ; Savulich, G; Smith, DG; Suckling, J; Tait, R; Taylor, EM | 1 |
| Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G | 1 |
| Dackis, C; Dundon, W; Gariti, P; Gelfand, L; Kampman, KM; Lynch, KG; O'Brien, CP; Oslin, DW; Pettinati, HM; Ten Have, T; Volpicelli, JR; Wortman, S | 1 |
| Grant, JE; Hollander, E; Kim, SW; Potenza, MN | 1 |
| Haile, CN; Kosten, TA; Kosten, TR | 1 |
| Bowers, TG; Snyder, JL | 1 |
| Ciraulo, D; Cox, CE; Gorroochurn, P; Mattson, ME; Pettinati, HM; Weiss, RD; Youngblood, M; Zweben, A | 1 |
| Gilpin, NW; Koob, GF; Richardson, HN | 1 |
| Farren, CK; Malley, SO; Scimeca, M; Wu, R | 1 |
| Batki, SL; Dimmock, JA; Leontieva, L; Ploutz-Snyder, R | 1 |
| Alexander, M; Bohn, MJ; Forman, R; Illeperuma, A; Lapham, S | 1 |
| Choi, SW; Choi, YS; Jae, YM; Kim, CM; Kim, HO; Kim, JG; Kim, SG; Kim, SY; Lee, HG; Oslin, DW; Son, BK | 1 |
| Cooney, NL; Krishnan-Sarin, S; Leeman, RF; Makuch, RW; McKee, SA; Meandzija, B; O'Malley, SS; Wu, R | 1 |
| Mitka, M | 1 |
| Albanese, M; Herman, J; Khantzian, E; Kueppenbender, K | 1 |
| O'Brien, CP | 8 |
| Kassed, CA; Kranzler, HR; Levit, KR; Mark, TL; Vandivort-Warren, R | 1 |
| Hutchison, KE; Leggio, L; Mackillop, J; Morgan, M; Ray, LA | 1 |
| Bogenschutz, MP; Pettinati, HM; Scott Tonigan, J | 1 |
| Aldridge, A; Bray, JW; Cisler, RA; Couper, DJ; Mills, MJ; Mitra, D; Zarkin, GA | 1 |
| Baltieri, DA; Daró, FR; de Andrade, AG; Ribeiro, PL | 2 |
| Hosking, JD; Locastro, JS; O'malley, SS; Swift, R; Weiss, RD | 1 |
| Meyer, F | 1 |
| Gastfriend, DR; Kranzler, HR; Montejano, L; Stephenson, JJ; Wang, S | 1 |
| Hyytiä, P; Kemppainen, H; Kiianmaa, K | 1 |
| Rosenbloom, DL | 1 |
| Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R; Yuan, Q | 1 |
| Dong, Q; Gastfriend, DR; Kranzler, HR; O'Malley, SS; Pettinati, HM | 1 |
| Garbutt, JC | 2 |
| Kato, H | 1 |
| Diehl, A; Herre, H; Kiefer, F; Mann, K; Mutschler, J; Vollmert, C | 1 |
| Czachowski, CL; Delory, MJ | 1 |
| Gann, H; Heinz, A; Kiefer, F; Mann, K; Smolka, M; Wellek, S | 1 |
| Boettiger, CA; D'Esposito, M; Fields, HL; Kelley, EA; Mitchell, JM | 1 |
| Gopalakrishnan, R; O'Brien, C; Oslin, D; Ross, J | 1 |
| Boakes, R; Colagiuri, B; Haber, P; Morley, K | 1 |
| Connor, JP; Feeney, GF; Walters, D; Young, RM | 1 |
| Kuehn, BM | 3 |
| Kenna, GA; Leggio, L; Ray, LA; Swift, RM | 1 |
| Alho, H; Hyytiä, P | 1 |
| Abraham, AJ; Ducharme, LJ; Roman, PM | 1 |
| Daoust, M; Houchi, H; Koeter, MW; Naassila, M; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R | 1 |
| Mattes, JA | 1 |
| Arias, A; Armeli, S; Chan, G; Covault, J; Kranzler, HR; Oncken, C; Tennen, H | 1 |
| Andrade, AG; Baltieri, DA; Daró, FR; Ribeiro, PL | 1 |
| Davidson, D; Gulliver, SB; Longabaugh, R; Wirtz, PW | 2 |
| de Silva, V; Hanwella, R | 1 |
| Adinoff, B; Brown, ES; Caetano, R; Carmody, TJ; John Rush, A; Schmitz, JM; Swann, AC | 1 |
| Oslin, DW; Ray, LA | 1 |
| Barr, CS; Chen, SA; Heilig, M; Lindell, SG; Schwandt, ML; Sun, H; Suomi, SJ | 1 |
| Kampman, KM; Oslin, DW; Pettinati, HM; Plebani, JG; Tirado, CF; Volpicelli, JR | 1 |
| Clarke, TK; Schumann, G; Stacey, D | 1 |
| Kmoch, V; Papezova, H; Yamamotova, A | 1 |
| Chen, YC; Cruz, MT; Holmes, A; McDevitt-Murphy, ME; Murphy, JG; Ray, LA; Richardson, HN; Roberto, M; Witkiewitz, K | 1 |
| Boyadjieva, NI; Sarkar, DK | 1 |
| Connery, HS; Fitzmaurice, G; Greenfield, SF; Lastimoso, CS; Livchits, V; Mathew, TA; Mishustin, SP; Shields, A; Shin, S; Strelis, AK; Yanov, SA | 1 |
| Kim, SG | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM; Rothrauff, TC | 1 |
| Gwaltney, CJ; MacKillop, J; McGeary, JE; Miranda, R; Monti, PM; Ray, LA; Rohsenow, DJ; Swift, RM; Tidey, JW | 1 |
| Banks, SL; Brogden, NK; Crooks, PA; Gill, HS; Paudel, KS; Pinninti, RR; Prausnitz, MR; Stinchcomb, AL | 1 |
| Chin, PF; Miotto, K; Ray, LA | 1 |
| Dackis, CA; Dundon, WD; Gallis, TL; Kampman, KM; O'Brien, CP; Oslin, DW; Pettinati, HM; Xie, H | 1 |
| Olive, MF | 1 |
| Bray, JW; Dunlap, LJ; Kivlahan, DR; Latham, P; McKay, JR; Mills, M; Tonigan, JS; Zarkin, GA | 1 |
| Bowe, T; Harris, AH; Humphreys, KN; Kivlahan, DR | 1 |
| DiRocco, D; Gourevitch, MN; Grossman, E; Hanley, K; Lee, JD; Rotrosen, J; Stevens, D; Truncali, A | 1 |
| Bristow, RE; Grahame, NJ; Heighton, ME; Oberlin, BG | 1 |
| Li, TK; Patkar, AA | 1 |
| Johnson, BA | 4 |
| Ashenhurst, JR; Hutchison, KE; Morrow, AL; Ray, LA | 1 |
| Dickson, SL; Egecioglu, E; Engel, JA; Jerlhag, E | 1 |
| Koob, GF; Walker, BM; Zorrilla, EP | 1 |
| Grosshans, M; Kiefer, F; Kobiella, A; Mutschler, J | 1 |
| O'Brien, C | 1 |
| Greenfield, SF; O'Malley, S; Pettinati, HM; Randall, CL; Randall, PK | 1 |
| Falk, D; Fertig, J; Johnson, B; Litten, RZ; Liu, L; Mattson, M; Ryan, M; Stout, R; Wang, XQ | 1 |
| Metzger, DS; Zhang, Y | 1 |
| Read, SL | 1 |
| Longabaugh, R; O'Malley, SS; Wirtz, PW; Zywiak, WH | 1 |
| Alvarez, S; Bobes, J; Flórez, G; García-Portilla, P; Nogueiras, L; Saiz, PA | 3 |
| Capone, C; Kahler, CW; O'Malley, SS; Swift, RM | 1 |
| Couper, D; Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Rounsaville, BJ; Wu, R | 2 |
| Burguete, T; Casas, M; Galan, J; Gonzalvo, B; Guardia, J; Roncero, C | 1 |
| Hackl-Herrwerth, A; Leucht, S; Rösner, S; Soyka, M; Srisurapanont, M; Vecchi, S | 1 |
| Bowen, S; Donovan, DM; Witkiewitz, K | 1 |
| Gastfriend, DR | 1 |
| Chalk, M; Gastfriend, DR; Kranzler, HR; Mark, TL; Montejano, LB | 1 |
| Carr, GD | 1 |
| Calvo Vecino, JM; del Blanco Narciso, BB; Orts Castro, A | 1 |
| Kim, SW; Thuras, P; Westermeyer, J; Yoon, G | 1 |
| Donovan, D; Hartzler, B; Villarroel, N; Witkiewitz, K | 1 |
| Akala, EO; Pan, G; Wiriyacoonkasem, P | 1 |
| Anton, RF; Baros, AM; Latham, PK; Myrick, H; Randall, PK; Waid, LR; Wright, TM | 1 |
| Gossop, M; Kunøe, N; Lobmaier, PP; Waal, H | 1 |
| Altamirano, LJ; Boettiger, CA; D'Esposito, M; Fields, HL | 1 |
| Battisti, JJ; Forman, R; Gastfriend, DR; Pettinati, HM; Schweizer, E; Silverman, BL | 1 |
| Bleich, S; Frieling, H; Heberlein, A; Hillemacher, T; Muschler, MA | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM | 1 |
| Finigan, MW; Parks, J; Perkins, T; Stringer, M; Zold-Kilbourn, P | 1 |
| Borawala, AS; Gill, P; Jan, S | 1 |
| Baser, O; Chalk, M; Gastfriend, DR; Rawson, R | 1 |
| Campanella, S; Kornreich, C; Noel, X; Petit, G; Verbanck, P | 1 |
| Eserian, JK; Fogaça, MN; Galduróz, JC; Santos-Galduróz, RF | 1 |
| Bryant, K; Fiellin, DA; Goulet, JL; Justice, AC; McGinnis, KA; Sullivan, LE; Tate, JP; Tetrault, JM | 1 |
| Lapham, SC; McMillan, GP | 1 |
| Bujarski, S; Chin, PF; Miotto, K; Ray, LA | 1 |
| Godinho, A; Mohapatra, S; Patra, J; Popova, S; Rehm, J; Schwappach, D | 1 |
| Cahill, S; Coller, JK; Edmonds, C; Farquharson, AL; Longo, M; Minniti, R; Somogyi, AA; Sullivan, T; White, JM | 1 |
| Lumbad, J; Yancey, JR | 1 |
| Alexander, M; Forman, R; Oslin, DW; Swift, R | 1 |
| Desai, N; Gueorguieva, R; Krystal, JH; Petrakis, IL; Ralevski, E; Rounsaville, B; Trevisan, L | 1 |
| Fabio, MC; Nizhnikov, ME; Pautassi, RM; Spear, NE | 1 |
| Krogh, J; Nordentoft, M; Petrov, I | 1 |
| Fennig, S; Lev-Ran, S; Nitzan, U | 1 |
| Bujarski, S; Courtney, KE; Ray, LA; Squeglia, LM | 1 |
| Kuwabara, H; McCaul, ME; Wand, GS; Weerts, EM; Wong, DF; Xu, X | 1 |
| Hunter-Reel, D; Witkiewitz, K; Zweben, A | 1 |
| Chambers, RA; Davidson, D; Kalapatapu, RK; Kruse, MI; Mehdiyoun, N; Radnovich, AJ | 1 |
| Doran, CM; Navarro, HJ; Petrie, DJ; Shakeshaft, A | 1 |
| Book, SW; Miller, PM; Stewart, SH | 1 |
| Harshberger, E; Valdez, GR | 1 |
| Chamorro, AJ; González-Sarmiento, R; Laso, FJ; Marcos, M; Mirón-Canelo, JA; Pastor, I | 1 |
| Chen, J; Isaac, M; Johnson, BA; Liu, L; O'Quigley, J; Wang, XQ; Zhang, D | 1 |
| Fucito, LM; Gueorguieva, RV; Gulliver, SB; Mattson, ME; O'Malley, SS; Park, A | 1 |
| Anton, RF; Myrick, H; Randall, PK; Tiffany, A; Voronin, KK | 1 |
| Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ | 1 |
| Cohoon, AJ; Farag, NH; King, AC; Lovallo, WR; Sorocco, KH; Vincent, AS | 1 |
| Bux, DA; Chen, AC; Kahler, CW; Kranzler, HR; Kuerbis, AN; Morgenstern, J | 1 |
| Reece, AS | 1 |
| Armeli, S; Covault, J; Kranzler, HR; Tennen, H | 1 |
| Gahr, M; Kölle, MA; Schönfeldt-Lecuona, C | 1 |
| Alho, H; Ariniemi, K; Heinälä, P; Lahti, T; Lillsunde, P; Sinclair, D | 1 |
| Dolan, SL; Martin, RA; Monti, PM; Rohsenow, DJ | 1 |
| Benkelfat, C; Leyton, M; Pihl, RO; Setiawan, E | 1 |
| Hulse, GK | 1 |
| Gourevitch, MN; Grossman, E; Huben, L; Lee, JD; Manseau, M; McNeely, J; Rotrosen, J; Stevens, D | 1 |
| Anton, RF; Henderson, S; Li, X; Myrick, H; Randall, PK; Schacht, JP; Voronin, KE | 1 |
| Albanese, AP | 1 |
| Hendershot, CS; Stoner, SA | 1 |
| Dundon, WD; O'Brien, CP; Pettinati, HM | 1 |
| Anton, RF; Batra, A; Berner, M; Heinz, A; Hermann, D; Hoffmann, S; Kiefer, F; Lemenager, T; Mann, K; Reinhard, I; Smolka, MN; Wellek, S; Wodarz, N; Zimmermann, US | 1 |
| Bujarski, S; Lunny, K; O'Malley, SS; Ray, LA | 1 |
| Bladström, A; Gual, A; Mann, K; Torup, L; van den Brink, W | 1 |
| Frost, JJ; Kuwabara, H; McCaul, ME; Wand, GS; Weerts, EM; Wong, DF; Xu, X | 1 |
| Kuerbis, A; Morgenstern, J; Muench, F; Schaumberg, K | 1 |
| Bowe, T; Ellerbe, L; Gordon, AJ; Hagedorn, H; Harris, AHS; Kivlahan, D; Lembke, A; Oliva, E; Reeder, RN; Trafton, JA | 1 |
| Blodgett, J; Del Re, AC; Finney, J; Maisel, N | 1 |
| Choi, IG; Kang, TC; Kim, JW; Lee, BC | 1 |
| Bravo García De Laguna, JL; Espí Martínez, F; Rubio Valladolid, G; Sanchís Fortea, M | 1 |
| Butelman, E; Kreek, MJ; LaForge, KS | 1 |
| Liu, X; Weiss, F | 1 |
| Modesto-Lowe, V; Van Kirk, J | 1 |
| Arias, F; Casas, M; Caso, C; Gonzalvo, B; Gual, A; Guardia, J; Mengual, I; Ramírez, M; Sanahuja, J; Segura, L; Trujols, J | 1 |
| Boyeson, MG; Dixon, RM; Goodman, AM; Hameed, MH; Hulot, T; Hunter, JA; Mason, BJ; Wesnes, K | 1 |
| Baker, RP; Boislard, J; Campbell, W; Cunningham, GM; Jovey, RD; Landry, M; Lemire, E; McKay, C; Mercier, C; Pépin, JM; Perreault, J; Romach, MK; Ryan, D; Sellers, EM; Somer, GR | 1 |
| Böning, J; Bonnet, U; Croop, R; Gastpar, M; Kielstein, V; Labriola, D; Mann, K; Schmidt, LG; Soyka, M; Wetterling, T | 1 |
| Gray, RW; Yeomans, MR | 1 |
| Alamo, C; Jimenez-Arriero, MA; Lopez-Muñoz, F; Manzanares, J; Palomo, T; Ponce, G; Rubio, G | 1 |
| Baehr, M; Briken, P; Helwig, H; Holzbach, R; Jahn, H; Kämpf, P; Kiefer, F; Naber, D; Stracke, R; Tarnaske, T; Wiedemann, K | 1 |
| Froehlich, JC; O'Malley, SS | 1 |
| Lee, S; McCarty, D; Swift, R; Thomas, CP; Wallack, SS | 1 |
| Anton, RF; Drobes, DJ; Thomas, SE; Voronin, K | 2 |
| Davidson, D; Farren, C; Froehlich, J; Hyytiä, P; O'Malley, S | 1 |
| Addolorato, G; Bernardi, M; Caputo, F; del RE, A; Domenicali, M; Gasbarrini, G; Greco, G; Lorenzini, F; Stefanini, GF | 1 |
| Abrams, DB; Colby, SM; Gulliver, SB; Monti, PM; Rohsenow, DJ; Swift, RM | 1 |
| Bransberger, P; Crosse, S; Kranzler, HR; Mark, TL; Poole, VH; Song, X | 1 |
| Berrettini, W; Gelernter, J; Kranzler, HR; O'Brien, CP; Oslin, DW; Pettinati, H; Volpicelli, JR | 1 |
| Chambers, RA; Ciraulo, DA; Couper, D; Johnson, BA; O'Malley, SS; Roache, JD; Sarid-Segal, O | 1 |
| Heinz, A; Mann, K; Wilwer, M | 1 |
| Honkanen, A; Ingman, K; Korpi, ER; Lazarus, L; Salvadori, S | 1 |
| Colker, AC | 1 |
| Balldin, J; Bendtsen, P; Berglund, M; Borg, S; Franck, J; Gustafsson, L; Halldin, J; Månsson, M; Nilsson, LH; Stolt, G; Willander, A | 1 |
| Farren, C; Namkoong, K; O'Connor, PG; O'Malley, SS; Robinson, J; Rounsaville, BJ; Wu, R | 1 |
| Brewer, C; Streel, E | 1 |
| Doran, CM; Fawcett, JE; Mattick, RP; Shakeshaft, AP; Shanahan, MD | 1 |
| Feinn, R; Kranzler, HR; Tennen, H | 1 |
| Conde Martel, A; Gómez Arnáiz, A | 1 |
| Leslie, D; Petrakis, IL; Rosenheck, R | 1 |
| Krystal, JH; McHugh-Strong, C; O'Malley, S; Petrakis, IL; Poling, J; Rounsaville, B | 1 |
| Cook, JM; Foster, KL; June, HL; McKay, PF; Milbourne, D; Sarma, PV; Seyoum, R; Yin, W | 1 |
| Han, BD; Kim, MJ; Kim, SG; Park, JM; Stromberg, MF | 1 |
| Kalivas, PW; Marlowe, AL; Middaugh, LD; Szumlinski, KK; Van Patten, Y | 1 |
| Anton, RF; Drobes, DJ; Durazo-Avizu, R; Moak, D; Voronin, K | 1 |
| Salaspuro, M | 1 |
| Littleton, J; Zieglgänsberger, W | 1 |
| Anton, RF; Swift, RM | 1 |
| Chick, J; Soyka, M | 1 |
| DeVries, A; Dimidjian, K; Harris, KM | 1 |
| Armeli, S; Feinn, R; Kranzler, HR; Tennen, H | 1 |
| Czachowski, CL; Grant, KA; Maners, N; Monti, PM; Pierre, P; Rohsenow, DJ; Sayette, M; Tidey, J | 1 |
| Pienaar, W | 1 |
| Amate, JM; Angeles, M; Bouza, C; Magro, A; Muñoz, A | 1 |
| Rohsenow, DJ | 1 |
| Anthenelli, R; Anton, RF; Bohn, MJ; Galloway, G; Garbutt, J; Gastfriend, D; Johnson, B; Kallio, A; Karhuvaara, S; Kranzler, HR; McCaul, ME; Pettinati, H; Salloum, I; Swift, R; Zweben, A | 1 |
| Davidson, D; Fyffe, J; O'Connor, S; Saha, C; Scifres, S; Selzer, C | 1 |
| Billot, L; Kranzler, HR; Wesson, DR | 1 |
| Hampton, T | 1 |
| Fiore, LD; Gagnon, DR; Hermos, JA; Young, MM | 1 |
| Harris, KM; Thomas, C | 1 |
| Gallate, JE; McGregor, IS | 1 |
| Anton, R; Myrick, H | 1 |
| Azar, MR; Costantini, LC; Kleppner, SR; McDonough, J; Patel, R | 1 |
| Ait-Daoud, N; Aubin, HJ; Ehrich, E; Guzzetta, R; Johnson, BA; Loewy, J; Silverman, B; Van Den Brink, W | 1 |
| Connor, JP; Feeney, GF; McPherson, A; Tucker, J; Young, RM | 2 |
| Anton, RF; Brady, KT; Faldowski, RA; Gold, PB; Killeen, TK; Simpson, KN; Tyson, C | 1 |
| Kosten, TR; Sofuoglu, M | 1 |
| Dean, RL | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Bares, R; Braus, DF; Braus, DH; Croissant, B; Dohmen, BM; Heinz, A; Hermann, D; Machulla, HJ; Mann, K; Mundle, G; Reimold, M; Schumann, G; Wrase, J | 1 |
| Hagan, JJ; Heidbreder, CA | 1 |
| Jarusuraisin, N; Srisurapanont, M | 4 |
| Baltieri, DA; Castro, LA | 1 |
| Bonnet, U; Overlack, M; Schürks, M | 1 |
| Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K | 1 |
| Cello, R; Galloway, GP; Koch, M; Smith, DE | 1 |
| Ehrich, EW; Garbutt, JC; Gastfriend, DR; Kranzler, HR; Loewy, JW; O'Malley, SS; Pettinati, HM; Silverman, BL | 1 |
| Carroll, K; Levinson, C; Nich, C; Petrakis, IL; Poling, J; Rounsaville, B | 1 |
| Oslin, DW | 1 |
| Feinn, R; Kranzler, HR | 1 |
| Demiralay, C; Jahn, H; Kiefer, F; Otte, C; Wiedemann, K; Wolf, K | 1 |
| Anton, RF; Latham, P; Moak, DH; Myrick, H; Thevos, A; Voronin, K; Waid, LR; Wang, W; Woolson, R | 1 |
| Jahn, H; Kiefer, F; Wiedemann, K | 1 |
| Adinoff, B; Junghanns, K; Kiefer, F; Krishnan-Sarin, S | 1 |
| Chen, CC; Chen, CH; Huang, MC; Yu, JM | 1 |
| Ameisen, O | 1 |
| Berglund, M; Johnson, BA; Lesch, OM; Litten, RZ; Mann, K; Swift, RM; Willenbring, ML | 1 |
| Litten, RZ; Mattson, ME | 1 |
| Anton, R; Goldman, D; O'Malley, S; Oroszi, G | 1 |
| Hosking, JD; Martin, DJ; Mason, BJ; O'Malley, SS | 1 |
| Pettinati, HM; Swift, R | 1 |
| Ait-Daoud, N; Johnson, BA; Roache, JD | 1 |
| Anton, R; Deas, D; Johnson, N; May, MP; Randall, C | 1 |
| Buonopane, A; Petrakis, IL | 1 |
| Williams, SH | 1 |
| Egli, M | 1 |
| de Jong, CA; de Waart, R; Kerkhof, AJ; Roozen, HG; van den Brink, W; van der Windt, DA | 1 |
| Sher, L | 1 |
| Belger, A; Brush, L; D'Souza, DC; Gueorguieva, R; Krystal, JH; Madonick, S; Perry, E; Wray, Y | 1 |
| Heading, CE | 1 |
| Boerngen de Lacerda, R; Fachin-Scheit, DJ; Frozino Ribeiro, A; Oliveira Goeldner, F; Pigatto, G | 1 |
| Jahn, H; Kiefer, F; Naber, D; Otte, C; Wiedemann, K | 1 |
| Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP | 1 |
| Egli, M; Heilig, M | 1 |
| Douglas, SD; Ho, WZ; Metzger, DS; O'Brien, CP; Peng, JS; Wang, X; Zhang, T | 1 |
| Armeli, S; Hernandez-Avila, CA; Kranzler, HR; Kuo, L; Song, C; Tennen, H | 1 |
| Jung, YC; Namkoong, K | 1 |
| Anton, RF; Ciraulo, DA; Cisler, RA; Couper, D; Donovan, DM; Gastfriend, DR; Hosking, JD; Johnson, BA; LoCastro, JS; Longabaugh, R; Mason, BJ; Mattson, ME; Miller, WR; O'Malley, SS; Pettinati, HM; Randall, CL; Swift, R; Weiss, RD; Williams, LD; Zweben, A | 1 |
| Leeman, RF; Starosta, AN; Volpicelli, JR | 1 |
| Escher, T; Mittleman, G | 1 |
| Balester-Mouret, S; Batel, P | 1 |
| Hong, JS; Ko, HC; Lu, RB; Tang, FI; Yen, MH | 1 |
| Beard, L; Brown, ES; Dobbs, L; Rush, AJ | 1 |
| Anton, RF; Back, SE; Brady, KT; McRae, AL; Randall, PK; Saladin, ME; Upadhyaya, HP; Waldrop, AE | 1 |
| Deas, D; Dosh, T; Kazura, A; Kratochvil, CJ; Martin, CA; Wilens, TE | 1 |
| McGeary, JE; Miranda, R; Monti, PM; Rohsenow, DJ; Swift, R; Tidey, J | 1 |
| Green, AI | 1 |
| Chen, F; Cowen, M; Lawrence, AJ; Overstreet, DH; Rezvani, AH | 1 |
| Berrettini, WH; O'Brien, CP; Oslin, DW | 1 |
| McKay, JR | 1 |
| Pettinati, HM; Rabinowitz, AR | 1 |
| Keam, SJ; Plosker, GL; Swainston Harrison, T | 2 |
| Kiefer, F | 1 |
| Siegel, S | 1 |
| Carroll, K; Levinson, C; Nich, C; Petrakis, IL; Poling, J; Ralevski, E; Rounsaville, B | 1 |
| Doggrell, SA | 1 |
| Bleich, S; Hillemacher, T; Kornhuber, J | 1 |
| Boettiger, CA; D'Esposito, M; Fields, HL; Mitchell, JM; Tavares, VC | 1 |
| Schmitt-Hönl, B | 1 |
| Roesner, S; Soyka, M | 1 |
| Dackis, CA; Kampman, KM; O'Brien, CP; Oslin, DW; Pettinati, HM; Rabinowitz, AR; Wortman, SP | 1 |
| Ducharme, LJ; Knudsen, HK; Roman, PM | 1 |
| Diehl, A; Mann, K | 1 |
| Lucchini, A; Manzato, E; Nava, F; Premi, S | 1 |
| Mørland, J | 1 |
| Baer, JS; Forcehimes, AA; Kenna, GA; Miller, WR; Tonigan, JS | 1 |
| Cramer, J; Gueorguieva, R; Krystal, JH; O'malley, SS; Pittman, B; Rosenheck, RA; Wu, R | 1 |
| Fields, HL; Joslyn, G; Meadoff, TM; Mitchell, JM; Rowbotham, MC; White, RL | 1 |
| Quertemont, E; Tambour, S | 1 |
| Davidson, D; Gulliver, SB; Longabaugh, R; Swift, R; Wirtz, PW | 1 |
| Bray, JW; Cisler, RA; Couper, DJ; Kivlahan, DR; Martin, DJ; Miller, WR; Mitra, D; Zarkin, GA | 1 |
| Krishnan-Sarin, S; Krystal, JH; O'Malley, SS; Pittman, B; Shi, J | 1 |
| Cramer, J; Gelernter, J; Gueorguieva, R; Kranzler, HR; Krystal, JH; Rosenheck, R; Zhang, H | 1 |
| Anton, RF; Baros, AM; Latham, PK; Moak, DH; Voronin, K | 1 |
| Capone, C; Farren, CK; Grilo, CM; McKee, SA; O'Malley, SS; Rounsaville, BJ; Sinha, R; Wu, R | 1 |
| Koeter, MW; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R | 1 |
| Andreoli, S; Di Nicola, M; Janiri, L; Martinotti, G; Moroni, N; Pozzi, G; Romanelli, R | 1 |
| Andreoli, M; Ashby, CR; Gardner, EL; Heidbreder, CA; Hutcheson, DM; Marcon, C | 1 |
| Carroll, K; Levinson, C; Nich, C; Petrakis, I; Poling, J; Ralevski, E; Rounsaville, B | 1 |
| Kallio, A; Karhuvaara, S; Löyttyniemi, E; Mäkelä, R; Nurminen, T; Rosberg, M; Simojoki, K; Virta, A | 1 |
| Koob, GF; Walker, BM | 1 |
| Dannals, RF; Frost, JJ; Kim, YK; Lee, JS; McCaul, ME; Wand, GS; Weerts, EM | 1 |
| Garnick, DW; Hodgkin, D; Horgan, CM; Merrick, EL; Reif, S | 1 |
| McGeary, JE; Miranda, R; Monti, PM; Rohsenow, DJ | 1 |
| Diehl, A; Jiménez-Arriero, MA; Kiefer, F; Klein, O; Rubio, G | 1 |
| Addolorato, G; Andreone, P; Bernardi, M; Caputo, F; Comaschi, C; Del Re, A; Francini, S; Lorenzini, F; Stoppo, M; Trevisani, F; Vignoli, T | 1 |
| D'Amelio, R; Falkai, P; Wobrock, T | 1 |
| Arnold-Reed, DE; Hansson, RC; Hulse, GK; Ngo, HT; Tait, RJ | 1 |
| Dackis, CA; Kampman, KM; Lynch, KG; O'Brien, CP; Oslin, DW; Pettinati, HM; Suh, JJ | 1 |
| Petry, N; Stitzer, M | 1 |
| Hutchison, KE; Ray, LA | 1 |
| Dong, Q; Garbutt, JC; Gastfriend, DR; Kranzler, HR; O'Malley, SS | 1 |
| Bernardi, M; Caputo, F; Francini, S; Stoppo, M; Vignoli, T | 1 |
| Saito, T | 1 |
| Mannelli, P; Masand, PS; Patkar, AA; Peindl, K | 1 |
| Dunbar, JL; Farrell, CB; Hayes, SC; Turncliff, RZ | 1 |
| Abrams, DB; Gwaltney, CJ; MacKillop, J; McGeary, JE; Miranda, R; Monti, PM; Paty, JA; Rohsenow, DJ; Shiffman, S; Swift, RM; Tidey, JW | 1 |
| Collins, J; Cramer, J; Gueorguieva, R; Krystal, JH; Rosenheck, R | 1 |
| Dackis, C; Kampman, KM; Lynch, KG; O'Brien, CP; Pettinati, HM; Rabinowitz, AR; Xie, H | 1 |
| Lehert, P; Leucht, S; Rösner, S; Soyka, M | 1 |
| Bergmark, A | 1 |
| Illeperuma, A; Lucey, MR; O'Brien, CP; Silverman, BL | 1 |
| Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R | 1 |
| Czarnecka, E; Dyr, W; Gorska, D; Zalewska-Kaszubska, J | 1 |
| Blanc, F; Perney, P; Rigole, H | 1 |
| Batki, SL; Dimmock, JA; Gallinger, L; Gately, PW; Leontieva, L; Ploutz-Snyder, R | 1 |
| Book, SW; Miller, PM; Randall, PK; Thomas, SE | 1 |
| Dundon, WD; Lynch, KG; Makadon, C; Oslin, DW; Pettinati, HM; Varillo, KM; Xie, H | 1 |
| Anton, RF; Baros, AM; Latham, PK | 1 |
| Arastu, MF; Dean, RL; Deaver, DR; Dong, N; Gastfriend, DR; Kriksciukaite, K; O'Driscoll, K; Reitano, K; Todtenkopf, MS | 1 |
| Ciraulo, DA; Dong, Q; Gastfriend, DR; Pettinati, HM; Silverman, BL | 1 |
| Shea, CW | 1 |
| Anton, RF; Henderson, S; Li, X; Myrick, H; Randall, PK; Voronin, K | 1 |
| June, HL | 1 |
| Addolorato, G; Berrino, L; Capuano, A; Maione, S; Rinaldi, B; Rossi, F; Stella, L | 1 |
| Heinrich, CJ; Hill, CJ | 1 |
| Chance, LE; Goldman, D; GreyWolf, I; Hodgkinson, CA; Levenson, AL; Meandzija, B; O'Malley, SS; Robin, RW; Robinson, J; Romano, D; Stillner, V; Wu, R | 1 |
| Baillie, A; Haber, P; Morley, K; Reid, S; Richardson, K; Sannibale, C; Teesson, M; Weltman, M | 1 |
| Gold, MS; Rea, WS | 1 |
| Altshuler, HL; Shippenberg, TS | 1 |
| Brewer, C | 1 |
| Volpicelli, JR | 2 |
| Clay, KL; O'Brien, CP; Volpicelli, JR; Watson, NT | 1 |
| King, AC; O'Brien, CP; Sherman, CE; Volpicelli, JR; Watson, NT | 1 |
| Nemecek, S | 1 |
| Nightingale, SL | 1 |
| Goldberg, G; Mantero-Atienza, E; Mason, BJ; Morgan, RO; Ritvo, EC; Salvato, FR; Welch, B | 1 |
| Mason, BJ; Salvato, FR | 1 |
| Wirschubsky, ZG | 1 |
| Froehlich, JC; Li, TK | 1 |
| Gordis, E | 1 |
| Goosen, C; Kornet, M; van Ree, JM | 1 |
| Agosti, V | 1 |
| Buongiorno, G; Hsuing, H; Kuznetsov, O; Swift, RM; Whelihan, W | 1 |
| Andrade, C; Rao, NS | 1 |
| O'Mara, NB; Wesley, LC | 1 |
| Gallant, D | 1 |
| Jaffe, AJ; O'Malley, SS; Rode, S; Rounsaville, BJ | 1 |
| O'Malley, SS | 5 |
| Chang, G; Jaffe, AJ; Meyer, RE; O'Malley, SS; Rode, S; Rounsaville, B; Schottenfeld, R | 1 |
| Anton, RF; Latham, PK; Moak, DH | 1 |
| O'Brien, CP; Volpicelli, JR; Volpicelli, LA | 1 |
| Llobell Segui, G; Martinez Ruiz, M; Peralba Vaño, JL; Toral Revuelta, JR | 1 |
| Gardell, LR; Hubbell, CL; Reid, LD | 1 |
| Pruett, SB; Wu, WJ | 1 |
| Kranzler, HR; Meza, E | 1 |
| Berg, BJ; Pettinati, HM; Volpicelli, JR | 1 |
| Measom, MO | 1 |
| Chang, G; Jaffe, AJ; Meyer, RE; O'Malley, SS; Rounsaville, B; Schottenfeld, RS | 2 |
| Litten, RZ | 1 |
| Overstreet, DH | 1 |
| Chattopadhyay, S; Gardell, LR; Hubbell, CL; Reid, LD | 1 |
| Ey, SR | 1 |
| Kaminer, Y; Wold, M | 1 |
| Ehrenreich, H; Poser, W | 1 |
| Herz, A | 1 |
| O'Brien, CP; Weinrieb, RM | 2 |
| Alterman, AI; Lifrak, PD; O'Brien, CP; Volpicelli, JR | 1 |
| McGee, MD | 1 |
| Spanagel, R; Zieglgänsberger, W | 1 |
| Compton, P; Pasero, CL | 1 |
| Hartmann, PM | 1 |
| Frazer, A; King, AC; O'Brien, CP; Volpicelli, JR | 1 |
| Farren, CK; O'Malley, S | 1 |
| McLellan, AT; O'Brien, CP | 1 |
| Adams, ML; Cicero, TJ; Meyer, ER | 1 |
| Dorow, JD; Phillips, TJ; Wenger, CD | 1 |
| Freed, PE; York, LN | 1 |
| Krois, S; Liberto, JG; O'Brien, J; Oslin, D | 1 |
| Gunduz, M; King, AC; Kreek, MJ; O'Brien, CP; Volpicelli, JR | 1 |
| Yeo, BK | 1 |
| Alterman, AI; O'Brien, CP; Rhines, JS; Rhines, KC; Volpicelli, JR; Volpicelli, LA | 1 |
| Alpert, N; Ciraulo, AM; Franko, KJ | 1 |
| Krois, S; Liberto, JG; Norbeck, J; O'Brien, J; Oslin, D | 1 |
| Drummond, DC; Moncrieff, J | 1 |
| Cavallaro, CA; Chattophadyay, S; Gardell, LR; Hubbell, CL; Reid, LD; Whalen, CA | 1 |
| Croop, RS; Faulkner, EB; Labriola, DF | 1 |
| Farren, CK; O'Connor, PG; O'Malley, SS; Rounsaville, BJ | 1 |
| Bauer, LO; Burleson, JA; Hersh, D; Kranzler, HR; Modesto-Lowe, V | 1 |
| Crockford, DN; el-Guebaly, N | 1 |
| Cornelius, JR; Daley, DC; Kirisci, L; Salloum, IM; Spotts, C; Thase, ME | 1 |
| Kranzler, HR; Modesto-Lowe, V; Nuwayser, ES | 1 |
| Finlayson, RE; Morse, RM; Tinsley, JA | 1 |
| Allen, JP; Litten, RZ | 2 |
| Hersh, D; Kranzler, HR; Van Kirk, JR | 1 |
| Sinclair, JD | 2 |
| Duncan, D; Femino, J; Nirenberg, T; Swift, RM | 1 |
| Borg, L; Gunduz, M; Ho, A; King, A; Kreek, MJ; Maniar, S; Perret, G; Porter, M; Schluger, JH | 1 |
| Gache, P; Siegrist, G | 1 |
| Osser, DN | 1 |
| Cummings, R; Durr, LF; Grey, C; Johnson, A; June, HL; Lawrence, A; Mason, D; McCane, S; Ricks-Cord, A; Warren-Reese, C; Williams, LS | 1 |
| O'Brien, CP; Stromberg, MF; Volpicelli, JR | 1 |
| Bonn, D | 1 |
| Bernà, L; Carrió, I; Casas, M; Catafau, AM; Estorch, M; Etcheberrigaray, A; Flotats, A; Guardia, J; Marí, C; Perez de los Cobos, J | 1 |
| Kampman, KM; O'Brien, CP; Oslin, DW; Pettinati, HM; Volpicelli, JR; Wolf, AL | 1 |
| Allen, JP; Anton, R; Sillamaukee, P | 1 |
| Farren, CK; Grebski, G; Kreek, MJ; Maniar, S; O'Malley, S; Porter, M | 1 |
| Albano, SA; Wiley, DB; Zaim, S | 1 |
| Bigot-Viale, A; Granry, JC; Pierrot, M; Tesson, B; Vigue, JP | 1 |
| Carey, TS; Crews, FT; Garbutt, JC; Lohr, KN; West, SL | 1 |
| De Vries, TJ; Homberg, JR; Mulder, AH; Nestby, P; Schoffelmeer, AN; Vanderschuren, LJ; Wardeh, G | 1 |
| Malerich, JA | 1 |
| Rueff, B | 1 |
| Mason, B | 1 |
| Cutler, RB; Mason, BJ; Ritvo, EC; Salvato, FR; Williams, LD | 1 |
| Farren, CK; O'Malley, SS | 1 |
| Farren, CK; Namkoong, K; O'Connor, PG; O'Malley, SS | 1 |
| Hölter, SM; Spanagel, R | 2 |
| Flannery, BA; Pettinati, HM; Volpicelli, JR | 1 |
| Abrams, DB; Brown, RA; Colby, SM; Gordon, A; Gulliver, SB; Hutchison, KE; Monti, PM; Mueller, TI; Rohsenow, DJ; Swift, RM | 1 |
| Davidson, D; Palfai, T; Swift, R | 1 |
| Alexandre, JY; Amraoui, A; Baron, P; Burgos, V | 1 |
| Anton, RF; Latham, PK; Moak, DH; Roberts, JS | 1 |
| Anton, RF; Dias, JK; Latham, PK; Malcolm, RJ; Moak, DH; Waid, LR | 1 |
| Adams, M; Curry, KH; Zador, DA | 1 |
| Connors, GJ; Dermen, KH; Rychtarik, RG; Stasiewicz, PR | 1 |
| Farren, C; Krishnan-Sarin, S; O'Connor, PG; O'Malley, SS | 1 |
| Brady, KT; Sonne, SC | 1 |
| Budzyński, J; Kosmowski, W; Kłopocka, M; Rybakowski, J; Swiatkowski, M; Torliński, L; Ziółkowski, M | 1 |
| Kranzler, HR; Modesto-Lowe, V; Van Kirk, J | 1 |
| Anton, RF; Drobes, DJ | 1 |
| O'Brien, CP; Pettinati, HM; Pierce, JD; Volpicelli, JR | 1 |
| Ait-Daoud, N; Johnson, BA; Prihoda, TJ | 1 |
| Ait-Daoud, N; Johnson, BA | 1 |
| Fuller, RK; Hiller-Sturmhöfel, S | 1 |
| Busto, UE | 1 |
| Lee, SM; McCaul, ME; Rohde, C; Wand, GS | 1 |
| Colby, SM; Eaton, CA; Gordon, A; Martin, RA; Monti, PM; Mueller, TI; Rohsenow, DJ; Swift, RM | 1 |
| Maxwell, S; Shinderman, MS | 1 |
| Chabane, N; Leboyer, M; Mouren-Simeoni, MC | 1 |
| Affleck, G; Armeli, S; Kranzler, HR; Tennen, H | 1 |
| Colby, SM; Hutchison, KE; Kaplan, GB; Monti, PM; Rohsenow, DJ; Swift, RM | 1 |
| Anton, RF; Dias, JK; Latham, PK; Malcolm, RJ; Moak, DH; Roberts, JS; Waid, LR | 1 |
| Kalb, C | 1 |
| Ochoa , E | 1 |
| Brady, KT; Malcolm, R; Myrick, H | 1 |
| Connor, JP; Czajkowski, F; Feeney, GF; Tucker, J; Young, RM | 1 |
| Ait-Daoud, N; Hargita, ID; Johnson, BA; Prihoda, TJ | 1 |
| Calarco, JS; Lucey, MR; McLellan, AT; Van Horn, DH; Volpicelli, JR; Weinrieb, RM | 1 |
| Kranzler, HR; Oncken, C; Van Kirk, J | 1 |
| Alho, H; Heinälä, P; Kiianmaa, K; Kuoppasalmi, K; Lönnqvist, J; Sinclair, JD | 1 |
| Boening, JA; Lesch, OM; Mason, BJ; Narita, M; Sinclair, D; Spanagel, R; Wiesbeck, GA; Wolffgramm, J | 1 |
| Ait-Daoud, N; Javors, M; Johnson, BA; Roache, JD; Zanca, NA | 1 |
| Gual Solé, A | 1 |
| Bean, P; Mattson, M | 1 |
| Carey, TS; Crews, FT; Garbutt, JC; Jackman, AM; Lohr, KN; Lux, LJ; Tolleson-Rinehart, S; West, SL | 1 |
| Gordon, SM | 1 |
| Korpi, E; Seppälä, T | 1 |
| Boedeker, KL; Douglass, AV; Hubbell, CL; Reid, LD; Reid, ML | 1 |
| Kranzler, HR; Van Kirk, J | 1 |
| Cornelius, JD; Salloum, IM; Thase, ME | 1 |
| Borrow, J; O'Leary, G; Weiss, RD | 1 |
| Abrams, DB; Asher, MK; Brown, RA; Colby, SM; Gordon, A; Gulliver, SB; Monti, PM; Mueller, TI; Niaura, RS; Rohsenow, DJ; Swift, RM | 1 |
| Yarborough, WH | 1 |
| Cramer, JA; Kirk, GF; Krol, WF; Krystal, JH; Rosenheck, RA | 1 |
| Fuller, RK; Gordis, E | 1 |
| Drummond, E; Gardiner, J; Hopwood, M; Morris, PL; Whelan, G | 1 |
| Drummond, C | 1 |
| Chick, J | 1 |
| Farren, C; Kreek, MJ; Krishnan-Sarin, S; O'Malley, SS; Sinha, R | 1 |
| Dhopesh, V; Fudala, PJ; Yu, E | 1 |
| Manzanares, J; Ponce, G; Rubio, G | 1 |
| Alho, H; Shinderman, M; Sinclair, JD | 1 |
| Borg, L; Gunduz, M; Ho, A; King, AC; Kreek, MJ; Perret, G; Schluger, J | 1 |
| Kopczyńska, E; Lampka, M; Torliński, L; Ziółkowski, M | 1 |
| Houseman, J; Jurd, S; Latt, NC; Wutzke, SE | 1 |
| Fideli, LP; Lejoyeux, M | 1 |
| Graham, R; Whelan, G; Wodak, AD | 1 |
| Hunt, RR | 1 |
| Ladewig, D | 1 |
| Lewis, DC | 1 |
| Alterman, AI; Hayashida, M; O'Brien, CP; Volpicelli, JR | 1 |
| Kosten, TA; Kosten, TR | 1 |
| Meyer, RE | 2 |
| Cammera, P; Griffiths, W; Swift, RM | 1 |
| Kotlińska, J; Langwiński, R | 1 |
| Van Ree, JM | 1 |
| Peachey, JE | 1 |
238 review(s) available for naltrexone and Alcoholism
| Article | Year |
|---|---|
Pharmacological interventions for alcohol misuse in correctional settings: A systematic review.
Topics: Alcohol Deterrents; Alcoholism; Correctional Facilities; Criminal Behavior; Disulfiram; Humans; Naltrexone; Recidivism; Treatment Outcome | 2022 |
Review of Evidence-Based Strategies to Treat Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone | 2021 |
Treatment of alcohol use disorder in patients with liver disease.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Liver Diseases; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2022 |
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate | 2022 |
Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Disulfiram; Humans; Naltrexone | 2022 |
Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Humans; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); National Institutes of Health (U.S.); United States | 2022 |
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
Topics: Acamprosate; Adolescent; Alcohol Drinking; Alcoholism; Disulfiram; Humans; Naltrexone; Primary Health Care; Randomized Controlled Trials as Topic; United States | 2023 |
The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.
Topics: Alcoholism; Analgesics, Opioid; Depressive Disorder, Major; Humans; Naltrexone; Narcotic Antagonists; Opioid Peptides; Opioid-Related Disorders | 2023 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; Middle Aged; Naltrexone | 2023 |
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; Naltrexone; Ondansetron; Topiramate | 2023 |
Overview of Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Child; Disulfiram; Ethanol; Humans; Naltrexone; United States | 2023 |
Medication treatment for alcohol use disorder in special populations.
Topics: Acamprosate; Adolescent; Alcoholism; Analgesics, Opioid; Disulfiram; Humans; Naltrexone; Narcotic Antagonists | 2023 |
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Drug-Related Side Effects and Adverse Reactions; Humans; Naltrexone; Prospective Studies; Psychosocial Intervention; Quality of Life; United States | 2023 |
Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Drug Development; Humans; Naltrexone | 2020 |
Safety of nalmefene for the treatment of alcohol use disorder: an update.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Drug Approval; Humans; Naltrexone; Narcotic Antagonists | 2020 |
Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Female; Genotype; Humans; Male; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Recurrence | 2020 |
[Pharmacological profile and clinical findings of nalmefene (Selincro
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials, Phase III as Topic; Humans; Japan; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Rats; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2020 |
Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.
Topics: Adult; Alcoholism; Female; HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome; Young Adult | 2020 |
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Disulfiram; Evidence-Based Medicine; Humans; Mass Screening; Naltrexone; Off-Label Use; Practice Guidelines as Topic | 2020 |
[Pharmacotherapy of alcohol withdrawal: update and new developments].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2021 |
Pharmacotherapies and personalized medicine for alcohol use disorder: a review.
Topics: Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Pharmacogenetics; Pharmacogenomic Testing; Precision Medicine | 2020 |
Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Animals; Comorbidity; Disulfiram; Female; Fetal Alcohol Spectrum Disorders; Humans; Naltrexone; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Substance Withdrawal Syndrome | 2021 |
Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Time Factors; Treatment Outcome | 2022 |
Alcohol Use Disorder: The Role of Medication in Recovery.
Topics: Acamprosate; Alcoholism; Humans; Naltrexone; Pharmaceutical Preparations; Quality of Life; United States | 2021 |
A meta-regression of methodological features that predict the effects of medications on the subjective response to alcohol.
Topics: Adolescent; Adult; Affect; Aged; Aged, 80 and over; Alcohol Drinking; Alcoholism; Behavior; Breath Tests; Child; Craving; Dose-Response Relationship, Drug; Ethanol; Humans; Hypnotics and Sedatives; Middle Aged; Naltrexone; Treatment Outcome; Young Adult | 2021 |
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.
Topics: Alcohol Deterrents; Alcoholism; Female; Genome-Wide Association Study; Humans; Male; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Taurine; Treatment Outcome | 2021 |
Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
Topics: Alcoholism; Analgesics, Opioid; Animals; Drug Interactions; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Substance Withdrawal Syndrome | 2017 |
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome | 2018 |
Addressing unhealthy alcohol use among people living with HIV: recent advances and research directions.
Topics: Alcohol Deterrents; Alcoholism; Biomedical Research; Disease Management; HIV Infections; Humans; Mass Screening; Naltrexone; Referral and Consultation; Treatment Outcome | 2018 |
Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions.
Topics: Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Humans; Naltrexone; Outcome Assessment, Health Care | 2018 |
Advances in Pharmacotherapy Development: Human Clinical Studies.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone | 2018 |
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans; Naltrexone; Quetiapine Fumarate | 2018 |
Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taurine; Treatment Outcome | 2018 |
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Disulfiram; Humans; Naltrexone; Taurine | 2018 |
Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Clinical Trials as Topic; Disulfiram; Naltrexone; Practice Patterns, Physicians'; Topiramate; United States; United States Department of Veterans Affairs; Veterans | 2019 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapentin; Humans; Naltrexone; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis.
Topics: Affect; Alcohol Deterrents; Alcoholism; Central Nervous System Depressants; Craving; Ethanol; Humans; Hypnotics and Sedatives; Naltrexone | 2019 |
[Ingestion of anabolic steroids and ischaemic stroke. A clinical case report and review of the literature].
Topics: Adult; Alcoholism; Anabolic Agents; Brain Ischemia; Cerebral Angiography; Clenbuterol; Doping in Sports; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Male; Martial Arts; Mechanical Thrombolysis; Naltrexone; Nandrolone; Nandrolone Decanoate; Stanozolol; Steroids; Substance-Related Disorders; Testosterone Propionate; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2013 |
Medications for unhealthy alcohol use: across the spectrum.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2011 |
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain Chemistry; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2008 |
Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials.
Topics: Alcoholism; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Psychotherapy; Treatment Outcome | 2013 |
Opioid pharmacogenetics of alcohol addiction.
Topics: Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Humans; Mice; Mutation, Missense; Naltrexone; Polymorphism, Single Nucleotide; Receptors, Opioid, mu | 2013 |
Medications for substance use disorders.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Behavior Therapy; Behavior, Addictive; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Disorder | 2013 |
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate | 2013 |
Pharmacotherapy for alcohol dependence: status of current treatments.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Taurine | 2013 |
[Alcohol dependence and mental adaptation disorders (the use of injectable extended-release naltrexone)].
Topics: Adaptation, Psychological; Alcoholism; Delayed-Action Preparations; Humans; Injections; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2013 |
Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Biomedical Research; Drug Industry; Health Services Needs and Demand; Humans; Insurance, Health, Reimbursement; Naltrexone; Narcotic Antagonists; Taurine | 2014 |
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2013 |
Nalmefene: a review of its use in the treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Humans; Internationality; Naltrexone; Randomized Controlled Trials as Topic | 2013 |
[Nalmefene: a novel pharmacotherapeutic option for alcoholism].
Topics: Alcoholism; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2014 |
Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2014 |
Nalmefene for the treatment of alcohol dependence: a current update.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2014 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate | 2013 |
Anticonvulsants for alcohol dependence.
Topics: Adult; Alcohol Abstinence; Alcoholism; Anticonvulsants; Female; Humans; Male; Naltrexone; Patient Dropouts; Randomized Controlled Trials as Topic; Risk Assessment | 2014 |
Bad medicine: nalmefene in alcohol misuse.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents | 2014 |
Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2014 |
Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
Topics: Alcoholism; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Humans; Micelles; Naltrexone; Nanoparticles; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Topics: Alcoholism; Delayed-Action Preparations; Health Care Costs; Humans; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
Nalmefene and its use in alcohol dependence.
Topics: Alcoholism; Drug Interactions; Humans; Naltrexone | 2014 |
A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bayes Theorem; Humans; Naltrexone; Randomized Controlled Trials as Topic; Review Literature as Topic; Taurine | 2014 |
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; Ethanol; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Plant Preparations; Receptors, GABA-A; Taurine; Topiramate | 2014 |
Pharmacologic treatment of alcoholism.
Topics: Acamprosate; Alcoholism; Animals; Brain; Humans; Naltrexone; Nerve Net; Neuroimaging; Pharmacogenetics; Taurine; Valproic Acid | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine | 2014 |
[Place of the opioid system in biology and treatment of Alcohol Use Disorder].
Topics: Alcoholism; Brain; Craving; Diagnostic and Statistical Manual of Mental Disorders; Dynorphins; Endorphins; Humans; International Classification of Diseases; Naltrexone; Neurotransmitter Agents; Receptors, Opioid | 2014 |
[Benefits in reducing alcohol consumption: how nalmefene can help].
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Cause of Death; Europe; Female; Humans; Male; Middle Aged; Naltrexone; Risk Factors; Treatment Outcome; Young Adult | 2014 |
[Nalmefene (Selincro) orally].
Topics: Administration, Oral; Alcohol Deterrents; Alcoholism; Humans; Naltrexone | 2014 |
Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Europe; Female; Global Health; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Recurrence; Taurine; Treatment Outcome | 2015 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Social Support | 2015 |
Nalmefene: A Novel Drug for an Old Disorder.
Topics: Alcohol Drinking; Alcoholism; Animals; Humans; Naltrexone | 2015 |
Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Benzodiazepines; Disulfiram; Female; Humans; Male; Naltrexone; Sex Factors; Taurine; Treatment Outcome | 2016 |
Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Randomized Controlled Trials as Topic | 2015 |
[Depression in alcohol addicted patients].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Taurine | 2015 |
Opioid Receptor Antagonists in the Treatment of Alcoholism.
Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists | 2015 |
Naltrexone: Not Just for Opioids Anymore.
Topics: Alcoholism; Animals; Behavior, Addictive; Delayed-Action Preparations; Drug Compounding; Humans; Injections; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Treatment Outcome | 2016 |
Should naltrexone be the first-line medicine to treat alcohol dependence in Aboriginal and Torres Strait Islander populations? An Australian perspective.
Topics: Alcoholism; Australia; Health Services Accessibility; Health Services, Indigenous; Humans; Naltrexone; Narcotic Antagonists; Native Hawaiian or Other Pacific Islander | 2015 |
Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2015 |
Opioid antagonists in broadly defined behavioral addictions: a narrative review.
Topics: Alcoholism; Bulimia; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Randomized Controlled Trials as Topic; Trichotillomania | 2016 |
Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.
Topics: Alcoholism; Analgesics, Opioid; Animals; Genotype; Humans; Models, Animal; Naltrexone; Reward | 2016 |
Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
Topics: Alcoholism; Animals; Clinical Trials, Phase III as Topic; Harm Reduction; Hospitalization; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2016 |
The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol Dependence.
Topics: Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Health Care Costs; Humans; Markov Chains; Models, Economic; Naltrexone; Psychotherapy; Quality-Adjusted Life Years; Treatment Outcome | 2016 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Nature and Treatment of Comorbid Alcohol Problems and Post Traumatic Stress Disorder Among American Military Personnel and Veterans.
Topics: Alcoholism; Behavior Therapy; Cognitive Behavioral Therapy; Comorbidity; Humans; Military Personnel; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic; United States; Veterans | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.
Topics: Alcoholism; Drug Approval; Europe; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic; United Kingdom | 2016 |
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain; Disulfiram; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Minisatellite Repeats; Monoamine Oxidase; Naltrexone; Narcotic Antagonists; Neuropeptide Y; Norepinephrine; Ondansetron; Polymorphism, Genetic; Serotonin; Synaptic Transmission; Taurine | 2016 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis - Comment to Naudet.
Topics: Alcoholism; Appetite Depressants; Humans; Naltrexone; Narcotic Antagonists | 2016 |
Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies.
Topics: Alcohol Drinking; Alcoholism; Central Nervous System Depressants; Craving; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Research Design; Self Administration | 2017 |
Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
Topics: Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 2016 |
Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bioethical Issues; Disulfiram; Humans; Naltrexone; Taurine | 2017 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome | 2017 |
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Taurine | 2017 |
Pharmacogenetic treatments for drug addiction: alcohol and opiates.
Topics: Alcoholism; beta-Endorphin; Buprenorphine; Cytochrome P-450 CYP2D6; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, Opioid, mu | 2008 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Single-Blind Method; Taurine | 2008 |
Naltrexone for the management of alcohol dependence.
Topics: Adult; Alcoholism; Combined Modality Therapy; Dopamine; Humans; Male; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic | 2008 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate | 2009 |
[Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].
Topics: Alcoholism; Animals; beta-Endorphin; Dopamine; GABA Antagonists; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Reinforcement, Psychology; Reward | 2008 |
[Recent results in relaps prevention of alcoholism with Disulfiram].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Aldehyde Dehydrogenase; Combined Modality Therapy; Disulfiram; Drug Interactions; Drug Therapy, Combination; Germany; Humans; Metabolic Clearance Rate; Motivation; Naltrexone; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine | 2008 |
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, Opioid; Secondary Prevention; Taurine; Temperance; Ventral Tegmental Area | 2008 |
The genetics of alcoholism.
Topics: Alcoholism; Animals; Corticotropin-Releasing Hormone; Disease Models, Animal; Excitatory Amino Acids; Genetic Predisposition to Disease; Humans; Mice; Naltrexone; Narcotic Antagonists; Rats; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Social Environment; Stress, Psychological | 2009 |
Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Brain; Brain Chemistry; Genetic Predisposition to Disease; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 2010 |
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Naltrexone; Narcotic Antagonists; Nausea | 2010 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; Fructose; Humans; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Ondansetron; Pituitary-Adrenal System; Prefrontal Cortex; Receptors, Dopamine D2; Receptors, GABA; Topiramate; Young Adult | 2010 |
Drug treatment as HIV prevention: expanding treatment options.
Topics: Alcoholism; Buprenorphine; Clinical Protocols; Drug Users; Health Promotion; HIV Infections; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Risk Reduction Behavior; Risk-Taking; Substance Abuse, Intravenous; Substance-Related Disorders | 2010 |
Nalmefene for treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone | 2010 |
Opioid antagonists for alcohol dependence.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2010 |
Intramuscular extended-release naltrexone: current evidence.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2011 |
Alcoholism: a modern look at an ancient illness.
Topics: Alcoholism; Genetic Predisposition to Disease; Humans; Naltrexone; Narcotic Antagonists; Primary Health Care; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors | 2011 |
Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
Topics: Alcoholism; Delayed-Action Preparations; Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2011 |
Opioid modulators for alcohol dependence.
Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists | 2011 |
How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognition; Humans; Naltrexone; Psychotherapy; Taurine | 2011 |
Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
Topics: Acamprosate; Alcoholism; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Naltrexone; Taurine; Treatment Outcome | 2012 |
Opioid antagonists for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine; Treatment Outcome | 2011 |
Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review.
Topics: Alcoholism; Humans; Medication Adherence; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Recurrence; Statistics, Nonparametric; Treatment Outcome | 2011 |
[Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Evidence-Based Medicine; Humans; Naltrexone; Taurine; Treatment Outcome | 2011 |
Medical treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Off-Label Use; Taurine; Topiramate; Treatment Outcome | 2011 |
Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
Topics: Alcoholism; Genotype; Heterozygote; Homozygote; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Prospective Studies; Receptors, Opioid, mu; Recurrence; Temperance | 2012 |
Clinical safety of 1500 mg oral naltrexone overdose.
Topics: Administration, Oral; Adult; Alcoholism; Behavior, Addictive; Dose-Response Relationship, Drug; Drug Overdose; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Naltrexone; Narcotic Antagonists; Patient Safety; Risk Assessment; Substance-Related Disorders | 2010 |
[Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Middle Aged; Naltrexone; Secondary Prevention; Taurine; Treatment Outcome | 2013 |
Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
Topics: Alcoholism; Alcohols; Euphoria; Genotype; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Opioid, mu | 2012 |
Improving clinical outcomes for naltrexone as a management of problem alcohol use.
Topics: Administration, Oral; Alcoholism; Biomarkers; Delayed-Action Preparations; Humans; Medication Adherence; Naltrexone; Narcotic Antagonists; Patient Selection | 2013 |
Management of alcohol abuse.
Topics: Alcoholism; Behavior Therapy; Complementary Therapies; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prevalence; Residential Treatment; Self-Help Groups; United States | 2012 |
Current status of co-occurring mood and substance use disorders: a new therapeutic target.
Topics: Alcoholism; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Double-Blind Method; Drug Therapy, Combination; Humans; Mood Disorders; Naltrexone; Narcotic Antagonists; Psychotropic Drugs; Sertraline; Substance-Related Disorders | 2013 |
The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis.
Topics: Alcoholism; Humans; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Time Factors; Treatment Outcome | 2013 |
The current situation of treatment systems for alcoholism in Korea.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Benzodiazepines; Humans; Naltrexone; Psychotherapy; Republic of Korea; Taurine | 2013 |
Pharmacotherapy of addictions.
Topics: Alcoholism; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance-Related Disorders | 2002 |
Clinical uses of naltrexone: a review of the evidence.
Topics: Alcoholism; Animals; Behavior, Addictive; Cocaine-Related Disorders; Feeding and Eating Disorders; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Opioid-Related Disorders; Schizophrenia; Self-Injurious Behavior; Substance-Related Disorders; Tobacco Use Disorder | 2002 |
Opioid peptides and the control of human ingestive behaviour.
Topics: Alcoholism; Appetite Regulation; Drinking Behavior; Feeding Behavior; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Receptors, Opioid; Reward; Substance-Related Disorders; Time Factors; Water Intoxication | 2002 |
Advances in the use of naltrexone: an integration of preclinical and clinical findings.
Topics: Alcohol Deterrents; Alcoholism; Genetic Predisposition to Disease; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Recurrence | 2003 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Double-Blind Method; Humans; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2003 |
Therapy and supportive care of alcoholics: guidelines for practitioners.
Topics: Alcohol-Related Disorders; Alcoholics Anonymous; Alcoholism; Ambulatory Care Facilities; Counseling; Day Care, Medical; Humans; Motivation; Naltrexone; Practice Guidelines as Topic; Psychotherapy, Brief; Secondary Prevention; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome; Temperance | 2003 |
Behavioral health issue brief: pharmacotherapy treatment of alcoholism and drug addiction: overview and bibliography: year end report-2002.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Buprenorphine; Drug Therapy; Humans; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; United States | 2002 |
Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive "immersion" methods of foreign language teaching.
Topics: Adaptation, Psychological; Alcohol Deterrents; Alcoholism; Behavior Control; Disulfiram; Humans; Language; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance-Related Disorders; Teaching | 2003 |
Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine | 2003 |
[Drug therapy of alcohol dependence--a critical review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2003 |
Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Brain; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Recurrence; Taurine | 2003 |
Current pharmacotherapies of alcoholism: a U.S. perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; United States | 2003 |
Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Europe; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Placebos; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Taurine; Treatment Outcome | 2003 |
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2004 |
What place does naltrexone have in the treatment of alcoholism?
Topics: Alcoholism; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Patient Compliance; Treatment Outcome | 2004 |
An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence.
Topics: Alcohol Deterrents; Alcoholism; Anticonvulsants; Behavior, Addictive; Biomarkers; Drug Therapy, Combination; Humans; Naltrexone; Serotonin Agents; Substance Withdrawal Syndrome | 2004 |
Naltrexone and pharmacy benefit management.
Topics: Alcoholism; Formularies as Topic; Health Policy; Health Services Accessibility; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Naltrexone; Narcotic Antagonists; Private Sector; Public Sector; United States | 2004 |
Recent advances in the pharmacotherapy of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Taurine; Topiramate | 2004 |
Pharmacologic management of relapse prevention in addictive disorders.
Topics: Administration, Cutaneous; Administration, Oral; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Disulfiram; Humans; Naltrexone; Narcotics; Nicotine; Smoking Cessation; Smoking Prevention; Substance-Related Disorders | 2004 |
The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence.
Topics: Alcoholism; Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Design; Drug Industry; Humans; Injections; Morphine; Naltrexone; Polymers; Rats; Receptors, Opioid, mu | 2005 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2.
Topics: Alcohol Deterrents; Alcoholism; Aripiprazole; Behavior Therapy; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Pharmacogenetics; Piperazines; Quinolones; Topiramate | 2004 |
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
Topics: Alcoholism; Clinical Trials as Topic; Cocaine-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Opioid-Related Disorders; Structure-Activity Relationship; Substance-Related Disorders; Tobacco Use Disorder | 2005 |
Opioid antagonists for alcohol dependence.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2005 |
Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; Cognitive Behavioral Therapy; Confidence Intervals; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Prospective Studies; Time Factors; Treatment Outcome | 2005 |
Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies?
Topics: Alcohol Drinking; Alcoholism; Humans; Models, Statistical; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Placebos; Publishing; Randomized Controlled Trials as Topic; Recurrence; Regression Analysis; Research Design | 2005 |
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Psychotropic Drugs; Secondary Prevention; Substance-Related Disorders; Tobacco Use Disorder | 2005 |
Combining treatments for alcoholism: why and how?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Taurine | 2005 |
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Topics: Acamprosate; Alcohol Dehydrogenase; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy; Genetic Markers; Genotype; Haplotypes; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine | 2005 |
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2005 |
Pharmacotherapy of alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Comorbidity; Disulfiram; Dopamine; Drug Interactions; Ethanol; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Male; Mental Disorders; Naltrexone; Narcotics; Serotonin; Taurine | 2005 |
Medications for treating alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; Treatment Outcome | 2005 |
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Naltrexone; Rodentia; Taurine | 2005 |
A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence.
Topics: Alcoholism; Clinical Trials as Topic; Humans; Long-Term Care; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychotherapy; Research Design | 2006 |
Alcoholism and suicidal behavior: a clinical overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; Depressive Disorder, Major; Humans; Hydroxyindoleacetic Acid; Naltrexone; Narcotic Antagonists; Personality Disorders; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Suicide; Suicide, Attempted; Taurine | 2006 |
Vivitrex (Alkermes/Cephalon).
Topics: Alcoholism; Animals; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate | 2006 |
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans; Models, Biological; Models, Neurological; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Neurons; Polymorphism, Genetic; Receptors, Opioid, mu; Recurrence; Taurine | 2006 |
A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence.
Topics: Administration, Oral; Alcoholism; Animals; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Sex Factors; Therapeutic Equivalency | 2006 |
Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
Topics: Alcohol Deterrents; Alcoholism; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Schizophrenia; Substance-Related Disorders; Treatment Outcome | 2006 |
Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.
Topics: Alcoholism; Animals; Choice Behavior; Disease Models, Animal; Excitatory Amino Acid Antagonists; Ibogaine; Naltrexone; Narcotics; Phytotherapy; Piperazines; Point Mutation; Pueraria; Rats; Rats, Inbred Strains; Receptors, Opioid; Serotonin; Serotonin Antagonists | 2006 |
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
Topics: Alcoholism; Alleles; Humans; Naltrexone; Narcotics; Polymorphism, Genetic; Receptors, Opioid, mu | 2006 |
Continuing care in the treatment of addictive disorders.
Topics: Alcoholism; Chronic Disease; Cognitive Behavioral Therapy; Continuity of Patient Care; Counseling; Humans; Naltrexone; Narcotic Antagonists; Retention, Psychology; Secondary Prevention | 2006 |
Choosing the right medication for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Choice Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate | 2006 |
Extended-release intramuscular naltrexone.
Topics: Adult; Alcoholism; Animals; Delayed-Action Preparations; Headache; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Nausea | 2006 |
Extended-release intramuscular naltrexone: a viewpoint by Falk Kiefer.
Topics: Administration, Oral; Alcoholism; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2006 |
[Neurobiological mechanisms and pharmacological treatment options for alcohol craving].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Neurotransmitter Agents; Receptors, Glutamate; Taurine | 2007 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate | 2006 |
The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Double-Blind Method; History, 20th Century; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Recurrence; Research Design; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
Trends in the adoption of medications for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine; United States | 2006 |
[Pharmacological relapse prevention in alcohol and tobacco dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder | 2007 |
Extended-release intramuscular naltrexone in alcohol dependence in adults: profile report.
Topics: Adult; Alcoholism; Drug Delivery Systems; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists | 2007 |
New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials.
Topics: Adult; Alcoholism; Analysis of Variance; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Retrospective Studies; Sample Size; Treatment Outcome | 2007 |
Preclinical and clinical pharmacology of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Dopamine; GABA Modulators; Glutamic Acid; Humans; Naltrexone; Narcotic Antagonists; Serotonin; Taurine | 2007 |
[Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].
Topics: Alcohol Deterrents; Alcoholism; Algorithms; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clinical Trials as Topic; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Schizophrenia; Substance-Related Disorders | 2008 |
Contingency management for treatment of substance abuse.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Patient Compliance; Reinforcement, Psychology; Substance-Related Disorders; Token Economy; Treatment Outcome | 2006 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2008 |
[Trends in therapy for alcoholism].
Topics: Alcoholism; Animals; Cognitive Behavioral Therapy; Family; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy, Group; Self-Help Groups; Social Support | 2007 |
Long-acting injectable naltrexone for the treatment of alcohol dependence.
Topics: Alcoholism; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists | 2007 |
Treatment of alcohol and other drug dependence.
Topics: Alcoholism; Behavior, Addictive; Comorbidity; Humans; Methadone; Naltrexone; Psychotherapy; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome | 2007 |
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Publication Bias; Secondary Prevention; Taurine | 2008 |
[Alcohol dependence: diagnosis and treatment].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Motivation; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine | 2008 |
The role of endorphins in opiate addiction, opiate withdrawal, and recovery.
Topics: Alcoholism; Brain; Endorphins; Humans; Hypothalamo-Hypophyseal System; Locus Coeruleus; Naltrexone; Norepinephrine; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Naltrexone in alcohol dependence.
Topics: Alcoholism; Animals; Clinical Trials as Topic; Double-Blind Method; Drug Approval; Humans; Naltrexone; Patient Compliance; Social Support; United States; United States Food and Drug Administration | 1995 |
Effect of naltrexone on human alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Humans; Naltrexone; Narcotic Antagonists; Opioid Peptides | 1995 |
Recent developments in alcoholism:opioid peptides.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Clinical Trials as Topic; Endorphins; Humans; Naltrexone; Neurotransmitter Agents; Receptors, Opioid | 1993 |
Neuropeptides and alcohol addiction in monkeys.
Topics: Alcoholism; Animals; beta-Endorphin; Ethanol; Humans; Macaca mulatta; Male; Morphine; Naltrexone; Neuropeptides; Rats; Reinforcement, Psychology; Self Administration | 1994 |
Treatment of alcoholism as a chronic disorder.
Topics: Adult; Alcoholism; Animals; Chronic Disease; Clinical Trials as Topic; Endorphins; Humans; Naltrexone; Patient Compliance; Recurrence | 1994 |
The efficacy of controlled trials of alcohol misuse treatments in maintaining abstinence: a meta-analysis.
Topics: Alcoholism; Cost-Benefit Analysis; Humans; Naltrexone; Randomized Controlled Trials as Topic; Temperance; Treatment Outcome | 1994 |
Naltrexone in the treatment of alcohol dependence.
Topics: Alcoholism; Animals; Breath Tests; Humans; Naltrexone; Randomized Controlled Trials as Topic; Recurrence; Surveys and Questionnaires | 1994 |
Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.
Topics: Alcoholism; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Randomized Controlled Trials as Topic; Recurrence; Time Factors | 1995 |
Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.
Topics: Alcoholism; Biomarkers; Humans; Motivation; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid Peptides; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 1996 |
Closing the gap between alcoholism research and practice: the case for pharmacotherapy.
Topics: Alcoholism; Antidepressive Agents, Tricyclic; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Research; Serotonin Agents | 1996 |
Dosing issues in the pharmacotherapy of alcoholism.
Topics: Administration, Oral; Adult; Alcoholism; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Imipramine; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 1996 |
A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.
Topics: Alcoholism; Dose-Response Relationship, Drug; Drug Interactions; Drug Overdose; Humans; Liver; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Risk Assessment; Substance-Related Disorders | 1996 |
[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
Topics: Alcoholism; Delayed-Action Preparations; Follow-Up Studies; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Treatment Outcome | 1996 |
Endogenous opioid systems and alcohol addiction.
Topics: Alcohol Drinking; Alcoholism; Animals; Ethanol; Humans; Mesencephalon; Naltrexone; Narcotic Antagonists; Narcotics; Receptors, Opioid | 1997 |
Naltrexone in the treatment of alcoholism.
Topics: Alcoholism; Double-Blind Method; Drug Approval; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 1997 |
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans; Naltrexone; Narcotic Antagonists; Neurons; Rats; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Synaptic Transmission; Taurine | 1997 |
Naltrexone in alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 1997 |
The pharmacological treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine | 1997 |
Naltrexone for the treatment of alcoholism.
Topics: Alcoholism; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Physician's Role; Primary Health Care | 1997 |
Treatment of alcohol dependence.
Topics: Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1997 |
Developments in the treatment of alcoholism.
Topics: Alcohol Deterrents; Alcoholism; Anti-Anxiety Agents; Benzodiazepines; Continuity of Patient Care; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy | 1998 |
Advances in development of medications for alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Drug Therapy, Combination; Humans; Naltrexone; Taurine | 1998 |
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions.
Topics: Alcoholism; Bromocriptine; Dopamine Agonists; Female; Fluoxetine; Humans; Male; Models, Psychological; Naltrexone; Narcotic Antagonists; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic | 1996 |
Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Recurrence | 1996 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 1999 |
Consensus Conference on the Neuropharmacology of Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Amsterdam, The Netherlands, September 16-17, 1994.
Topics: Alcoholism; Animals; Brain Chemistry; Humans; Naltrexone; Narcotic Antagonists; Neurochemistry; Neuropharmacology | 1996 |
Pharmacological treatment of alcohol dependence: a review of the evidence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Lithium; Naltrexone; Narcotic Antagonists; Serotonin Agents; Taurine | 1999 |
[Evaluation of drug treatment of primary alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Self-Help Groups; Taurine; Treatment Outcome | 1999 |
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, N-Methyl-D-Aspartate; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine | 2000 |
Alcoholism treatment in the United States. An overview.
Topics: Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome; United States | 1999 |
Opioid antagonists for alcohol dependence.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2000 |
Opiate antagonists in children and adolescents.
Topics: Adolescent; Adolescent Psychiatry; Alcoholism; Autistic Disorder; Child; Feeding and Eating Disorders; Female; Humans; Intellectual Disability; Male; Naltrexone; Narcotic Antagonists | 2000 |
[Naltrexone in the treatment of alcohol addiction].
Topics: Alcoholism; Humans; Morphinans; Naltrexone | 2000 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carbamazepine; Drug Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Ritanserin; Serotonin Agents; Sodium Oxybate; Substance Withdrawal Syndrome; Taurine; Valproic Acid; Vigabatrin | 2001 |
Adverse effects of oral naltrexone: analysis of data from two clinical trials.
Topics: Administration, Oral; Adult; Affective Symptoms; Alcoholism; Chi-Square Distribution; Cross-Sectional Studies; Fatigue; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Models, Biological; Models, Psychological; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Secondary Prevention | 2001 |
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Naltrexone; Narcotic Antagonists; Prosencephalon; Rats; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Serotonin Agents; Taurine | 2001 |
Pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Health Policy; Humans; Lithium; Naltrexone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; United States | 1999 |
[Alcohol--mechanism of action, interactions and treatment of alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine | 1998 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
Pharmacologic approaches to the management of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Clinical Trials as Topic; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2001 |
Comorbid alcoholism and depression: treatment issues.
Topics: Alcohol Deterrents; Alcoholism; Antidepressive Agents; Clinical Trials as Topic; Combined Modality Therapy; Comorbidity; Counseling; Depressive Disorder; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Alcohol abuse and alcoholism: an overview.
Topics: Alcohol-Related Disorders; Alcoholism; Attitude to Health; Clinical Trials as Topic; Cost Savings; Female; Health Care Costs; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Prevalence; Stereotyping; Treatment Outcome; United States | 2001 |
Opioid antagonists in the treatment of alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2001 |
[Long-term treatment of alcohol dependance].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Disulfiram; Family Therapy; Humans; Long-Term Care; Naltrexone; Psychotherapy; Self-Help Groups; Social Support; Social Work; Taurine; Treatment Outcome | 2002 |
Opioid antagonists for alcohol dependence.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2002 |
New pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Self-Help Groups; Taurine; Treatment Outcome | 2002 |
Clinical inquiries. How effective are pharmacologic agents for alcoholism?
Topics: Alcoholism; Clinical Trials as Topic; Counseling; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic; Recurrence | 2002 |
[The treatment of drug-dependence (author's transl)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Alcoholism; Amphetamines; Barbiturates; Communication; Drug Tolerance; Female; Halfway Houses; Humans; Male; Methadone; Middle Aged; Morphine Dependence; Motivation; Naltrexone; Personality Disorders; Psychotherapy; Social Control, Formal; Social Control, Informal; Substance-Related Disorders | 1978 |
Pharmacological blocking agents for treating substance abuse.
Topics: Alcoholism; Animals; Behavior Therapy; Disulfiram; Drug Antagonism; Drug Design; Humans; Naltrexone; Narcotic Antagonists; Neurosciences; Opioid-Related Disorders; Rats; Substance-Related Disorders | 1991 |
Prospects for a rational pharmacotherapy of alcoholism.
Topics: Alcoholism; Animals; Benzodiazepines; Cognition; Ethanol; Humans; Naltrexone; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1989 |
296 trial(s) available for naltrexone and Alcoholism
| Article | Year |
|---|---|
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Topics: Adult; Alcoholism; Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Injections, Intramuscular; Middle Aged; Models, Econometric; Naltrexone; Narcotic Antagonists; Primary Health Care; Socioeconomic Factors | 2019 |
Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.
Topics: Alcoholism; Ethanol; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Naltrexone; Polymorphism, Single Nucleotide; Treatment Outcome | 2021 |
Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone.
Topics: Alcoholism; Female; HIV Infections; Homosexuality, Male; Humans; Male; Naltrexone; Peru; Sexual and Gender Minorities; Transgender Persons | 2022 |
Naltrexone moderates the association of alcohol use and affect among adolescent drinkers in daily life.
Topics: Adolescent; Alcohol Deterrents; Alcoholism; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Naltrexone; Underage Drinking | 2022 |
Within- and between-person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation.
Topics: Alcohol Drinking; Alcoholism; Craving; Double-Blind Method; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Young Adult | 2022 |
Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis.
Topics: Alcohol Drinking; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists | 2022 |
ON-ICE trial: Investigation of the combined effects of oxytocin and naltrexone on stress-induced and alcohol cue-induced craving in alcohol use disorder-Study protocol of a phase II randomised double-blind placebo-controlled parallel-group trial.
Topics: Alcoholism; Clinical Trials, Phase II as Topic; Craving; Cues; Humans; Naltrexone; Neoplasm Recurrence, Local; Oxytocin; Randomized Controlled Trials as Topic | 2022 |
The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting-state fMRI study.
Topics: Alcoholism; Brain Mapping; Cross-Over Studies; Female; Humans; Magnetic Resonance Imaging; Naltrexone | 2022 |
Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Treatment Outcome; World Health Organization | 2022 |
Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial.
Topics: Alcohol Drinking; Alcoholism; Binge Drinking; Ethanol; Humans; Male; Naltrexone; Sexual and Gender Minorities | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; Naltrexone; Patient Readmission; Pilot Projects; Young Adult | 2022 |
Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Naltrexone; Treatment Outcome; Varenicline; World Health Organization | 2022 |
Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial.
Topics: Alcohol Drinking; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists | 2023 |
Low rates of prescribing alcohol relapse prevention medicines in Australian Aboriginal Community Controlled Health Services.
Topics: Acamprosate; Adult; Alcoholism; Australia; Australian Aboriginal and Torres Strait Islander Peoples; Chronic Disease; Disulfiram; Health Services, Indigenous; Humans; Male; Middle Aged; Naltrexone; Secondary Prevention | 2023 |
Opioid receptor antagonism and neural response to monetary rewards: Pilot studies in light and heavy alcohol users.
Topics: Alcoholism; Analgesics, Opioid; Humans; Magnetic Resonance Imaging; Naltrexone; Narcotic Antagonists; Pilot Projects; Receptors, Opioid; Reward | 2023 |
Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Precision Medicine; Reward; Treatment Outcome | 2019 |
Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
Topics: Alcohol Drinking; Alcoholism; Elasticity; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2020 |
The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study.
Topics: Adult; Aged; Alcoholism; Cross-Over Studies; Double-Blind Method; Emotions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Psychomotor Performance; Treatment Outcome | 2019 |
An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Topics: Adult; Age Factors; Alcohol Abstinence; Alcohol Drinking; Alcoholism; DNA Methylation; Double-Blind Method; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Pharmacogenomic Variants; Promoter Regions, Genetic; Receptors, Opioid, mu; Recurrence; Time Factors; Treatment Outcome; United States | 2020 |
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Female; Health Surveys; Humans; Male; Mental Health; Middle Aged; Motivational Interviewing; Naltrexone; Risk; Treatment Outcome; United Kingdom; United States; World Health Organization | 2020 |
Drink goal difficulty effect on outcomes in moderation-based alcohol treatment for sexual minority men.
Topics: Alcohol Drinking; Alcoholism; Goals; Humans; Male; Naltrexone; Sexual and Gender Minorities; Treatment Outcome | 2020 |
Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy.
Topics: Administration, Oral; Adolescent; Adult; Alcoholism; Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Naltrexone; Safety; Transgender Persons; Treatment Outcome; Young Adult | 2020 |
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Outcome Assessment, Health Care; Schizophrenia | 2020 |
Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Time Factors | 2020 |
Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Topics: Alcoholism; Catechol O-Methyltransferase; Dopamine Plasma Membrane Transport Proteins; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Treatment Outcome | 2020 |
Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder.
Topics: Acamprosate; Adult; Age of Onset; Alcohol Deterrents; Alcoholism; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Patient Acceptance of Health Care; Socioeconomic Factors; Treatment Outcome | 2020 |
A novel human laboratory model for screening medications for alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Humans; Laboratories; Naltrexone; Varenicline | 2020 |
Reward drinking and naltrexone treatment response among young adult heavy drinkers.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Blood Alcohol Content; Female; Humans; Male; Naltrexone; Reward; Young Adult | 2021 |
Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial.
Topics: Alcoholism; Chronic Pain; HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Pilot Projects; Treatment Outcome | 2023 |
Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
Topics: Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Community Mental Health Centers; Delayed-Action Preparations; Female; Harm Reduction; Humans; Ill-Housed Persons; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Quality of Life | 2021 |
Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.
Topics: Adult; Alcoholism; Craving; Cross-Over Studies; Cues; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Prospective Studies; Ventral Striatum; Young Adult | 2021 |
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.
Topics: Adult; Alcoholism; Cartilage Oligomeric Matrix Protein; DNA Methylation; Dopamine Plasma Membrane Transport Proteins; Epigenesis, Genetic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Receptors, Opioid, mu; Treatment Outcome | 2022 |
Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Topics: Alcoholism; Brain; Brain Mapping; Cues; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenomic Variants; Prognosis; Receptors, Opioid, mu; Reward; Severity of Illness Index; Single-Blind Method; Smoking; Visual Perception | 2017 |
Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof-of-Concept Study.
Topics: Administration, Oral; Adult; Aged; Alcoholism; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Pilot Projects; Proof of Concept Study; Treatment Outcome | 2017 |
Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results.
Topics: Adult; Alcoholism; Black or African American; Double-Blind Method; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Substance-Related Disorders | 2017 |
Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine Outpatient Treatment of Alcohol-Dependent Patients.
Topics: Acamprosate; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Outpatients; Psychoanalytic Therapy; Psychotherapy, Group; Recurrence; Secondary Prevention; Taurine; Treatment Outcome | 2018 |
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Phosphatidylethanol in Comparison to Self-Reported Alcohol Consumption Among HIV-Infected Women in a Randomized Controlled Trial of Naltrexone for Reducing Hazardous Drinking.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Female; Glycerophospholipids; HIV Infections; Humans; Middle Aged; Naltrexone; Self Report | 2018 |
Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Phenotype; Precision Medicine; Reward; Treatment Outcome | 2018 |
Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.
Topics: Adult; Alcoholism; Craving; Cues; Double-Blind Method; Ecological Momentary Assessment; Female; Humans; Male; Monitoring, Ambulatory; Naltrexone; Narcotic Antagonists; Receptors, Dopamine D4; Treatment Outcome | 2018 |
Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Naltrexone; Nicotine; Sialoglycoproteins; Smoking; Transferrin; Treatment Outcome; Young Adult | 2018 |
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Placebos; Prisoners; RNA, Viral; Viral Load | 2018 |
Patient predictors of substance use disorder treatment initiation in primary care.
Topics: Adult; Age Factors; Alcoholism; Buprenorphine, Naloxone Drug Combination; Cognitive Behavioral Therapy; Cooperative Behavior; Female; Health Services Accessibility; Humans; Logistic Models; Male; Middle Aged; Motivational Interviewing; Multivariate Analysis; Naltrexone; Opioid-Related Disorders; Primary Health Care; Psychotherapy, Brief; Sex Factors | 2018 |
Post-intervention Durability of Alcohol Care Management: 1-Year Follow-up of a Randomized Controlled Trial.
Topics: Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Primary Health Care; Single-Blind Method | 2018 |
Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Reported Outcome Measures; Receptors, Opioid, mu; Treatment Outcome | 2018 |
A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?
Topics: Adult; Alcoholism; Behavior, Addictive; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Risk | 2019 |
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Anti-Retroviral Agents; CD4 Lymphocyte Count; Counseling; Delayed-Action Preparations; Double-Blind Method; Female; HIV; HIV Infections; Humans; Injections, Intramuscular; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2019 |
Predictors of treatment initiation for alcohol use disorders in primary care.
Topics: Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Multivariate Analysis; Naltrexone; Patient Acceptance of Health Care; Primary Health Care; Psychotherapy, Brief; Time Factors | 2018 |
Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Topics: Adolescent; Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Clinical Protocols; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Gene Frequency; Homozygote; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; New South Wales; Pharmacogenomic Variants; Prospective Studies; Receptors, Kainic Acid; Receptors, Opioid, mu; Recurrence; Research Design; Time Factors; Topiramate; Treatment Outcome; Young Adult | 2018 |
Drinking goals and attainment in a naltrexone trial of young adult heavy drinkers.
Topics: Adolescent; Adult; Alcoholism; Combined Modality Therapy; Counseling; Double-Blind Method; Female; Goals; Humans; Male; Naltrexone; Narcotic Antagonists; Treatment Outcome; Young Adult | 2018 |
Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Craving; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Reference Values; Treatment Outcome | 2019 |
Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Impulsive Behavior; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Psychomotor Performance; Substance-Related Disorders; Young Adult | 2019 |
Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.
Topics: Adult; Alcoholism; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Neuroprotective Agents; Primary Health Care; Psychotherapy; Treatment Outcome; Young Adult | 2018 |
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Craving; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Naltrexone; Pilot Projects | 2019 |
Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
Topics: Adult; Alcohol Drinking; Alcoholism; Breath Tests; Craving; Double-Blind Method; Drug Interactions; Ethanol; Female; Humans; Male; Naltrexone; Smokers; Smoking; Smoking Cessation; Tobacco Products; Young Adult | 2019 |
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Risk Assessment; Topiramate; Varenicline | 2019 |
Treating Alcohol Use Disorder in U.S. Veterans: The Role of Traumatic Brain Injury.
Topics: Adult; Alcohol Deterrents; Alcoholism; Brain Injuries, Traumatic; Comorbidity; Double-Blind Method; GABA Agents; Humans; Male; Middle Aged; Naltrexone; Recurrence; Stress Disorders, Post-Traumatic; United States; Valproic Acid; Veterans | 2019 |
Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
Topics: Adult; Alcoholism; Asia, Eastern; Asian People; Brain; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroimaging; Young Adult | 2019 |
Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Risk; Treatment Outcome | 2019 |
Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Feasibility Studies; Female; Humans; Male; Naltrexone; Patient Compliance; Russia; Treatment Outcome; Tuberculosis | 2013 |
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2013 |
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Naltrexone; Narcotic Antagonists; Poisson Distribution; Risk-Taking; Taurine; Temperance; Treatment Outcome | 2013 |
Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.
Topics: Adult; Alcoholism; Brain; Brain Mapping; Cues; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Volunteers | 2013 |
Aversion to injection limits acceptability of extended-release naltrexone among homeless, alcohol-dependent patients.
Topics: Administration, Oral; Alcoholism; Delayed-Action Preparations; Fear; Humans; Ill-Housed Persons; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Needles; Patient Acceptance of Health Care; Pilot Projects; Veterans | 2013 |
Cravings as a mediator and moderator of drinking outcomes in the COMBINE study.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires; Treatment Outcome | 2013 |
Training and fidelity monitoring of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia: the IMPACT Effectiveness Trial.
Topics: Alcoholism; Guideline Adherence; Naltrexone; Narcotic Antagonists; Physicians; Russia; Tuberculosis | 2013 |
Quality of life in veterans with alcohol dependence and co-occurring mental illness.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Analysis of Variance; Brief Psychiatric Rating Scale; Comorbidity; Connecticut; Diagnosis, Dual (Psychiatry); Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Massachusetts; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Psychotropic Drugs; Quality of Life; Severity of Illness Index; Treatment Outcome; Veterans | 2014 |
Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.
Topics: Adult; Alcoholism; Counseling; Female; Humans; Implosive Therapy; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Severity of Illness Index; Single-Blind Method; Stress Disorders, Post-Traumatic; Time Factors; Treatment Outcome | 2013 |
A randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics versus specialty addiction treatment.
Topics: Adult; Aged; Alcoholism; Ambulatory Care; Delivery of Health Care; Female; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Patient Selection; Primary Health Care; Single-Blind Method; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans | 2014 |
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
Topics: Adult; Alcoholism; Anti-Retroviral Agents; Delayed-Action Preparations; Double-Blind Method; Health Status; HIV Infections; Humans; Medication Adherence; Mental Health; Naltrexone; Narcotic Antagonists; Prisoners; Research Design; Risk-Taking; Secondary Prevention; Socioeconomic Factors | 2014 |
Can alcohol dependent patients adhere to an 'as-needed' medication regimen?
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Self Care; Treatment Outcome | 2014 |
Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Fructose; Humans; Naltrexone; Narcotic Antagonists; Topiramate; Treatment Outcome | 2014 |
Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2014 |
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Delayed-Action Preparations; Female; gamma-Glutamyltransferase; HIV Infections; Humans; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners | 2014 |
Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Biomarkers; Counseling; Craving; Delayed-Action Preparations; Female; Harm Reduction; Health Services; Humans; Ill-Housed Persons; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Public Assistance; Quality of Life; Research Design | 2014 |
Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
Topics: Adult; Alcoholism; Benzazepines; Brain; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2015 |
5-HTTLPR moderates naltrexone and psychosocial treatment responses in heavy drinking men who have sex with men.
Topics: Adult; Alcoholism; Cognitive Behavioral Therapy; Homosexuality, Male; Humans; Male; Middle Aged; Naltrexone; Polymorphism, Genetic; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome | 2014 |
What happens when people discontinue taking medications? Lessons from COMBINE.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Naltrexone; Patient Dropouts; Recurrence; Taurine | 2014 |
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
Topics: Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Naltrexone; Public Health; Risk Assessment; Social Support | 2014 |
In with the old and out with the new? A comparison of the old and new binge drinking standards.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholic Intoxication; Alcoholism; Binge Drinking; Counseling; Double-Blind Method; Drinking Behavior; Ethanol; Female; Humans; Male; Naltrexone; Regression Analysis; Risk Factors; Self Report; Sex Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
Topics: Adult; Alcoholism; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Predictive Value of Tests; Treatment Outcome | 2014 |
Posttraumatic stress disorder and alcohol dependence: does order of onset make a difference?
Topics: Adult; Alcoholism; Analysis of Variance; Cognitive Behavioral Therapy; Comorbidity; Female; Humans; Implosive Therapy; Male; Middle Aged; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Sex Factors; Stress Disorders, Post-Traumatic; Treatment Outcome | 2014 |
Depression outcome in alcohol dependent patients: an evaluation of the role of independent and substance-induced depression and other predictors.
Topics: Adolescent; Adult; Aged; Alcoholism; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Personality Inventory; Treatment Outcome; Young Adult | 2015 |
Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients.
Topics: Adult; Alcoholism; Ethanol; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Treatment Outcome; Ventral Striatum; Young Adult | 2014 |
Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Social Support; Treatment Outcome; Young Adult | 2015 |
A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.
Topics: Adult; Affect; Alcoholism; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Treatment Outcome | 2015 |
OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.
Topics: Alcoholism; Depressive Disorder, Major; Female; Genotype; Humans; Male; Naltrexone; Polymorphism, Single Nucleotide; Receptors, Opioid, mu | 2015 |
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Ethanol; Female; Humans; Male; Motivational Interviewing; Naltrexone; Social Facilitation; Young Adult | 2015 |
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Asparagine; Aspartic Acid; Double-Blind Method; Drug Administration Schedule; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Polymorphism, Single Nucleotide; Recurrence; Treatment Outcome | 2015 |
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2015 |
Mechanisms of symptom reduction in a combined treatment for comorbid posttraumatic stress disorder and alcohol dependence.
Topics: Adult; Alcoholism; Combined Modality Therapy; Comorbidity; Counseling; Craving; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome | 2015 |
Concurrent treatment of posttraumatic stress disorder and alcohol dependence: Predictors and moderators of outcome.
Topics: Adult; Alcoholism; Combined Modality Therapy; Comorbidity; Female; Humans; Implosive Therapy; Male; Middle Aged; Naltrexone; Outcome and Process Assessment, Health Care; Stress Disorders, Post-Traumatic | 2016 |
Personality Predictors of Drinking Outcomes in Depressed Alcohol-Dependent Patients.
Topics: Adult; Alcoholism; Character; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Personality Inventory; Prognosis; Temperament; Treatment Outcome; Young Adult | 2016 |
Therapist empathy, combined behavioral intervention, and alcohol outcomes in the COMBINE research project.
Topics: Acamprosate; Adaptation, Psychological; Affect; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Empathy; Health Personnel; Humans; Middle Aged; Naltrexone; Taurine; Treatment Outcome | 2016 |
The impact of treatment condition and the lagged effects of PTSD symptom severity and alcohol use on changes in alcohol craving.
Topics: Adult; Alcoholism; Comorbidity; Craving; Female; Humans; Implosive Therapy; Male; Naltrexone; Severity of Illness Index; Stress Disorders, Post-Traumatic; Substance-Related Disorders; Treatment Outcome | 2016 |
Predictors of dropout in concurrent treatment of posttraumatic stress disorder and alcohol dependence: Rate of improvement matters.
Topics: Adult; Alcoholism; Combined Modality Therapy; Female; Humans; Implosive Therapy; Male; Middle Aged; Naltrexone; Patient Dropouts; Predictive Value of Tests; Severity of Illness Index; Stress Disorders, Post-Traumatic; Treatment Outcome | 2016 |
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Reproducibility of Results; Reward; Taurine; Treatment Outcome | 2017 |
Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis.
Topics: Adult; Aged; Alcoholism; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Receptors, Opioid, mu; Tissue Banks; Ventral Striatum | 2017 |
Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task.
Topics: Adult; Alcoholism; Corpus Striatum; Delay Discounting; Double-Blind Method; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Reward; Substance-Related Disorders; United Kingdom | 2017 |
Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial.
Topics: Adult; Alcoholism; Craving; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Phenotype; Taste; Temperance; Treatment Outcome | 2016 |
Changes in coping behavior in a randomized controlled trial of concurrent treatment for PTSD and alcohol dependence.
Topics: Adaptation, Psychological; Adult; Alcoholism; Combined Modality Therapy; Comorbidity; Female; Humans; Implosive Therapy; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome; Young Adult | 2017 |
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Topics: Alcoholism; British Columbia; Chicago; Delayed-Action Preparations; Feasibility Studies; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Treatment Outcome | 2017 |
Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report.
Topics: Adult; Alcoholism; Borderline Personality Disorder; Comorbidity; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Research Report | 2017 |
Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
Topics: Administration, Intravenous; Adult; Alcoholism; Anticipation, Psychological; Corpus Striatum; Double-Blind Method; Drug Synergism; Ethanol; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Reward | 2017 |
Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.
Topics: Adult; Adult Survivors of Child Adverse Events; Alcoholism; Amygdala; Brain; Case-Control Studies; Cocaine-Related Disorders; Cross-Over Studies; Cues; Double-Blind Method; Female; Functional Neuroimaging; Gyrus Cinguli; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neural Pathways; Opioid-Related Disorders; Prefrontal Cortex; Substance-Related Disorders; Young Adult | 2017 |
Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.
Topics: Adult; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Piperazines; Quinolones; Secondary Prevention; Substance Withdrawal Syndrome | 2009 |
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Participation; Primary Health Care; Treatment Outcome | 2008 |
Predicting response to opiate antagonists and placebo in the treatment of pathological gambling.
Topics: Adult; Age Factors; Aged; Alcoholism; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gambling; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Psychometrics; Severity of Illness Index; Treatment Outcome; Young Adult | 2008 |
Relationship between medication adherence and treatment outcomes: the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Taurine; Temperance; Treatment Outcome; United States | 2008 |
A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.
Topics: Adult; Age of Onset; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Ethnicity; Female; Humans; Male; Marital Status; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Selection; Psychiatric Status Rating Scales; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2009 |
A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Topics: Adult; Alcoholism; Alleles; Asian People; Cognitive Behavioral Therapy; Female; Humans; Korea; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Prospective Studies; Receptors, Opioid, mu; Recurrence; Temperance | 2009 |
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.
Topics: Adult; Alcohol Drinking; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naltrexone; Smoking; Smoking Cessation | 2009 |
Effects of alcoholism typology on response to naltrexone in the COMBINE study.
Topics: Adult; Age Factors; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Temperance | 2009 |
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Taurine; Temperance | 2008 |
Comparing topiramate with naltrexone in the treatment of alcohol dependence.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Socioeconomic Factors; Topiramate; Treatment Outcome; Young Adult | 2008 |
Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Negativism; Placebo Effect; Secondary Prevention; Taurine; Temperance; Treatment Outcome | 2008 |
Behavioral consequences of repeated nicotine during adolescence in alcohol-preferring AA and alcohol-avoiding ANA rats.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Employment; Ethnicity; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Quality of Life; Social Behavior; Social Support; Surveys and Questionnaires | 2009 |
Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Employment; Ethnicity; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Quality of Life; Social Behavior; Social Support; Surveys and Questionnaires | 2009 |
Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Dopamine Agents; Double-Blind Method; Excitatory Amino Acid Agents; Female; Germany; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Psychotherapy; Reflex; Taurine; United States; Young Adult | 2009 |
Course of late-life depression with alcoholism following combination therapy.
Topics: Aging; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Sertraline; Severity of Illness Index; Treatment Outcome | 2009 |
The role of alcoholic beverage preference in the severity of alcohol dependence and adherence to the treatment.
Topics: Adolescent; Adult; Alcoholic Beverages; Alcoholism; Beer; Fructose; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Patient Compliance; Topiramate; Treatment Outcome | 2009 |
Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Blood Glucose; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Taurine | 2009 |
Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cues; Female; Genotype; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, GABA-A; Receptors, Opioid, mu; Taurine; Treatment Outcome | 2009 |
Targeted naltrexone for problem drinkers.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Counseling; Drug Administration Schedule; Female; Humans; Linear Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Sex Factors; Time Factors; Treatment Outcome | 2009 |
Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients.
Topics: Adolescent; Adult; Alcoholism; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Fructose; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Patient Compliance; Secondary Prevention; Smoking; Smoking Cessation; Socioeconomic Factors; Topiramate; Treatment Outcome; Young Adult | 2009 |
Extended naltrexone and broad spectrum treatment or motivational enhancement therapy.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Temperance; Time Factors; Treatment Outcome | 2009 |
A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence.
Topics: Adult; Affect; Alcoholism; Bipolar Disorder; Diagnosis, Dual (Psychiatry); Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Psychiatric Status Rating Scales; Regression Analysis; Survival Analysis | 2009 |
Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Black or African American; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2009 |
Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Cocaine-Related Disorders; Female; gamma-Glutamyltransferase; Hepatitis C; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Risk Factors; Risk-Taking; Transferrin | 2010 |
Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Delivery of Health Care, Integrated; Humans; Monitoring, Physiologic; Naltrexone; Narcotic Antagonists; Patient Care Management; Patient Compliance; Patient Selection; Physicians; Psychiatric Status Rating Scales; Russia; Treatment Outcome; Tuberculosis; United States | 2010 |
A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.
Topics: Adult; Alcoholism; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation.
Topics: Adult; Alcohol Drinking; Alcoholism; Alleles; Amino Acid Substitution; Aspartic Acid; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Pregnanolone; Receptors, Opioid, mu; Young Adult | 2010 |
[Impact of functional social support for abstinence after inpatient detoxification].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Psychotherapy, Group; Retreatment; Secondary Prevention; Social Support; Surveys and Questionnaires; Taurine | 2010 |
Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Prognosis; Social Support; Taurine; Temperance; Treatment Outcome | 2010 |
Topiramate for the treatment of alcohol dependence: comparison with naltrexone.
Topics: Alcohol Drinking; Alcoholism; Excitatory Amino Acid Agents; Female; Fructose; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Quality of Life; Time Factors; Topiramate; Treatment Outcome | 2011 |
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Sex Characteristics; Substance-Related Disorders; Taurine; Treatment Outcome | 2011 |
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Temperance | 2011 |
A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Pilot Projects; Quetiapine Fumarate; Single-Blind Method; Treatment Outcome; Young Adult | 2011 |
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2011 |
Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Professional-Patient Relations; Self Efficacy; Taurine; Treatment Outcome | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2011 |
Interaction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol.
Topics: Adult; Alcohol Drinking; Alcoholism; Analgesics, Opioid; Choice Behavior; Decision Making; Ethanol; Female; Humans; Impulsive Behavior; Internal-External Control; Male; Motor Activity; Naltrexone; Pedigree | 2011 |
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Delayed-Action Preparations; Disease Progression; Double-Blind Method; Female; Humans; Injections; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychiatric Status Rating Scales; Temperance; Time Factors; Treatment Outcome | 2011 |
The effects of polyunsaturated fatty acids in alcohol dependence treatment--a double-blind, placebo-controlled pilot study.
Topics: Adult; Alcoholism; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Fatty Acids, Unsaturated; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Placebos | 2011 |
Trial watch: Nalmefene reduces alcohol use in phase III trial.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2011 |
Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Topics: Adrenocorticotropic Hormone; Adult; Alcohol Dehydrogenase; Alcoholic Intoxication; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Alleles; Asian; Behavior, Addictive; Double-Blind Method; Ethanol; Female; Genotype; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Receptors, Opioid, mu | 2012 |
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Taurine; Temperance; Treatment Outcome | 2012 |
Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence.
Topics: Adrenergic Agonists; Adult; Alcoholism; Antidepressive Agents; Comorbidity; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Serotonin Receptor Agonists; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans | 2012 |
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Forecasting; Humans; Male; Middle Aged; Naltrexone; Social Support; Spouses; Taurine; Treatment Outcome | 2012 |
Effects of alcohol availability, access to alcohol, and naltrexone on self-reported craving and patterns of drinking in response to an alcohol-cue availability procedure.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Cues; Dose-Response Relationship, Drug; Double-Blind Method; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Self Report | 2012 |
The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Alcoholism; Cost-Benefit Analysis; Female; General Practitioners; Humans; Male; Naltrexone; New South Wales; Postal Service; Practice Patterns, Physicians'; Taurine | 2012 |
Trajectory analyses in alcohol treatment research.
Topics: Acamprosate; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Algorithms; Behavior Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Double-Blind Method; Female; Fructose; Humans; Linear Models; Male; Middle Aged; Models, Statistical; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Nonlinear Dynamics; Regression Analysis; Research; Research Design; Taurine; Topiramate; Treatment Outcome; Young Adult | 2012 |
Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking; Taurine; Treatment Outcome | 2012 |
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Social Environment; Treatment Outcome; Young Adult | 2012 |
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Humans; Markov Chains; Naltrexone; Quality of Life; Taurine; Treatment Outcome | 2012 |
Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project.
Topics: Adult; Affect; Alcoholism; Biomarkers; Double-Blind Method; Family Health; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Saliva; Sex Characteristics | 2012 |
A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Homosexuality, Male; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Treatment Outcome | 2012 |
Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Alleles; Counseling; Data Interpretation, Statistical; Female; Genotype; Heterozygote; Humans; Male; Medical Records; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Placebos; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Opioid, mu; Treatment Outcome; Young Adult | 2013 |
Urge-specific and lifestyle coping strategies of alcoholics: relationships of specific strategies to treatment outcome.
Topics: Adaptation, Psychological; Adult; Alcoholism; Behavior Therapy; Combined Modality Therapy; Communication; Cues; Female; Humans; Life Style; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2013 |
Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Primary Health Care; Temperance; Time Factors | 2012 |
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Topics: Adult; Alcohol Drinking; Alcoholism; Cues; Dopamine Plasma Membrane Transport Proteins; Female; Genetic Variation; Humans; Magnetic Resonance Imaging; Male; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Binding; Receptors, Opioid, mu; Tandem Repeat Sequences; Treatment Outcome; Young Adult | 2013 |
A randomized trial evaluating an mHealth system to monitor and enhance adherence to pharmacotherapy for alcohol use disorders.
Topics: Adult; Alcoholism; Cell Phone; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Telemedicine | 2012 |
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Counseling; Disease-Free Survival; Double-Blind Method; Female; Germany; Hospitalization; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Placebos; Randomized Controlled Trials as Topic; Research Design; Taurine; Treatment Outcome; United States | 2013 |
The effects of drinking goal on treatment outcome for alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Goals; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Recurrence; Taurine; Treatment Outcome | 2013 |
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
Topics: Alanine Transaminase; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Female; gamma-Glutamyltransferase; Humans; Liver; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention | 2013 |
Attributions of change and self-efficacy in a randomized controlled trial of medication and psychotherapy for problem drinking.
Topics: Adolescent; Adult; Aged; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Homosexuality, Male; Humans; Male; Middle Aged; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Self Efficacy; Treatment Outcome | 2013 |
A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.
Topics: Adult; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Recurrence; Survival Analysis | 2002 |
A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
Topics: Acamprosate; Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brain; Cognition; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Reaction Time; Taurine | 2002 |
Naltrexone in the treatment of alcohol dependence: a Canadian trial.
Topics: Adult; Alcohol Deterrents; Alcoholism; Canada; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naltrexone | 2002 |
Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Double-Blind Method; Female; gamma-Glutamyltransferase; Germany; Humans; Male; Naltrexone; Narcotic Antagonists; Recurrence; Surveys and Questionnaires; Temperance; Treatment Outcome | 2002 |
Naltrexone improves outcome of a controlled drinking program.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2002 |
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
Topics: Acamprosate; Alcoholism; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2003 |
A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Environment; Female; Humans; Male; Middle Aged; Naltrexone | 2003 |
Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study.
Topics: Alcohol Drinking; Alcoholism; Female; Humans; Hydroxybutyrates; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Temperance; Time Factors; Treatment Outcome | 2003 |
Naltrexone treatment for alcoholics: effect on cigarette smoking rates.
Topics: Adult; Alcoholism; Analysis of Variance; Female; Health Promotion; Humans; Incidence; Male; Naltrexone; Narcotic Antagonists; Smoking; Smoking Cessation; Time Factors; Treatment Outcome | 2003 |
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
Topics: Adult; Alcoholism; Confidence Intervals; Female; Gene Frequency; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Odds Ratio; Polymorphism, Genetic; Receptors, Opioid, mu; Survival Analysis | 2003 |
Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
Topics: Acamprosate; Adult; Alcoholism; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Neuropsychological Tests; Taurine | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine | 2003 |
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Pilot Projects; Taurine | 2003 |
A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.
Topics: Adult; Alcoholism; Ambulatory Care; Analysis of Variance; Behavior Therapy; Chi-Square Distribution; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone | 2003 |
Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Cognitive Behavioral Therapy; Combined Modality Therapy; Connecticut; Female; gamma-Glutamyltransferase; Humans; Male; Medicine; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Participation; Primary Health Care; Specialization; Time; Treatment Outcome | 2003 |
Psychometric properties of the short index of problems as a measure of recent alcohol-related problems.
Topics: Adult; Alcohol-Related Disorders; Alcoholism; Attitude to Health; Connecticut; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Personality Inventory; Psychometrics; Sensitivity and Specificity; Social Adjustment | 2003 |
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.
Topics: Alcoholism; Comorbidity; Double-Blind Method; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; New England; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2004 |
Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Case-Control Studies; Central Nervous System Depressants; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Time Factors | 2004 |
Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers.
Topics: Affect; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2004 |
A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.
Topics: Adult; Alcoholism; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone | 2004 |
Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Compulsive Behavior; Counseling; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Psychiatric Status Rating Scales; Treatment Outcome | 2004 |
Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Analysis of Variance; Delayed-Action Preparations; Double-Blind Method; Female; gamma-Glutamyltransferase; Humans; Male; Middle Aged; Naltrexone | 2004 |
Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population.
Topics: Adult; Aged; Aged, 80 and over; Alcoholism; Confidence Intervals; Disulfiram; Drug Prescriptions; Humans; Middle Aged; Multivariate Analysis; Naltrexone; New England; Survival Analysis; Veterans | 2004 |
A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence.
Topics: Adult; Alcoholism; Delayed-Action Preparations; Double-Blind Method; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Naltrexone; Pilot Projects | 2004 |
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone | 2004 |
Alcohol dependence: the impact of cognitive behaviour therapy with or without naltrexone on subjective health status.
Topics: Adult; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Health Status; Humans; Male; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires | 2004 |
Effectiveness of naltrexone in a community treatment program.
Topics: Adult; Alcoholism; Chi-Square Distribution; Community Health Services; Female; Humans; Male; Middle Aged; Naltrexone; Substance Abuse Treatment Centers; Survival Analysis | 2004 |
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotics; Predictive Value of Tests; Prospective Studies; Secondary Prevention; Somatoform Disorders; Surveys and Questionnaires; Taurine; Treatment Outcome | 2005 |
Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Treatment Outcome | 2005 |
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
Topics: Adult; Alcoholism; Double-Blind Method; Drug Carriers; Female; Humans; Injections, Intramuscular; Lactic Acid; Male; Microspheres; Middle Aged; Naltrexone; Narcotic Antagonists; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Psychotherapy, Brief | 2005 |
Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; Cognitive Behavioral Therapy; Confidence Intervals; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Prospective Studies; Time Factors; Treatment Outcome | 2005 |
Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders.
Topics: Alcohol Deterrents; Alcoholism; Diagnosis, Dual (Psychiatry); Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Treatment Outcome | 2005 |
Treatment of late-life depression complicated by alcohol dependence.
Topics: Age of Onset; Aged; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Empathy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sertraline; Social Support | 2005 |
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Leptin; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Recurrence; Taurine | 2005 |
Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.
Topics: Adult; Alcoholism; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Severity of Illness Index; Treatment Outcome | 2005 |
A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan.
Topics: Adult; Alcoholism; Double-Blind Method; Humans; Male; Middle Aged; Naltrexone; Recurrence; Taiwan | 2005 |
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence.
Topics: Alcoholism; Delayed-Action Preparations; Double-Blind Method; Humans; Injections, Intravenous; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2005 |
Naltrexone treatment of adolescent alcoholics: an open-label pilot study.
Topics: Adolescent; Adult; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Pilot Projects | 2005 |
Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Synergism; Ethanol; Female; Humans; Ketamine; Male; Naltrexone; Receptors, N-Methyl-D-Aspartate | 2006 |
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Topics: Acamprosate; Adrenocorticotropic Hormone; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Taurine; Time Factors | 2006 |
Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Sex Characteristics; Time Factors | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Taurine | 2006 |
The impact of alcohol dependence and posttraumatic stress disorder on cold pressor task response.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Alcoholism; Cold Temperature; Comorbidity; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Psychomotor Performance; Severity of Illness Index; Stress Disorders, Post-Traumatic; Touch | 2006 |
Genetic moderators of naltrexone's effects on alcohol cue reactivity.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Analysis of Variance; Chi-Square Distribution; Cues; Ethanol; Female; Genetic Variation; Genotype; Humans; Male; Naltrexone; Receptors, Dopamine D4; Receptors, Opioid, mu | 2006 |
Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder.
Topics: Adult; Alcohol Deterrents; Alcoholism; Analysis of Variance; Diagnosis, Dual (Psychiatry); Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic; Temperance; Treatment Outcome | 2006 |
Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls.
Topics: Adult; Alcoholism; Bias; Brain; Causality; Central Nervous System Depressants; Choice Behavior; Decision Making; Double-Blind Method; Ethanol; Female; Humans; Impulsive Behavior; Male; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Opioid Peptides; Personality; Psychomotor Performance; Reward; Treatment Outcome | 2007 |
Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Biomarkers; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Sodium Oxybate; Temperance | 2006 |
Psychometrics of the Drinker Inventory of Consequences (DrInC).
Topics: Acamprosate; Alcoholism; Combined Modality Therapy; Factor Analysis, Statistical; Follow-Up Studies; Humans; Naltrexone; Narcotic Antagonists; Psychometrics; Psychotherapy; Surveys and Questionnaires; Taurine | 2007 |
The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.
Topics: Adult; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Treatment Outcome | 2007 |
Building better cognitive-behavioral therapy: is broad-spectrum treatment more effective than motivational-enhancement therapy for alcohol-dependent patients treated with naltrexone?
Topics: Adolescent; Adult; Aged; Alcoholism; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Psychotherapy; Social Environment; Temperance | 2007 |
Measuring economic outcomes of alcohol treatment using the Economic Form 90.
Topics: Absenteeism; Acamprosate; Accidents, Traffic; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Criminal Law; Employment; Female; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Male; Middle Aged; Models, Economic; Naltrexone; Prisons; Taurine; Treatment Outcome; United States | 2007 |
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Topics: Adult; Alcoholism; Confidence Intervals; DNA; Double-Blind Method; Exons; Female; Genetic Variation; Genotype; Humans; Linear Models; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Proportional Hazards Models; Psychiatric Status Rating Scales; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Smoking; Treatment Outcome; United States; United States Department of Veterans Affairs | 2007 |
What role does measuring medication compliance play in evaluating the efficacy of naltrexone?
Topics: Adult; Alcoholism; Drug Monitoring; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Riboflavin; Sample Size; Treatment Outcome | 2007 |
Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Attitude; Body Mass Index; Bulimia; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Feeding and Eating Disorders; Female; gamma-Glutamyltransferase; Humans; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Treatment Outcome | 2007 |
The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Topics: Acamprosate; Affect; Alcohol Deterrents; Alcoholism; Autonomic Nervous System; Cues; Double-Blind Method; Galvanic Skin Response; Heart Rate; Humans; Hydrocortisone; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Patient Compliance; Psychiatric Status Rating Scales; Surveys and Questionnaires; Taurine | 2007 |
High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.
Topics: Adult; Alcoholism; Analgesics, Non-Narcotic; Analysis of Variance; Carbamazepine; Chi-Square Distribution; Compulsive Behavior; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Status Schedule; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2007 |
Naltrexone and disulfiram in patients with alcohol dependence and current depression.
Topics: Alcohol Deterrents; Alcoholism; Bipolar Disorder; Cocaine-Related Disorders; Comorbidity; Connecticut; Depressive Disorder, Major; Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Gastrointestinal Diseases; Humans; Male; Massachusetts; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans | 2007 |
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Finland; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Placebos; Sleep Initiation and Maintenance Disorders; Substance Abuse Treatment Centers; Temperance; Treatment Outcome | 2007 |
Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment.
Topics: Adolescent; Adult; Aged; Alcoholism; Anxiety; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Time Factors; Treatment Outcome; Withholding Treatment | 2007 |
Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics.
Topics: Adult; Age of Onset; Alcohol Drinking; Alcoholism; Antisocial Personality Disorder; Cocaine-Related Disorders; Comorbidity; Double-Blind Method; Family; Female; Genetic Predisposition to Disease; Humans; Male; Marijuana Abuse; Naltrexone | 2007 |
Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study.
Topics: Adult; Alcoholism; Anesthetics, Intravenous; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sodium Oxybate; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2007 |
Blood naltrexone levels over time following naltrexone implant.
Topics: Adult; Alcoholism; Confidence Intervals; Dose-Response Relationship, Drug; Drug Implants; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Retrospective Studies; Time Factors | 2008 |
Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence.
Topics: Adolescent; Adult; Aged; Alcoholism; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sex Factors | 2008 |
Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Breath Tests; Double-Blind Method; Emotions; Ethanol; Female; Genetic Variation; Genotype; Humans; Male; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Placebos; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Opioid, mu; Reward | 2007 |
Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
Topics: Adult; Alcohol Drinking; Alcoholism; Counseling; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Glutamyltransferase; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prospective Studies; Temperance | 2007 |
Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism".
Topics: Alcohol Drinking; Alcoholism; Antidepressive Agents; Female; Humans; Male; Mood Disorders; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome | 2008 |
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2008 |
Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone | 2008 |
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Topics: Acamprosate; Adult; Alcoholism; Alleles; Amino Acid Substitution; Asparagine; Aspartic Acid; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Genetic Carrier Screening; Genetic Markers; Genotype; Homozygote; Humans; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Prognosis; Receptors, Opioid, mu; Taurine; Temperance; Treatment Outcome | 2008 |
The therapeutic alliance in medical-based interventions impacts outcome in treating alcohol dependence.
Topics: Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Care Team; Surveys and Questionnaires; Temperance | 2008 |
Early treatment response in alcohol dependence with extended-release naltrexone.
Topics: Adult; Aged; Alcoholism; Counseling; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Magnetic Resonance Imaging; Male; Naltrexone; Narcotics; Ondansetron; Oxygen; Photic Stimulation; Serotonin Antagonists; Severity of Illness Index | 2008 |
An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients.
Topics: Adult; Alcoholism; Citalopram; Drug Therapy, Combination; Female; Humans; Hydroxybutyrates; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors | 2008 |
Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
Topics: Adult; Alaska; Alcoholism; Drug Therapy, Combination; Female; Humans; Indians, North American; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Receptors, Opioid, mu; Rural Population; Selective Serotonin Reuptake Inhibitors; Sertraline | 2008 |
Using topiramate or naltrexone for the treatment of alcohol-dependent patients.
Topics: Adult; Alcoholism; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Psychological Tests; Severity of Illness Index; Topiramate | 2008 |
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Taurine; Treatment Outcome | 2008 |
Naltrexone in the treatment of alcoholism: predicting response to naltrexone.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Ambulatory Care; Combined Modality Therapy; Humans; Male; Middle Aged; Naltrexone; Personality Inventory; Placebos; Probability; Treatment Outcome | 1995 |
Effect of naltrexone on alcohol "high" in alcoholics.
Topics: Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Double-Blind Method; Emotions; Humans; Male; Memory; Naltrexone; Placebos; Temperance | 1995 |
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
Topics: Alcoholism; Body Weight; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Patient Admission; Pilot Projects; Treatment Outcome | 1994 |
Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Function Tests; Naltrexone; Narcotic Antagonists | 1994 |
Naltrexone-induced alterations in human ethanol intoxication.
Topics: Administration, Oral; Adult; Affect; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Ambulatory Care; Animals; Cognition; Double-Blind Method; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Psychomotor Performance; Recurrence; Sensation | 1994 |
Experience of a "slip" among alcoholics treated with naltrexone or placebo.
Topics: Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Emotions; Humans; Naltrexone; Placebos; Recurrence | 1996 |
Current strategies for the treatment of alcohol dependence in the United States.
Topics: Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome; United States | 1995 |
Six-month follow-up of naltrexone and psychotherapy for alcohol dependence.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Naltrexone; Placebos; Psychotherapy; Regression Analysis; Treatment Outcome | 1996 |
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Obsessive-Compulsive Disorder; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Temperance; Treatment Outcome | 1996 |
[Evaluation of the efficacy of naltrexone in alcoholism by the determination of serum carbohydrate-deficient transferrin].
Topics: Adult; Alcoholism; Biomarkers; Drug Evaluation; Drug Tolerance; Humans; Male; Naltrexone; Narcotic Antagonists; Radioimmunoassay; Time Factors; Transferrin | 1995 |
Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Personality Assessment; Recurrence; Treatment Outcome; Verbal Learning | 1996 |
Naltrexone for alcoholic adolescents.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Ambulatory Care; Humans; Naltrexone; Treatment Outcome | 1997 |
Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Breath Tests; Double-Blind Method; Ethanol; Humans; Male; Naltrexone; Narcotic Antagonists; Risk Factors | 1997 |
Tolerability of naltrexone in treating older, alcohol-dependent patients.
Topics: Age Factors; Alcoholism; Anxiety; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sleep | 1997 |
Naltrexone and alcohol dependence. Role of subject compliance.
Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Protocols; Combined Modality Therapy; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Placebos; Psychotherapy | 1997 |
Naltrexone as an adjunctive treatment for older patients with alcohol dependence.
Topics: Aged; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Recurrence; Severity of Illness Index | 1997 |
The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Dizziness; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Male; Middle Aged; Naltrexone; Nausea; Substance Abuse Treatment Centers | 1997 |
Effects of naltrexone on cue-elicited craving for alcohol and cocaine.
Topics: Adolescent; Adult; Affect; Alcoholism; Cocaine-Related Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Visual Perception | 1997 |
Naltrexone utility in depressed alcoholics.
Topics: Adult; Alcoholism; Depressive Disorder; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Pilot Projects | 1998 |
Sustained-release naltrexone for alcoholism treatment: a preliminary study.
Topics: Administration, Oral; Adult; Alcoholism; Biological Availability; Delayed-Action Preparations; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 1998 |
Naltrexone treatment of comorbid alcohol and cocaine use disorders.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cocaine-Related Disorders; Compliance; Double-Blind Method; Female; Humans; Male; Naltrexone | 1998 |
The effects of naltrexone on alcohol and cocaine use in dually addicted patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Cocaine-Related Disorders; Combined Modality Therapy; Comorbidity; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prevalence; Psychotherapy; Treatment Outcome | 1999 |
Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism.
Topics: Adult; Alcoholism; Biomarkers; Clinical Enzyme Tests; Female; gamma-Glutamyltransferase; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sensitivity and Specificity; Transferrin; Treatment Outcome | 1999 |
Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study.
Topics: Adrenocorticotropic Hormone; Adult; Alcoholism; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Prolactin; Radioimmunoassay; Stimulation, Chemical; Surveys and Questionnaires; Temperance | 1999 |
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
Topics: Administration, Oral; Alcohol Drinking; Alcoholism; Breath Tests; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Temperance; Treatment Outcome | 1999 |
Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications.
Topics: Alcohol Drinking; Alcoholic Beverages; Alcoholism; Ambulatory Care; Drug Administration Schedule; Drug Monitoring; Drug Packaging; Female; Humans; Male; Microcomputers; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychiatric Status Rating Scales; Self Administration; Temperance; Treatment Outcome | 1999 |
Naltrexone's effect on cue-elicited craving among alcoholics in treatment.
Topics: Adult; Alcoholism; Analysis of Variance; Behavior, Addictive; Blood Pressure; Cues; Double-Blind Method; Female; Heart Rate; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Salivation | 1999 |
Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies.
Topics: Adult; Alcoholism; Beer; Cross-Over Studies; Cues; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Reinforcement, Psychology; Taste; Time Factors; Treatment Outcome | 1999 |
Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale.
Topics: Adult; Alcoholism; Factor Analysis, Statistical; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Predictive Value of Tests; Proportional Hazards Models; Psychiatric Status Rating Scales; Reproducibility of Results; Temperance | 1999 |
Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Selection; Placebos; Recurrence; Reproducibility of Results; Treatment Outcome | 1999 |
Clinical experience with naltrexone maintenance in a hospital drug and alcohol outpatient setting.
Topics: Alcoholism; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Outpatient Clinics, Hospital; Patient Selection | 1999 |
Naltrexone exerts a favourable effect on plasma lipids in abstinent patients with alcohol dependence.
Topics: Adult; Alcoholism; Anticonvulsants; Antidepressive Agents; Carbamazepine; Double-Blind Method; Humans; Lipoproteins; Lithium Carbonate; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Temperance | 2000 |
Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Piperazines; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Time Factors; Triazoles | 2000 |
Drinking in alcoholics following an alcohol challenge research protocol.
Topics: Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Research; Temperance | 2000 |
Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients.
Topics: Adult; Alcoholism; Ambulatory Care; Combined Modality Therapy; Day Care, Medical; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Physician-Patient Relations; Treatment Outcome | 2000 |
Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Topics: Adult; Aged; Alcoholism; Analysis of Variance; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Ondansetron; Serotonin Antagonists | 2000 |
Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2000 |
Predictors of compliance with naltrexone among alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Fatigue; Female; Humans; Male; Middle Aged; Naltrexone; Nausea; Patient Compliance; Placebos; Time Factors | 2000 |
Does affect mediate the association between daily events and alcohol use?
Topics: Adolescent; Adult; Affect; Alcohol Drinking; Alcoholism; Arousal; Drug Administration Schedule; Female; Humans; Life Change Events; Male; Middle Aged; Motivation; Naltrexone | 2000 |
Naltrexone's effects on reactivity to alcohol cues among alcoholic men.
Topics: Adult; Alcohol Drinking; Alcoholism; Arousal; Attention; Cues; Humans; Male; Middle Aged; Motivation; Naltrexone; Substance Withdrawal Syndrome; Taste | 2000 |
Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism.
Topics: Adult; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2001 |
Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Serotonin Antagonists | 2001 |
Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial.
Topics: Adaptation, Psychological; Adult; Alcoholism; Cognitive Behavioral Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Prospective Studies; Recurrence; Survival Analysis | 2001 |
Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Topics: Adult; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Placebos; Serotonin Antagonists; Transferrin | 2001 |
[Naltrexone in the treatment of alcoholism. Clinical evolution, safety and efficacy in a sample of 198 patients].
Topics: Adult; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prognosis; Prospective Studies | 2001 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Communication; Double-Blind Method; Humans; Liver; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Dropouts; Patient Education as Topic; Placebos; Treatment Outcome | 2001 |
Naltrexone in the treatment of alcohol dependence.
Topics: Alcoholics Anonymous; Alcoholism; Combined Modality Therapy; Counseling; Double-Blind Method; Female; Humans; Male; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Patient Compliance; Recurrence; Treatment Failure | 2001 |
Naltrexone for alcohol dependence: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Analysis of Variance; Chi-Square Distribution; Diagnosis, Dual (Psychiatry); Double-Blind Method; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Psychological Tests; Survival Analysis; Temperance; Treatment Outcome | 2001 |
Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
Topics: Adrenocorticotropic Hormone; Adult; Alcohol Drinking; Alcoholism; Central Nervous System Depressants; Ethanol; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Naltrexone; Narcotic Antagonists; Nausea; Pituitary-Adrenal System; Psychiatric Status Rating Scales; Surveys and Questionnaires | 2002 |
Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting.
Topics: Adolescent; Adult; Aged; Alcoholism; Behavior Therapy; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Proportional Hazards Models; Secondary Prevention; Survival Analysis; Time Factors | 2002 |
Naltrexone in the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Combined Modality Therapy; Double-Blind Method; Humans; Male; Naltrexone; Nausea; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Psychotherapy; Recurrence; Severity of Illness Index; Treatment Outcome | 1992 |
Naltrexone and coping skills therapy for alcohol dependence. A controlled study.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Person-Centered Psychotherapy; Placebos; Psychiatric Status Rating Scales; Psychotherapy; Recurrence; Severity of Illness Index; Temperance | 1992 |
Conditioning phenomena and the problem of relapse in opioid addicts and alcoholics.
Topics: Alcoholism; Clinical Trials as Topic; Conditioning, Psychological; Double-Blind Method; Female; Heroin Dependence; Humans; Male; Naltrexone; Recurrence | 1988 |
400 other study(ies) available for naltrexone and Alcoholism
| Article | Year |
|---|---|
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
Topics: Alcohol Drinking; Alcoholism; Amides; Animals; Binding, Competitive; Drug Evaluation, Preclinical; Ethanol; Humans; Hydrogen Bonding; Liver; Mice; Microsomes, Liver; Molecular Structure; Morphinans; Naltrexone; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 2008 |
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
Topics: Alcohol Deterrents; Alcoholism; Animals; Humans; Liver; Male; Mice; Naltrexone; Nociceptin Receptor; Protein Binding; Rats; Rats, Wistar; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Structure-Activity Relationship | 2009 |
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities.
Topics: Alcoholism; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Patient Outcome Assessment; Schizophrenia; Smoking; Varenicline | 2021 |
Commentary on Murphy et al.: What will it take to prescribe extended-release naltrexone to treat alcohol use disorder?
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2022 |
Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Psychometrics; Reward | 2022 |
Monitoring alcohol-use-disorder medication compliance by LC-MS/MS determination of urinary ethyl glucuronide, acamprosate, naltrexone, and 6β-naltrexol using zirconia-based hybrid solid-phase extraction.
Topics: Acamprosate; Alcoholism; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glucuronates; Humans; Medication Adherence; Naltrexone; Solid Phase Extraction; Tandem Mass Spectrometry; Zirconium | 2022 |
Provider perspectives on emergency department initiation of medication assisted treatment for alcohol use disorder.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Naltrexone; Opioid-Related Disorders | 2022 |
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Naltrexone; Retrospective Studies; Topiramate | 2022 |
Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders.
Topics: Adult; Alcoholism; Black People; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Pain Threshold; Receptors, Opioid, kappa; White People | 2022 |
Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system.
Topics: Adult; Alcoholism; Colorado; Delivery of Health Care; Ethanol; Female; Humans; Naltrexone; Opioid-Related Disorders | 2022 |
Availability of Medications for Alcohol Use Disorder Treatment in Medicare Part D, 2014-2018.
Topics: Aged; Alcoholism; Humans; Medicare Part D; Naltrexone; United States | 2022 |
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease.
Topics: Adult; Alcoholism; Humans; Liver Cirrhosis; Liver Diseases; Naltrexone; Retrospective Studies | 2022 |
Impact of Hospital-Administered Extended-Release Naltrexone on Readmission Rates in Patients With Alcohol Use Disorder: A Pilot Study.
Topics: Adult; Alcoholism; Hospitals; Humans; Naltrexone; Patient Readmission; Pilot Projects; Retrospective Studies | 2022 |
Extended-Release Naltrexone and Case Management for Treatment of Alcohol Use Disorder in the Emergency Department.
Topics: Adult; Alcohol Drinking; Alcoholism; Case Management; Humans; Naltrexone; Narcotic Antagonists; Prospective Studies; Quality of Life | 2023 |
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine | 2023 |
Extended-release naltrexone for people with alcohol use disorder on therapeutic anticoagulation: A case series.
Topics: Alcoholism; Anticoagulants; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2022 |
Naltrexone-induced psychosis in a patient with alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Humans; Naltrexone; Psychotic Disorders | 2023 |
Clustering of KOR PET images separates people with AUD into distinct responses to naltrexone.
Topics: Alcohol Drinking; Alcoholism; Humans; Magnetic Resonance Imaging; Naltrexone; Positron-Emission Tomography; Receptors, Opioid, kappa | 2023 |
Intravenous ketamine for severe alcohol use disorder at Moi Teaching & Referral Hospital, Kenya: a case report.
Topics: Adult; Alcoholism; Hospitals; Humans; Kenya; Ketamine; Male; Naltrexone; Referral and Consultation; Smoking Cessation; Tobacco Use Cessation Devices | 2023 |
Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Naltrexone; Retrospective Studies | 2023 |
Education Intervention to Increase Naltrexone Use Among Adult Inpatients With Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Inpatients; Naltrexone; Narcotic Antagonists | 2023 |
Medications for Alcohol Use Disorder and Retention in Care in Medicaid-Enrolled Youth, 2014-2019.
Topics: Adolescent; Alcoholism; Child; Humans; Medicaid; Naltrexone; Retention in Care; Retrospective Studies; United States; Young Adult | 2023 |
Thermosensitive biomaterial gels with chemical permeation enhancers for enhanced microneedle delivery of naltrexone for managing opioid and alcohol dependency.
Topics: Alcoholism; Analgesics, Opioid; Animals; Benzyl Alcohols; Dimethyl Sulfoxide; Drug Delivery Systems; Gels; Humans; Naltrexone; Poloxamer; Skin Absorption; Swine | 2023 |
The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving.
Topics: Adult; Alcoholism; Brain; Brain Mapping; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Receptors, Opioid, kappa; Young Adult | 2019 |
Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
Topics: Alcohol Drinking; Alcoholism; Analgesics, Opioid; Animals; Drinking; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Morphinans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu; Recurrence; Secondary Prevention; Spiro Compounds | 2019 |
Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Research Design | 2019 |
Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Retrospective Studies; United States; United States Department of Veterans Affairs; United States Food and Drug Administration; Veterans | 2019 |
Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
Kappa Opioid Receptors and Mu Opioid Receptors as Combined Targets for Medication Development for Alcoholism.
Topics: Alcoholism; Craving; Drug Development; Humans; Naltrexone; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2019 |
Trends in first-time treatment admissions for older adults with alcohol use disorder: Availability of medical and specialty clinical services in hospital, residential, and outpatient facilities.
Topics: Aged; Alcoholism; Ambulatory Care; Ambulatory Care Facilities; Databases, Factual; Female; Hospitalization; Humans; Male; Mental Health Services; Middle Aged; Naltrexone; Patient Admission; Substance Abuse Treatment Centers | 2019 |
Changes in the elimination and resurgence of alcohol-maintained behavior in rats and the effects of naltrexone.
Topics: Alcohol Deterrents; Alcoholism; Animals; Conditioning, Operant; Ethanol; Extinction, Psychological; Male; Naltrexone; Rats; Reinforcement, Psychology; Self Administration | 2020 |
Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Prevalence; Veterans | 2020 |
Response to 'Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption'.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergency Service, Hospital; Female; Gabapentin; Humans; Male; Middle Aged; Naltrexone; Ontario; Opioid-Related Disorders; Patient Acceptance of Health Care; Primary Health Care; Referral and Consultation; Socioeconomic Factors; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Young Adult | 2020 |
OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Craving; Female; Genotype; Humans; Latent Class Analysis; Male; Medication Adherence; Middle Aged; Multilevel Analysis; Naltrexone; Polymorphism, Genetic; Random Allocation; Receptors, Opioid, mu; Telemedicine | 2020 |
Comparison of Disulfiram and Naltrexone in Cases of Alcohol Dependence Syndrome.
Topics: Adult; Alcohol Deterrents; Alcoholism; Cross-Sectional Studies; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Nepal; Prospective Studies; Recurrence; Treatment Outcome | 2020 |
Commentary on Hartwell et al. (2020): Alcohol use disorder treatment response-where is the variability?
Topics: Alcoholism; Humans; Naltrexone; Receptors, Opioid, mu | 2020 |
A Bayesian approach to discrete multiple outcome network meta-analysis.
Topics: Acamprosate; Alcoholism; Algorithms; Bayes Theorem; Humans; Monte Carlo Method; Naltrexone; Network Meta-Analysis; Safety | 2020 |
[Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene].
Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Japan; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid | 2020 |
Bioresponsive nanostructured systems for sustained naltrexone release and treatment of alcohol use disorder: Development and biological evaluation.
Topics: Alcohol Deterrents; Alcoholism; Animals; Delayed-Action Preparations; Drug Development; Drug Evaluation, Preclinical; Ethanol; Injections, Subcutaneous; Male; Mice; Mice, Inbred C57BL; Naltrexone; Nanostructures | 2020 |
Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.
Topics: Alcohol Drinking; Alcoholism; Attitude; Female; Health Belief Model; Humans; Infant, Newborn; Male; Naltrexone | 2020 |
Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving.
Topics: Alcohol Drinking; Alcoholism; Craving; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa | 2021 |
The Persistent Challenge of Developing Addiction Pharmacotherapies.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-Related Disorders; Drug Therapy; Humans; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Smoking Cessation Agents; Substance-Related Disorders; Varenicline | 2021 |
Predictive factors of long-term follow-up in treatment of Korean alcoholics with naltrexone or acamprosate.
Topics: Acamprosate; Adult; Alcoholics; Alcoholism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone | 2020 |
Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Ambulatory Care; Depressive Disorder, Major; Female; Hospitalization; Humans; Ill-Housed Persons; Male; Mental Health Services; Middle Aged; Morbidity; Naltrexone; Psychotherapy; Psychotropic Drugs; Schizophrenia; Socioeconomic Factors; United States; United States Department of Veterans Affairs; Veterans | 2021 |
Effect of Withania somnifera (L.) Dunal aqueous root extract on reinstatement using conditioned place preference and brain GABA and dopamine levels in alcohol dependent animals.
Topics: Alcoholism; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Female; gamma-Aminobutyric Acid; Male; Medicine, Ayurvedic; Mice; Naltrexone; Plant Extracts; Plant Roots; Rats, Wistar; Withania | 2021 |
Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
Topics: Acamprosate; Aged; Alcohol Deterrents; Alcoholism; Cohort Studies; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Naltrexone; Quality-Adjusted Life Years; Treatment Outcome | 2021 |
Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cohort Studies; Female; Humans; Male; Naltrexone; Sweden | 2021 |
[Four cases of alcoholic liver cirrhosis in alcohol-dependent patients treated with nalmefene].
Topics: Alcohol Drinking; Alcoholism; Europe; Humans; Japan; Liver Cirrhosis, Alcoholic; Naltrexone | 2021 |
Treatment of Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Naltrexone | 2021 |
Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long-Evans rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Amphetamines; Animals; Central Nervous System Depressants; Drug Interactions; Ethanol; Hallucinogens; Male; Naltrexone; Rats; Rats, Long-Evans; Serotonin 5-HT2 Receptor Agonists | 2021 |
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Topics: Accidental Falls; Adult; Alcohol-Related Disorders; Alcoholism; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; Drug Overdose; Ethanol; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Protective Factors; Wounds and Injuries; Young Adult | 2021 |
A new approach to treating alcohol use disorder in people experiencing homelessness.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Behavior Therapy; Case-Control Studies; Financing, Government; Harm Reduction; Humans; Ill-Housed Persons; Middle Aged; Naltrexone; North America; Placebos; Prevalence; Quality of Life; Randomized Controlled Trials as Topic; Veterans | 2021 |
FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study.
Topics: Alcoholism; Humans; Magnetic Resonance Imaging; Naltrexone; Recurrence; Reproducibility of Results; Treatment Outcome | 2021 |
Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; Female; Humans; Insurance Claim Review; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Anticraving medication for moderate to severe alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Craving; Female; Humans; Male; Naltrexone | 2021 |
Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.
Topics: Alcohol Drinking; Alcoholism; Cues; Double-Blind Method; Humans; Naltrexone; Smokers; Varenicline | 2021 |
Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies.
Topics: Adult; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Prospective Studies; Retrospective Studies | 2021 |
An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
Topics: Alcoholism; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
How prescribing available pharmacotherapies for alcohol use disorder can impact the healthcare system: A retrospective quality improvement study.
Topics: Alcoholism; Delivery of Health Care; Humans; Naltrexone; Quality Improvement; Retrospective Studies | 2021 |
Topics: Alcohol Deterrents; Alcoholism; Appetite Depressants; Humans; Naltrexone; Social Support; Topiramate | 2021 |
Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; California; Delayed-Action Preparations; Emergency Service, Hospital; Emergency Treatment; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2021 |
Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Middle Aged; Naltrexone; Substance-Related Disorders | 2021 |
Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
Topics: Adult; Aged; Alcoholism; Analgesics, Opioid; Female; France; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pancreatitis; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Evaluation of effect of minocycline on rewarding potential and alcohol relapse in place preference model in mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Conditioning, Classical; Conditioning, Operant; Disease Models, Animal; Ethanol; Extinction, Psychological; Male; Mice; Minocycline; Naltrexone; Reward; Secondary Prevention | 2017 |
Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Interviews as Topic; Male; Naltrexone; Residential Treatment; Taurine; United States; United States Department of Veterans Affairs; Veterans | 2017 |
First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Naltrexone; Ontario; Population Surveillance; Retrospective Studies; Single-Payer System; Taurine; Young Adult | 2017 |
Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drinking Behavior; Female; Humans; Male; Naltrexone; Risk; Taurine; Treatment Outcome; United Kingdom; United States | 2017 |
Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders.
Topics: Adult; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Pilot Projects; Social Stigma; Text Messaging | 2018 |
Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
Topics: Adult; Alcohol-Related Disorders; Alcoholism; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists | 2017 |
Efficacy of Naltrexone for the Treatment of Alcohol Dependence in Latino Populations.
Topics: Adult; Alcoholism; Behavior Therapy; Black or African American; Female; Hispanic or Latino; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2017 |
Gambling Disorder and Concurrent Alcohol Use Disorder Treated With Naltrexone.
Topics: Adult; Alcoholism; Depressive Disorder; Gambling; Humans; Male; Naltrexone; Narcotic Antagonists | 2017 |
Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Baclofen; Disease Models, Animal; GABA-B Receptor Agonists; Naltrexone; Papio; Reinforcement, Psychology; Self Administration | 2017 |
Screening, treatment initiation, and referral for substance use disorders.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Mass Screening; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Tobacco Use Disorder | 2017 |
Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
Topics: Alcoholism; Antisocial Personality Disorder; Buprenorphine; Heroin Dependence; Humans; Male; Medication Errors; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2017 |
Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model.
Topics: Alcohol Drinking; Alcoholism; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Naltrexone; Quality-Adjusted Life Years; Risk | 2017 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate | 2018 |
Implementation of a Process for Initiating Naltrexone in Patients Hospitalized for Alcohol Detoxification or Withdrawal.
Topics: Alcohol Deterrents; Alcoholism; Counseling; Emergency Service, Hospital; Female; Health Plan Implementation; Humans; Male; Middle Aged; Naltrexone; Patient Discharge; Patient Readmission | 2018 |
Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2018 |
Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2018 |
Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Cohort Studies; Crime; Drug Overdose; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Factors; Suicidal Ideation; Young Adult | 2018 |
Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis.
Topics: Alcoholism; Animals; Conditioning, Operant; Dynorphins; Ethanol; Gene Expression Regulation; Male; Maze Learning; Naltrexone; Rats; Receptors, Opioid, kappa; RNA, Messenger; Self Administration; Septal Nuclei; Substance Withdrawal Syndrome; Up-Regulation; Vocalization, Animal | 2018 |
Adherence to extended release naltrexone: Patient and treatment characteristics.
Topics: Adult; Alcoholism; Delayed-Action Preparations; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Retrospective Studies; United States; Veterans; Veterans Health | 2018 |
Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention.
Topics: Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Medication Adherence; Naltrexone; Self Report | 2018 |
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Databases, Factual; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Off-Label Use; Risk Assessment; Socioeconomic Factors | 2018 |
Exploring Sex Differences in the Attenuation of Ethanol Drinking by Naltrexone in Dependent Rats During Early and Protracted Abstinence.
Topics: Administration, Inhalation; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Ethanol; Female; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Self Administration; Sex Characteristics; Substance Withdrawal Syndrome | 2018 |
Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.
Topics: Acamprosate; Alcoholism; Alleles; Computer Simulation; Cost-Benefit Analysis; Genotype; Health Care Costs; Humans; Markov Chains; Models, Statistical; Naltrexone; Pharmacogenetics; Quality-Adjusted Life Years; Receptors, Opioid, mu; Treatment Outcome | 2018 |
Tackling addiction in primary care.
Topics: Alcoholism; Buprenorphine; Drug Combinations; Humans; Illicit Drugs; Interdisciplinary Communication; Intersectoral Collaboration; Mass Screening; Minnesota; Naloxone; Naltrexone; Opioid-Related Disorders; Prescription Drugs; Primary Health Care; Referral and Consultation; Substance-Related Disorders | 2017 |
Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
Topics: Adult; Alcohol Drinking; Alcoholism; Cigarette Smoking; Craving; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Smokers; Smoking Cessation; Stress, Psychological; Varenicline; Young Adult | 2018 |
Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone.
Topics: Adult; Alcohol Abstinence; Alcoholism; Brain; Craving; Cues; Germany; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2020 |
Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders.
Topics: Alcoholism; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Models, Animal; Ethanol; Models, Biological; Naltrexone; Narcotic Antagonists | 2019 |
Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz.
Topics: Alcohol Drinking; Alcoholism; Antidepressive Agents; Humans; Ketamine; Naltrexone; Narcotic Antagonists; Population; Receptors, Opioid | 2019 |
Prescription Drug and Alcohol Use Disorders: Alcohol Use Disorder.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone | 2019 |
Therapeutic Drug Monitoring and the Clinical Significance of Naltrexone Blood Levels at the Time of a First Drink: Relevance to the Sinclair Method.
Topics: Alcohol Drinking; Alcoholism; Drug Monitoring; Humans; Naltrexone; Narcotic Antagonists; Time Factors | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect-Reply.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
[Medical rehabilitation of patients with alcohol dependency at risk of parental rights deprivation].
Topics: Adult; Alcoholism; Child; Humans; Naltrexone; Narcotic Antagonists; Parent-Child Relations; Parents | 2019 |
Dispensing of medication for alcohol use disorder; an examination of large databases in a New Zealand context.
Topics: Alcohol Deterrents; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; New Zealand; Quetiapine Fumarate | 2019 |
Should Long-Acting Depot Intramuscular Naltrexone Be Prescribed Every 3 Weeks for Alcohol Use Disorder?
Topics: Adult; Alcoholism; Delayed-Action Preparations; Drug Administration Schedule; Humans; Male; Naltrexone; Narcotic Antagonists | 2019 |
Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Drug Utilization; Female; Germany; Humans; Male; Middle Aged; Naltrexone; Practice Patterns, Physicians'; Specialization | 2020 |
The Prescription of Anticraving Medication and its Economic Consequences.
Topics: Alcohol Deterrents; Alcoholism; Cost Savings; Female; Germany; Hospitalization; Humans; Inpatients; Length of Stay; Male; Middle Aged; Naltrexone; Patient Readmission; Practice Patterns, Physicians' | 2019 |
Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation.
Topics: Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Genetic Variation; Humans; Male; Middle Aged; Naltrexone; Outcome Assessment, Health Care; Receptors, Opioid, mu | 2019 |
Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study.
Topics: Adult; Aged; Alcoholism; Analysis of Variance; Comorbidity; Diagnosis, Dual (Psychiatry); Drug Utilization; Female; Humans; Logistic Models; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Socioeconomic Factors; United States; United States Department of Veterans Affairs; Veterans | 2013 |
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Naltrexone; Patient Compliance; Patient Satisfaction; Taurine; Time Factors; Treatment Outcome | 2013 |
Naltrexone and nalmefene: any meaningful difference?
Topics: Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Secondary Prevention | 2013 |
Naltrexone-loaded poly[La-(Glc-Leu)] polymeric microspheres for the treatment of alcohol dependence: in vitro characterization and in vivo biocompatibility assessment.
Topics: Alcoholism; Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Emulsions; Lactic Acid; Leucine; Microspheres; Naltrexone; Particle Size; Polyglycolic Acid; Polymers; Rats; Rats, Wistar; Solvents | 2014 |
Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the dynorphin/kappa opioid receptor system.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcoholism; Analgesics, Non-Narcotic; Animals; Anxiety; Dose-Response Relationship, Drug; Dynorphins; Ethanol; Male; Maze Learning; Motor Activity; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, kappa; Stress, Psychological; Substance Withdrawal Syndrome | 2013 |
Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Combinations; Drug Synergism; Male; Naltrexone; Narcotic Antagonists; Prazosin; Rats; Rats, Wistar; Treatment Outcome | 2013 |
Treatment of comorbid substance dependence and posttraumatic stress disorder.
Topics: Alcoholism; Female; Humans; Implosive Therapy; Male; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic | 2013 |
Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Humans; Naltrexone; Narcotic Antagonists | 2013 |
Predictors of dropout in an outpatient treatment for problem drinkers including cognitive-behavioral therapy and the opioid antagonist naltrexone.
Topics: Adult; Aged; Alcoholism; Ambulatory Care; Analysis of Variance; Cognitive Behavioral Therapy; Female; Humans; Length of Stay; Male; Medication Adherence; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Outpatients; Patient Dropouts; Severity of Illness Index; Socioeconomic Factors; Young Adult | 2013 |
Therapy for posttraumatic stress and alcohol dependence.
Topics: Alcoholism; Female; Humans; Implosive Therapy; Male; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic | 2013 |
Therapy for posttraumatic stress and alcohol dependence--reply.
Topics: Alcoholism; Female; Humans; Implosive Therapy; Male; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic | 2013 |
Outcome predictors for problem drinkers treated with combined cognitive behavioral therapy and naltrexone.
Topics: Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Prognosis; Treatment Outcome | 2014 |
Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Bad medicine: using surrogate markers.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Treatment of fetishism with naltrexone: a case report.
Topics: Adult; Alcoholism; Fetishism, Psychiatric; Humans; Male; Marijuana Abuse; Naltrexone; Treatment Outcome | 2014 |
Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse.
Topics: Alcoholism; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Ethanol; Male; Naltrexone; Nicotine; Rats; Rats, Long-Evans; Self Administration; Smoking | 2014 |
Drug effects on multiple and concurrent schedules of ethanol- and food-maintained behaviour: context-dependent selectivity.
Topics: Alcoholism; Amphetamines; Animals; Chlordiazepoxide; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Eating; Ethanol; Food; Male; Morphinans; Naltrexone; Piperazines; Rats; Rats, Inbred Lew | 2014 |
Wim van den Brink and colleagues reply to Des Spence and Alain Braillon.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Light alcohol intake during adolescence induces alcohol addiction in a neurodevelopmental model of schizophrenia.
Topics: Alcohol Drinking; Alcoholism; Animals; Animals, Newborn; Central Nervous System Depressants; Conditioning, Operant; Disease Models, Animal; Drug-Seeking Behavior; Ethanol; Hippocampus; Male; Naltrexone; Narcotic Antagonists; Rats, Sprague-Dawley; Schizophrenia | 2015 |
Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Counseling; Craving; Delayed-Action Preparations; Feasibility Studies; Female; Glucuronates; Harm Reduction; Humans; Ill-Housed Persons; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Treatment Outcome | 2015 |
▼Nalmefene for alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Drug Approval; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prevalence; Sex Factors; United Kingdom | 2014 |
Difference of the naltrexone's effects in social drinkers by spicy food preference.
Topics: Adult; Alcohol Drinking; Alcoholism; Capsaicin; Food Preferences; Humans; Male; Naltrexone; Narcotic Antagonists; Sensory System Agents; Surveys and Questionnaires; Young Adult | 2014 |
Commentary on Garbutt et al. (2014): Can we predict who benefits from naltrexone in the treatment of alcohol dependence?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2014 |
Nalmefene. Alcohol dependence: no advance.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
Informed consent abandoned--patient given contraindicated drug.
Topics: Alcoholism; Contraindications; Depressive Disorder; Humans; Informed Consent; Male; Medication Reconciliation; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Pain; Risk Management; Treatment Outcome | 2014 |
A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Computer Simulation; England; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Naltrexone; Narcotic Antagonists; Wounds and Injuries | 2014 |
[Drug therapy supports reduction of alcohol consumption].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Taurine | 2014 |
Decision to recommend drug to cut drink dependence proves controversial.
Topics: Administration, Oral; Adult; Alcoholism; Decision Making; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Selection; Practice Guidelines as Topic; Risk Assessment; State Medicine; Treatment Outcome; United Kingdom | 2014 |
German evaluation says new drug for alcohol dependence is no better than old one.
Topics: Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone | 2014 |
Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Eating; Ethanol; Male; Naltrexone; Pregnanolone; Rats; Rats, Long-Evans; Self Administration; Taurine | 2015 |
Qualitatively and quantitatively evaluating harm-reduction goal setting among chronically homeless individuals with alcohol dependence.
Topics: Adult; Alcohol Abstinence; Alcoholism; Cohort Studies; Counseling; Female; Goals; Harm Reduction; Humans; Ill-Housed Persons; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient-Centered Care; Pilot Projects; Prospective Studies; Qualitative Research; Quality of Life; Temperance | 2015 |
Naltrexone reduces heavy drinking in problem drinkers across the spectrum of dependence.
Topics: Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone | 2015 |
[Acamprosate and naltrexone: similar efficacy for relapse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Taurine | 2014 |
Men Who Have Sex With Men in Peru: Acceptability of Medication-Assisted Therapy for Treating Alcohol Use Disorders.
Topics: Adult; Alcoholism; Focus Groups; Homosexuality, Male; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Peru | 2017 |
Views about responsibility for alcohol addiction and negative evaluations of naltrexone.
Topics: Adolescent; Adult; Alcoholism; Attitude of Health Personnel; Counseling; Data Collection; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2015 |
[We do not want more pills].
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Physician-Patient Relations | 2015 |
[Influence of nalmefene on psychosocial intervention in alcohol-dependent patients].
Topics: Alcohol Deterrents; Alcoholism; Humans; Naltrexone | 2015 |
Severe opioid withdrawal syndrome after a single dose of nalmefene.
Topics: Adult; Alcoholism; Analgesics, Opioid; Codeine; Contraindications; Drug Interactions; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2015 |
The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Demography; Female; Humans; Male; Middle Aged; Naltrexone; Patient Outcome Assessment; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2015 |
Dissociating Motivational From Physiological Withdrawal in Alcohol Dependence: Role of Central Amygdala κ-Opioid Receptors.
Topics: Administration, Intranasal; Alcoholism; Animals; Central Amygdaloid Nucleus; Central Nervous System Depressants; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats, Wistar; Receptors, Opioid, kappa; Self Administration; Substance Withdrawal Syndrome | 2016 |
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Autoradiography; Behavior, Animal; Central Nervous System Depressants; Cross-Over Studies; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Ethanol; Indans; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Radiopharmaceuticals; Receptors, Opioid, mu; Self Administration; Triazoles; Tritium | 2015 |
Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Drug Therapy, Combination; Male; Naltrexone; Narcotic Antagonists; Prazosin; Rats; Substance Withdrawal Syndrome; Treatment Outcome | 2015 |
Comparing treatment policies with assistance from the structural nested mean model.
Topics: Alcoholism; Algorithms; Computer Simulation; Data Interpretation, Statistical; Decision Making; Humans; Models, Statistical; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic | 2016 |
[Reduction of consumption as the first goal of therapy].
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2015 |
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pharmacovigilance; Substance Withdrawal Syndrome | 2015 |
Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
Topics: Administration, Oral; Alcoholism; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Injections, Intravenous; Models, Biological; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 2016 |
[Alcohol use disorders: current approaches to diagnosis and treatment].
Topics: Alcohol Drinking; Alcoholism; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; Female; Humans; International Classification of Diseases; Male; Naltrexone; Narcotic Antagonists; Remission Induction | 2015 |
Opioid antagonists block acetaldehyde-induced increments in dopamine neurons activity.
Topics: Acetaldehyde; Alcoholism; Animals; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Rats; Rats, Wistar; Ventral Tegmental Area | 2016 |
Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder.
Topics: Aged; Alcoholism; Disorders of Excessive Somnolence; Fatigue; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2016 |
Meta-analysis finds no evidence for efficacy of nalmefene in treating alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone | 2015 |
Association between a brief alcohol craving measure and drinking in the following week.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; United States | 2016 |
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Alcohols; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sodium Oxybate; Treatment Outcome | 2016 |
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost of Illness; Cost-Benefit Analysis; Crime; Efficiency; Female; Health Care Costs; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Naltrexone; Patient Acceptance of Health Care; Psychotherapy; Risk; United Kingdom; Young Adult | 2016 |
Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
Topics: Alcoholism; Animals; Brain; Disease Models, Animal; Ethanol; Female; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid | 2017 |
Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy?
Topics: Alcoholism; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2016 |
Multi-modal MRI classifiers identify excessive alcohol consumption and treatment effects in the brain.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Central Nervous System Depressants; Disease Models, Animal; Ethanol; Longitudinal Studies; Magnetic Resonance Imaging; Naltrexone; Narcotic Antagonists; Rats | 2017 |
A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Computer Simulation; Europe; Harm Reduction; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Outcome and Process Assessment, Health Care; Public Health; Social Support | 2016 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin?
Topics: Alcoholism; Appetite Depressants; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2016 |
National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Drug Administration Schedule; Female; Guideline Adherence; Humans; Insurance Claim Review; Male; Naltrexone; Patient Compliance; Retrospective Studies; Taurine; Temperance | 2016 |
Reductions in Alcohol Craving Following Naltrexone Treatment for Heavy Drinking.
Topics: Adult; Alcoholism; Case-Control Studies; Craving; Female; Humans; Male; Naltrexone; Narcotic Antagonists | 2016 |
Pharmacotherapy for Adults with Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2016 |
Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Rats; Rodentia; Treatment Outcome; Varenicline | 2016 |
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Female; Humans; Naltrexone | 2016 |
Comment on: "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence".
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2016 |
Evaluation in alcohol use disorders - insights from the nalmefene experience.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Female; Harm Reduction; Humans; Male; Naltrexone; Narcotic Antagonists | 2016 |
Functional modulation on macrophage by low dose naltrexone (LDN).
Topics: Alcoholism; Analgesics, Opioid; Animals; Cells, Cultured; Humans; Immunologic Factors; Interleukin-12; Lymphocyte Activation; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Naltrexone; Nitric Oxide; Receptors, IgG; Receptors, Opioid, delta; Substance-Related Disorders; Tumor Necrosis Factor-alpha | 2016 |
▼Nalmefene-time for last orders?
Topics: Alcoholism; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists | 2016 |
Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Topics: Acamprosate; Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Marijuana Use; Middle Aged; Naltrexone; Narcotic Antagonists; Prognosis; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2017 |
Nalmefene for alcohol dependence: a NICE decision?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic; State Medicine; United Kingdom | 2016 |
Naltrexone-Associated Acute Pancreatitis.
Topics: Adult; Alcohol Deterrents; Alcoholism; Humans; Male; Naltrexone; Narcotic Antagonists; Pancreatitis | 2016 |
A SMART data analysis method for constructing adaptive treatment strategies for substance use disorders.
Topics: Adaptive Clinical Trials as Topic; Alcoholism; Behavior Therapy; Data Interpretation, Statistical; Disease Management; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Regression Analysis; Telephone; Treatment Outcome | 2017 |
Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Australia; Drug Prescriptions; Female; Health Services Accessibility; Healthcare Disparities; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Retrospective Studies; Social Class; Taurine; Vulnerable Populations; Young Adult | 2017 |
A 35-year-old woman with low mood and concerns about her alcohol use.
Topics: Adult; Alcoholism; Antidepressive Agents; Counseling; Depressive Disorder, Major; Female; Humans; Naltrexone; Narcotic Antagonists; Patient Care Planning; Sertraline | 2017 |
Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals.
Topics: Adult; Alcohol Deterrents; Alcoholism; Brain; Female; Functional Neuroimaging; Healthy Volunteers; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Neural Pathways; Substance-Related Disorders; Young Adult | 2018 |
Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.
Topics: Alcohol Drinking; Alcoholism; Animals; Central Nervous System Agents; Diterpenes; Diterpenes, Clerodane; Drinking; Ethanol; Female; Male; Mesylates; Mice; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2017 |
Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence.
Topics: Alcoholism; Genetic Markers; Genetic Predisposition to Disease; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2008 |
Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Central Nervous System Depressants; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Ethanol; Food Preferences; Male; Naltrexone; Narcotic Antagonists; Pyrimidines; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid | 2008 |
[Pharmacotherapy of alcohol dependence].
Topics: Acamprosate; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Ambulatory Care; Anticonvulsants; Benzodiazepines; Chlormethiazole; Ethanol; Family Practice; Humans; Naltrexone; Patient Admission; Secondary Prevention; Substance Withdrawal Syndrome; Taurine | 2008 |
Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Cocaine-Related Disorders; Cognition Disorders; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Euphoria; Female; Humans; Male; Marijuana Abuse; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2008 |
The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Female; Holidays; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Social Support; Temperance; Young Adult | 2009 |
Alcohol dependence drug prompts warning.
Topics: Alcoholism; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists | 2008 |
"Narcotics helped, I thought." Recurrent traumatization and recovery from drug dependence.
Topics: Adaptation, Psychological; Adult; Alcoholism; Anxiety Disorders; Behavior Therapy; Child; Child Abuse; Child Abuse, Sexual; Combined Modality Therapy; Comorbidity; Countertransference; Diagnosis, Dual (Psychiatry); Family Therapy; Female; Humans; Life Change Events; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Physician-Patient Relations; Psychotherapy; Psychotherapy, Group; Reactive Attachment Disorder; Recurrence; Spouse Abuse | 2008 |
Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy, Combination; Genetic Carrier Screening; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Prognosis; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine; Treatment Outcome | 2008 |
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Delayed-Action Preparations; Disulfiram; Drug Costs; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osteopathic Medicine; Physicians; Physicians, Family; Psychiatry; Taurine; United States | 2009 |
Effects of naltrexone on cortisol levels in heavy drinkers.
Topics: Adult; Alcoholism; Central Nervous System Depressants; Dopamine; Ethanol; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires; Synaptic Transmission; Young Adult | 2009 |
Alleviation of both binge eating and sexual dysfunction with naltrexone.
Topics: Alcoholism; Antidepressive Agents; Bulimia; Child; Child Abuse; Depression; Female; Heroin Dependence; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Sex Work; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Stress Disorders, Post-Traumatic | 2008 |
Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Drug Prescriptions; England; Female; Health Services; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Retrospective Studies; Young Adult | 2008 |
Holidays, triggers, and willpower--is there a role for medications? A commentary on "The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients".
Topics: Alcohol Drinking; Alcoholism; Delayed-Action Preparations; Holidays; Humans; Naltrexone; Narcotic Antagonists | 2009 |
OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
Topics: Adult; Alcoholism; Amino Acid Substitution; Female; Gene Frequency; Haplotypes; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Treatment Outcome | 2009 |
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Body Weight; Conditioning, Operant; Data Interpretation, Statistical; Male; Naltrexone; Rats; Rats, Long-Evans; Sucrose; Taste; Taurine | 2009 |
Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network.
Topics: Adult; Alcoholism; Brain Mapping; Brain-Derived Neurotrophic Factor; Choice Behavior; Decision Making; DNA; Endorphins; Female; Genotype; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Naltrexone; Narcotic Antagonists; Nerve Net; Oxygen; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, Opioid, mu; Young Adult | 2009 |
Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Taurine; Treatment Outcome | 2009 |
The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence.
Topics: Adult; Aged; Alcoholism; Analysis of Variance; Australia; Cognitive Behavioral Therapy; Cost-Benefit Analysis; Female; Hospitals; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Quality-Adjusted Life Years; Substance Abuse Treatment Centers; Young Adult | 2009 |
Findings on alcohol dependence point to promising avenues for targeted therapies.
Topics: Alcoholism; Animals; Benzazepines; Humans; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Nicotinic Agonists; Pharmacogenetics; Pyridines; Quinoxalines; Receptors, Corticotropin-Releasing Hormone; Receptors, Opioid, mu; Stress, Psychological; Triazoles; Varenicline | 2009 |
[Pharmacological therapy of dependency on alcohol].
Topics: Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone | 2009 |
Counselor attitudes toward pharmacotherapies for alcohol dependence.
Topics: Alcoholism; Attitude of Health Personnel; Counseling; Female; Humans; Information Dissemination; Male; Middle Aged; Models, Statistical; Naltrexone | 2009 |
Questionable efficacy for naltrexone in patients with Asp40.
Topics: Alcoholism; Alleles; Cognitive Behavioral Therapy; Combined Modality Therapy; Epistasis, Genetic; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Treatment Outcome | 2009 |
Treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate; Vitamins | 2009 |
Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
Topics: Alcoholism; Animals; Aspartame; Conditioning, Operant; Disease Models, Animal; Female; Food Preferences; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Sweetening Agents | 2010 |
Two patients with eating disorders treated by naltrexone.
Topics: Adult; Affect; Alcoholism; Feeding and Eating Disorders; Female; Humans; Naltrexone; Narcotic Antagonists; Self-Assessment | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
Young Investigator Award symposium.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Alcoholism; Animals; Awards and Prizes; Corticotropin-Releasing Hormone; Excitatory Amino Acid Antagonists; Female; Humans; Hydrocortisone; Longitudinal Studies; Male; Mice; Naltrexone; Stress Disorders, Post-Traumatic; Stress, Psychological | 2009 |
Opioid-like activity of naltrexone on natural killer cell cytolytic activity and cytokine production in splenocytes: effects of alcohol.
Topics: Administration, Oral; Alcoholism; Animals; Cells, Cultured; Cytokines; Cytotoxicity, Immunologic; Drug Implants; Ethanol; Immunomodulation; Infusions, Subcutaneous; Killer Cells, Natural; Male; Naltrexone; Rats; Recovery of Function; Spleen | 2010 |
Gender differences in the genetic risk for alcohol dependence--the results of a pharmacogenetic study in Korean alcoholics.
Topics: Alcohol Dehydrogenase; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Asian People; Female; Genotype; Heterozygote; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Receptors, Opioid, mu; Risk; Sex Characteristics | 2009 |
The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Diffusion of Innovation; Follow-Up Studies; Health Services Research; Humans; Naltrexone; Nitrosamines; Organizational Culture; Organizational Innovation; Substance Abuse Treatment Centers; Taurine; United States | 2010 |
Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.
Topics: Adult; Alcoholism; Environment; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Receptors, Dopamine D4; Receptors, Opioid, mu; Tandem Repeat Sequences | 2010 |
Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.
Topics: Administration, Cutaneous; Alcoholism; Animals; Drug Delivery Systems; Female; Guinea Pigs; Male; Naltrexone; Skin; Skin Absorption | 2010 |
Pharmacotherapies for alcoholism: the old and the new.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Disease Models, Animal; Disulfiram; Drug Design; Humans; Naltrexone; Narcotic Antagonists; Neuropeptides; Neuropharmacology; Neurotransmitter Agents; Receptors, Neurotransmitter; Taurine | 2010 |
Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Financing, Personal; Health Expenditures; Humans; Naltrexone; Patient Acceptance of Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Taurine; United States | 2010 |
Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
Topics: Acamprosate; Administration, Oral; Adult; Age Factors; Alcohol Deterrents; Alcoholism; Ambulatory Care; Comorbidity; Delayed-Action Preparations; Disulfiram; Drug Therapy, Combination; Drug Utilization; Female; Humans; Injections, Intramuscular; Male; Mental Disorders; Middle Aged; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sex Factors; Substance Abuse Treatment Centers; Taurine; United States; Veterans | 2010 |
Extended-release naltrexone for treatment of alcohol dependence in primary care.
Topics: Adult; Alcohol Drinking; Alcoholism; Cohort Studies; Delayed-Action Preparations; Female; Hospitals, Public; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Primary Health Care | 2010 |
Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice.
Topics: Alcohol Drinking; Alcoholism; Amphetamine; Animals; Behavior, Addictive; Choice Behavior; Female; Impulsive Behavior; Male; Memantine; Mice; Naltrexone; Reaction Time | 2010 |
Treatments for alcohol dependence: rethinking the role of comorbidity and clinical subtypes.
Topics: Alcoholism; Cognitive Behavioral Therapy; Comorbidity; Depressive Disorder, Major; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Glutamatergic regulation of ghrelin-induced activation of the mesolimbic dopamine system.
Topics: 2-Amino-5-phosphonovalerate; Alcoholism; Animals; Benzoxazoles; Dopamine; Ghrelin; Limbic System; Male; Mesencephalon; Mice; Mice, Inbred Strains; Motor Activity; Naltrexone; Naphthyridines; Narcotic Antagonists; Nerve Net; Nucleus Accumbens; Orexin Receptors; Peptide Hormones; Receptors, G-Protein-Coupled; Receptors, N-Methyl-D-Aspartate; Receptors, Neuropeptide; Signal Transduction; Urea; Ventral Tegmental Area | 2011 |
Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats.
Topics: Administration, Inhalation; Alcohol Deterrents; Alcoholism; Animals; Dose-Response Relationship, Drug; Dynorphins; Ethanol; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Premedication; Rats; Rats, Wistar; Receptors, Opioid, kappa; Self Administration; Substance Withdrawal Syndrome | 2011 |
A patient-supported clinical trial.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists | 2010 |
Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Sex Characteristics; Taurine; Treatment Outcome | 2010 |
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Temperance; Time Factors; Topiramate; Treatment Outcome | 2010 |
Naltrexone effects in patients with dementia.
Topics: Age Factors; Aged; Aged, 80 and over; Alcoholism; Alzheimer Disease; Behavior, Addictive; Comorbidity; Female; Humans; Male; Naltrexone; Treatment Outcome | 2010 |
Comparison of healthcare utilization among patients treated with alcoholism medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Female; Health Services; Health Status Indicators; Humans; Inpatients; Insurance Claim Review; Male; Middle Aged; Naltrexone; Narcotics; Propensity Score; Retrospective Studies; Taurine; United States | 2010 |
Study suggests gene may predict success of therapies for alcohol dependence.
Topics: Alcoholism; Genetic Predisposition to Disease; Humans; Naltrexone; Narcotic Antagonists; Ondansetron; Predictive Value of Tests; Receptors, Opioid, mu; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome | 2011 |
[Anesthetic considerations in a patient taking disulfiram and naltrexone for chronic alcoholism].
Topics: Alcohol Deterrents; Alcoholism; Anesthesia; Disulfiram; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2011 |
Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study.
Topics: Adult; Alcoholism; Dizziness; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Nausea; Pilot Projects; Treatment Outcome | 2011 |
Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.
Topics: Alcoholism; Chromatography, Gel; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Lactic Acid; Microspheres; Molecular Weight; Naltrexone; Narcotic Antagonists; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Temperature; Time Factors; Transition Temperature | 2011 |
[Amisulpride for the treatment of alcohol dependence].
Topics: Alcoholism; Amisulpride; Anticonvulsants; Antipsychotic Agents; Female; Fructose; Humans; Male; Naltrexone; Narcotic Antagonists; Sulpiride; Topiramate | 2011 |
A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Databases, Factual; Disulfiram; Drug Utilization; Ethanol; Humans; Longitudinal Studies; Naltrexone; Practice Patterns, Physicians'; Substance Abuse Treatment Centers; Time Factors | 2011 |
Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
Topics: Adult; Alcohol Drinking; Alcoholism; Automobile Driving; Criminal Law; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Michigan; Missouri; Naltrexone; Narcotic Antagonists; Pilot Projects; Retrospective Studies; Substance Abuse Detection; Substance Withdrawal Syndrome; Temperance | 2011 |
Adapting treatment to patient problems.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Humans; Naltrexone; Research Design; Sertraline | 2011 |
Utilization patterns of extended-release naltrexone for alcohol dependence.
Topics: Alcoholism; Costs and Cost Analysis; Female; Health Care Costs; Health Services; Humans; Male; Naltrexone; Narcotic Antagonists; Retrospective Studies; Time Factors; United States | 2011 |
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Chi-Square Distribution; Databases, Factual; Disulfiram; Female; Health Care Costs; Health Services; Humans; Male; Naltrexone; Narcotic Antagonists; Propensity Score; Retrospective Studies; Statistics as Topic; Statistics, Nonparametric; Taurine; Treatment Outcome; United States | 2011 |
Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.
Topics: Adult; Aged; Alanine Transaminase; Alcoholism; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Databases, Factual; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; RNA, Viral; Veterans | 2012 |
Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
Topics: Adult; Alcohol Drinking; Alcoholism; Automobile Driving; Biomarkers; Breath Tests; Criminals; Delayed-Action Preparations; Feasibility Studies; Female; Humans; Injections, Intravenous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Protective Devices; Recurrence; Treatment Outcome; Young Adult | 2011 |
OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Topics: Adult; Alcoholism; Australia; Cognitive Behavioral Therapy; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; White People | 2011 |
Early maternal separation affects ethanol-induced conditioning in a nor-BNI insensitive manner, but does not alter ethanol-induced locomotor activity.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Animals, Newborn; Appetitive Behavior; Behavior, Animal; Conditioning, Psychological; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Male; Maternal Deprivation; Motor Activity; Naltrexone; Narcotic Antagonists; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reinforcement, Psychology; Severity of Illness Index | 2012 |
Contributions of a relational psychoanalytic approach to dealing with the nonadherent psychiatric patient.
Topics: Alcoholism; Attitude of Health Personnel; Diagnosis, Dual (Psychiatry); Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Narration; Obsessive-Compulsive Disorder; Physician-Patient Relations; Psychoanalytic Therapy; Selective Serotonin Reuptake Inhibitors | 2011 |
Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Topics: Acamprosate; Alcoholism; Alleles; Disulfiram; Genetic Markers; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Opioid, mu; Serotonin Plasma Membrane Transport Proteins; Taurine | 2012 |
The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects.
Topics: Adrenocorticotropic Hormone; Adult; Alcoholism; Area Under Curve; Case-Control Studies; Dose-Response Relationship, Drug; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Ligands; Limbic System; Linear Models; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Positron-Emission Tomography; Receptors, Opioid, delta; Stress, Psychological; Young Adult | 2013 |
κ opioid regulation of anxiety-like behavior during acute ethanol withdrawal.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcoholism; Animals; Anxiety; Behavior, Animal; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Receptors, Opioid, kappa; Substance Withdrawal Syndrome | 2012 |
Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography.
Topics: Acetates; Adolescent; Adult; Aged; Alcoholism; Chromatography, High Pressure Liquid; Female; Humans; Hydrogen-Ion Concentration; Liquid-Liquid Extraction; Male; Middle Aged; Nalorphine; Naltrexone; Narcotic Antagonists; Perchlorates; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2012 |
Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.
Topics: Adult; Alcoholism; Brain; Brain Mapping; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Receptors, Opioid, mu; Severity of Illness Index; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Tobacco Use Disorder | 2014 |
Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Disulfiram; Drug Utilization; Female; Formularies as Topic; Health Care Surveys; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Preference; Practice Guidelines as Topic; Practice Patterns, Physicians'; Qualitative Research; Taurine; United States; United States Department of Veterans Affairs; Veterans Health | 2013 |
[Naltrexone use in the treatment of alcoholism in Spain].
Topics: Adult; Alcoholism; Drug Utilization; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Prospective Studies; Spain | 2002 |
Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms.
Topics: Administration, Inhalation; Alcoholism; Animals; Appetitive Behavior; Behavior, Animal; Conditioning, Psychological; Corticotropin-Releasing Hormone; Cues; Disease Models, Animal; Drug Synergism; Electroshock; Ethanol; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid; Recurrence; Self Administration; Stress, Physiological | 2002 |
Combining naltrexone and behavior therapy.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2002 |
Research to practice: adoption of naltrexone in alcoholism treatment.
Topics: Alcoholism; Attitude of Health Personnel; Drug Utilization; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Surveys and Questionnaires | 2003 |
Preclinical and clinical studies on naltrexone: what have they taught each other?
Topics: Alcoholism; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Naltrexone | 2003 |
Physicians' opinions about medications to treat alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Clinical Competence; Disulfiram; Health Care Surveys; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2003 |
Selective delta-opioid receptor antagonist N,N(CH3)2-Dmt-Tic-OH does not reduce ethanol intake in alcohol-preferring AA rats.
Topics: Alcoholism; Animals; Behavior, Animal; Brain; Choice Behavior; Dipeptides; Drug Administration Schedule; Enkephalin, D-Penicillamine (2,5)-; Ethanol; Locomotion; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid, delta; Tetrahydroisoquinolines | 2003 |
New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Humans; Naltrexone; Taurine; Treatment Refusal | 2003 |
[Use of naltrexone in the treatment of alcoholism in Spain].
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Spain | 2003 |
Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs.
Topics: Adult; Alcoholism; Chi-Square Distribution; Databases, Factual; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Naltrexone; Odds Ratio; Retrospective Studies; United States; United States Department of Veterans Affairs | 2003 |
GABA(A) and opioid receptors of the central nucleus of the amygdala selectively regulate ethanol-maintained behaviors.
Topics: Alcoholism; Amygdala; Analysis of Variance; Animals; Behavior, Addictive; Carbolines; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Female; GABA-A Receptor Antagonists; Male; Microinjections; Naltrexone; Narcotic Antagonists; Putamen; Rats; Rats, Inbred Strains; Receptors, GABA-A; Receptors, Opioid; Reinforcement, Psychology; Sucrose; Time Factors | 2004 |
Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone.
Topics: Alcoholism; Animals; Cues; Dopamine; Dopamine Antagonists; Drug Tolerance; Extracellular Fluid; Male; Mice; Mice, Inbred C57BL; Naltrexone; Nucleus Accumbens | 2003 |
Datapoints: Trends in naltrexone use among members of a large private health plan.
Topics: Alcoholism; Drug Therapy; Humans; Insurance, Health; Naltrexone; United States | 2004 |
Building bridges: the transdisciplinary study of craving from the animal laboratory to the lamppost.
Topics: Alcoholism; Animals; Behavior, Addictive; Disease Models, Animal; Humans; Naltrexone; Societies, Medical; United States | 2004 |
The treatment of alcohol dependence--new horizons.
Topics: Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Contraindications; Disulfiram; Humans; Naltrexone | 2004 |
Genes harbor clues to addiction, recovery.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Receptors, Dopamine D2; Receptors, Opioid, mu; Tobacco Use Disorder | 2004 |
Rats on the grog: novel pharmacotherapies for alcohol craving.
Topics: Alcoholism; Animals; Baclofen; Beer; Behavior, Addictive; Cannabinoid Receptor Antagonists; Corticotropin-Releasing Hormone; Humans; Models, Animal; Naltrexone; Narcotic Antagonists; Neuropeptide Y; Piperidines; Pyrazoles; Rats; Receptors, Corticotropin-Releasing Hormone; Receptors, GABA-B; Research Design; Rimonabant | 2004 |
Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
Topics: Alcoholism; Animals; Area Under Curve; Delayed-Action Preparations; Equipment Design; Humans; Infusion Pumps, Implantable; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Technology, Pharmaceutical | 2004 |
The mosaic of addiction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, Animal; Endorphins; Ethanol; Euphoria; Humans; Naltrexone; Receptors, Dopamine D2; Receptors, Opioid; Secondary Prevention; Taurine | 2004 |
Acamprosate campral for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Diarrhea; Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Taurine | 2005 |
Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil.
Topics: Adult; Alcohol Drinking; Alcoholism; Basal Ganglia; Behavior, Addictive; Carbon Radioisotopes; Fentanyl; Hospitalization; Humans; Male; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Psychiatric Status Rating Scales; Receptors, Opioid, mu; Severity of Illness Index; Temperance | 2005 |
[The pharmacologic treatment of the alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression.
Topics: Alcoholism; Amitriptyline; Depressive Disorder, Major; Ethanol; Humans; Male; Middle Aged; Morphine; Morphine Dependence; Naltrexone; Narcotics; Severity of Illness Index; Substance Withdrawal Syndrome | 2005 |
A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Secondary Prevention; Sex Characteristics; Taurine | 2005 |
Suppression of the HPA axis stress-response: implications for relapse.
Topics: Adrenocorticotropic Hormone; Alcoholism; Arousal; Drive; Genetic Predisposition to Disease; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Naltrexone; Pituitary-Adrenal System; Recurrence; Risk | 2005 |
Naltrexone treatment for alcohol dependency.
Topics: Administration, Oral; Alcoholism; Animals; Baclofen; Ethanol; GABA Agonists; Humans; Naltrexone; Narcotic Antagonists | 2005 |
Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.
Topics: Academies and Institutes; Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cooperative Behavior; Cross-Cultural Comparison; Disulfiram; Drug Approval; Drug Industry; Drugs, Investigational; Evidence-Based Medicine; Humans; Interprofessional Relations; Naltrexone; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Taurine | 2005 |
Drug treatment for alcoholism today.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine; Topiramate | 2005 |
How pilot studies improve large-scale clinical trials: lessons learned from the COMBINE Study.
Topics: Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Pilot Projects | 2005 |
Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Research Design; Taurine; Treatment Outcome | 2005 |
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Guidelines as Topic; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Observer Variation; Surveys and Questionnaires; Taurine; Terminology as Topic | 2005 |
New alcohol abuse drugs emerging. Anti-craving meds are finally here to treat alcohol dependence, recognized as a disease of the brain.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 2005 |
Development of a mouse model of ethanol addiction: naltrexone efficacy in reducing consumption but not craving.
Topics: Alcoholism; Animals; Anxiety; Disease Models, Animal; Individuality; Male; Mice; Motor Activity; Naltrexone; Narcotic Antagonists; Reproducibility of Results; Self Administration | 2006 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 2006 |
Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes.
Topics: Adult; Alcohol Deterrents; Alcoholism; beta-Endorphin; Cells, Cultured; Disease Susceptibility; Drug Evaluation, Preclinical; Ethanol; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hybrid Cells; Leukemia Virus, Murine; Lymphocytes; Male; Middle Aged; Naltrexone; Peptide Fragments; Peptides; Receptors, Opioid, mu; RNA, Messenger; Somatostatin; T-Lymphocytes; Up-Regulation; Virion; Virus Replication | 2006 |
The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Attitude to Health; Disulfiram; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychological Theory; Psychology; Psychotherapy; Taurine | 2006 |
Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Appetitive Behavior; Dose-Response Relationship, Drug; Drinking; Hunger; Injections, Intraperitoneal; Male; Mice; Mice, Inbred Strains; Naltrexone; Reinforcement Schedule; Taurine; Thirst | 2006 |
[Maintaining abstinence after alcohol detoxification].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ambulatory Care; Behavior Therapy; Clinical Protocols; Cognitive Behavioral Therapy; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Patient Care Planning; Psychoanalytic Therapy; Psychotherapy, Group; Psychotropic Drugs; Social Support; Taurine; Temperance | 2006 |
Study of hepatotoxicity of naltrexone in the treatment of alcoholism.
Topics: Adolescent; Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Time Factors | 2006 |
Naltrexone in patients with bipolar disorder and alcohol dependence.
Topics: Adult; Alcoholism; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pilot Projects; Psychiatric Status Rating Scales; Psychotropic Drugs; Secondary Prevention; Substance Abuse Detection; Substance-Related Disorders; Treatment Outcome | 2006 |
Pharmacological management of a teen with significant alcohol use and depression.
Topics: Adolescent; Alcoholism; Antidepressive Agents; Depression; Female; Humans; Naltrexone; Narcotic Antagonists; Sertraline | 2006 |
Naltrexone (vivitrol)--a once-monthly injection for alcoholism.
Topics: Alcoholism; Counseling; Drug Interactions; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2006 |
Treatment of alcoholism: new results.
Topics: Alcohol Deterrents; Alcoholism; Behavior Therapy; Humans; Interview, Psychological; Naltrexone; Self-Help Groups | 2006 |
Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Taurine | 2006 |
Extended-release intramuscular naltrexone: a viewpoint by Steven Siegel.
Topics: Alcoholism; Delayed-Action Preparations; Humans; Injections, Intramuscular; Lactic Acid; Microspheres; Naltrexone; Narcotic Antagonists; Patient Compliance; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Treatment Outcome | 2006 |
Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2006 |
[Alcohol dependence. Behavior therapy is effective with naltrexone].
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2006 |
[Drugs against alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Drug Evaluation; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2006 |
Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
Topics: Adult; Alcohol Drinking; Alcoholism; Behavior, Addictive; Choice Behavior; Dose-Response Relationship, Drug; Family; Female; Genetic Predisposition to Disease; Humans; Male; Naltrexone; Narcotic Antagonists; Reward; Sex Factors; Treatment Outcome | 2007 |
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Nitriles; Receptors, Dopamine D3; Taurine; Tetrahydroisoquinolines | 2007 |
Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
Topics: Administration, Inhalation; Alcoholism; Animals; Central Nervous System Depressants; Conditioning, Operant; Data Interpretation, Statistical; Dynorphins; Ethanol; Injections, Intraventricular; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome | 2008 |
Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects.
Topics: Adult; Alcoholism; Analgesics, Opioid; Data Interpretation, Statistical; Female; Fentanyl; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Temperance | 2008 |
Availability of addiction medications in private health plans.
Topics: Alcohol Deterrents; Alcoholism; Buprenorphine; Cost Sharing; Data Collection; Disulfiram; Drugs, Generic; Formularies as Topic; Health Services Accessibility; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States | 2008 |
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Genetic Predisposition to Disease; Germany; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Randomized Controlled Trials as Topic; Recurrence; Spain; Taurine; Treatment Outcome | 2008 |
GABAergic medications for treating alcohol dependence.
Topics: Alcoholism; Baclofen; Drug Therapy, Combination; GABA Agonists; gamma-Aminobutyric Acid; Humans; Hydroxybutyrates; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, GABA-B; Substance Withdrawal Syndrome; Temperance | 2007 |
Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.
Topics: Adolescent; Adult; Aged; Alcoholism; Delayed-Action Preparations; Female; Humans; Injections; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Naltrexone; Narcotic Antagonists | 2007 |
Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Topics: Adult; Age of Onset; Alcohol Drinking; Alcoholism; Environment; Female; Humans; Male; Minisatellite Repeats; Naltrexone; Narcotic Antagonists; Patient Compliance; Polymorphism, Single Nucleotide; Receptors, Dopamine D4; Receptors, Opioid, mu; Reproducibility of Results; Sex Factors; Time Factors | 2008 |
New therapies for alcohol dependence open options for office-based treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family Practice; Fructose; Humans; Naltrexone; Taurine; Topiramate | 2007 |
On treatment mechanisms--what can we learn from the COMBINE study?
Topics: Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Needs Assessment | 2008 |
Prospects for a genomic approach to the treatment of alcoholism.
Topics: Alcoholism; Alleles; Animals; Clinical Trials as Topic; Disease Models, Animal; Genetic Markers; Genomics; Humans; Macaca mulatta; Naltrexone; Narcotic Antagonists; Opioid Peptides; Receptors, Opioid, mu | 2008 |
Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol-preferring rats chronically treated with naltrexone.
Topics: Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Behavior, Animal; beta-Endorphin; Central Nervous System Depressants; Disease Models, Animal; Ethanol; Female; Naltrexone; Narcotic Antagonists; Rats; Time Factors | 2008 |
Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders.
Topics: Adult; Alcoholism; Female; Humans; Male; Motivation; Naltrexone; Narcotics; Schizophrenia; Token Economy | 2008 |
Improving acceptance of naltrexone in community addiction treatment centers: a pilot study.
Topics: Adult; Alcoholism; Community Health Services; Data Collection; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Inservice Training; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Substance Abuse Treatment Centers | 2008 |
Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist?
Topics: Adult; Aged; Alcoholism; Cognitive Behavioral Therapy; Data Interpretation, Statistical; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Randomized Controlled Trials as Topic; Sex Factors; Treatment Outcome | 2008 |
Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone.
Topics: Alcoholism; Analgesics, Opioid; Animals; Delayed-Action Preparations; Drug Interactions; Fentanyl; Humans; Hydrocodone; Male; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Plethysmography, Whole Body; Rats; Rats, Sprague-Dawley; Respiration | 2008 |
From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Receptors, Dopamine; Receptors, GABA; Receptors, Opioid; Taurine | 2008 |
Preclinical models to evaluate potential pharmacotherapeutic agents in treating alcoholism and studying the neuropharmacological bases of ethanol-seeking behaviors in rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Disease Models, Animal; Drug Evaluation, Preclinical; Ethanol; Female; Male; Naltrexone; Rats; Reinforcement Schedule | 2002 |
Role of state policies in the adoption of naltrexone for substance abuse treatment.
Topics: Adult; Alcoholism; Cost Control; Cross-Sectional Studies; Diffusion of Innovation; Drug Costs; Drugs, Generic; Humans; Naltrexone; Narcotic Antagonists; Policy Making; State Government; United States | 2008 |
Tetrahydroisoquinoline and opioid substrates of alcohol actions.
Topics: Alcoholism; Animals; Disease Models, Animal; Ethanol; Humans; Isoquinolines; Macaca mulatta; Male; Naloxone; Naltrexone; Narcotics; Rats; Rats, Inbred Strains; Self Administration; Tetrahydroisoquinolines | 1982 |
Naltrexone in alcohol dependence.
Topics: Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Patient Compliance | 1995 |
Naltrexone for alcohol dependence.
Topics: Alcoholism; Clinical Trials as Topic; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Interactions; Humans; Naltrexone; Pain; Randomized Controlled Trials as Topic; Thioridazine | 1995 |
Naltrexone gains alcoholism indication.
Topics: Alcoholism; Humans; Naltrexone; Treatment Outcome | 1995 |
I get no kick from CH3CH2OH.
Topics: Alcoholism; Drug Approval; Humans; Naltrexone; United States; United States Food and Drug Administration | 1995 |
From the Food and Drug Administration.
Topics: Alcoholism; Diabetes Mellitus, Type 2; Drug Approval; Enzyme-Linked Immunosorbent Assay; HIV Antibodies; HIV Infections; HIV-1; Humans; Metformin; Naltrexone; Saliva; United States; United States Food and Drug Administration | 1995 |
[USA approves of a new drug that decreases the craving for alcohol].
Topics: Alcoholism; Drug Approval; Humans; Naltrexone; Substance Withdrawal Syndrome; United States | 1995 |
From the National Institutes of Health.
Topics: Alcoholism; Animals; Brain Chemistry; Humans; Naltrexone; National Institutes of Health (U.S.); Neurotransmitter Agents; United States | 1994 |
Naltrexone and alcohol dependence: some methodological issues.
Topics: Alcoholism; Chi-Square Distribution; Humans; Naltrexone; Probability; Psychiatric Status Rating Scales; Research Design | 1994 |
Amethystic agents and adjunct behavioral therapy and psychotherapy.
Topics: Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyanamide; Humans; Naltrexone; Outcome and Process Assessment, Health Care; Psychotherapy; Substance Abuse Detection | 1993 |
Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Taste | 1996 |
Strategies to maximize the efficacy of naltrexone for alcohol dependence.
Topics: Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Social Support | 1995 |
Suppression of splenic natural killer cell activity in a mouse model for binge drinking. II. Role of the neuroendocrine system.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alcoholism; Animals; Azides; Benzodiazepines; Carbolines; Catecholamines; Corticosterone; Diazepam; Disease Models, Animal; Female; GABA-A Receptor Agonists; Glucocorticoids; Immunity, Cellular; Immunity, Innate; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mifepristone; Nadolol; Naltrexone; Neurosecretory Systems; Oxidopamine; Phentolamine; Picrotoxin; Propranolol; Receptors, GABA-A; Spleen; Sympathetic Nervous System | 1996 |
Misuse of naltrexone.
Topics: Adult; Alcoholism; Humans; Male; Naltrexone; Schizophrenia, Paranoid; Substance-Related Disorders | 1996 |
Pharmacotherapy of alcoholism--10 years of progress.
Topics: Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Humans; Naltrexone; Psychotherapy; Serotonin Agents; Treatment Outcome | 1996 |
International update: new findings on promising medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity; Europe; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Taurine; United States | 1996 |
Alternatives to naltrexone in animal models.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Haplorhini; Humans; Naltrexone; Narcotic Antagonists; Rats; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; Thyrotropin-Releasing Hormone | 1996 |
Periodic naltrexone and propensity to take alcoholic beverage.
Topics: Alcohol Drinking; Alcoholism; Animals; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Taste; Temperance | 1996 |
Naltrexone hydrochloride use in the treatment of alcoholism.
Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 1996 |
Naltrexone for alcohol abuse.
Topics: Adolescent; Alcoholism; Humans; Male; Naltrexone | 1997 |
Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone.
Topics: Adult; Alcoholism; Borderline Personality Disorder; Female; Humans; Naltrexone; Self Mutilation | 1997 |
Managing pain in addicted patients.
Topics: Alcoholism; Analgesics; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Pain; Recurrence; Substance-Related Disorders | 1997 |
Sequential use of naltrexone in the treatment of relapsing alcoholism.
Topics: Adult; Alcohol Drinking; Alcoholism; Drug Administration Schedule; Humans; Male; Naltrexone; Recurrence | 1997 |
Addiction medicine.
Topics: Alcoholism; Behavior Therapy; Clinical Medicine; Humans; Liver Transplantation; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 1997 |
Interactions between alcohol- and opioid-induced suppression of rat testicular steroidogenesis in vivo.
Topics: Alcoholism; Animals; Dose-Response Relationship, Drug; Ethanol; Luteinizing Hormone; Male; Morphine; Naltrexone; Narcotic Antagonists; Opioid Peptides; Rats; Testis; Testosterone | 1997 |
Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Dose-Response Relationship, Drug; Drug Implants; Female; Mice; Mice, Inbred C57BL; Motivation; Naltrexone; Narcotic Antagonists; Opioid Peptides; Receptors, Opioid | 1997 |
Naltrexone: a controversial therapy for alcohol dependence.
Topics: Alcoholics Anonymous; Alcoholism; Behavior, Addictive; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Psychiatric Nursing; Temperance | 1997 |
Naltrexone biotransformation and incidence of subjective side effects: a preliminary study.
Topics: Administration, Oral; Adult; Alcoholism; Biotransformation; Humans; Male; Metabolic Clearance Rate; Naltrexone; Narcotic Antagonists; Patient Compliance | 1997 |
What you need to know: addiction--prescribing naltrexone.
Topics: Alcoholism; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1997 |
Current research in the treatment of alcoholism in liver transplant recipients.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Liver Diseases, Alcoholic; Liver Transplantation; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Recurrence; Research Design | 1997 |
New drug treatments for alcohol problems: a critical appraisal.
Topics: Acamprosate; Alcoholism; Anti-Anxiety Agents; Buspirone; Dopamine Antagonists; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Taurine | 1997 |
Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Synergism; Drug Tolerance; Fluoxetine; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors | 1997 |
A preliminary investigation of the management of alcohol dependence with naltrexone by primary care providers.
Topics: Alcohol Drinking; Alcoholism; Counseling; Female; Humans; Liver; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Primary Health Care; Treatment Outcome | 1997 |
Naltrexone in the treatment of pathological gambling and alcohol dependence.
Topics: Alcoholism; Combined Modality Therapy; Comorbidity; Gambling; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 1998 |
New treatment options for substance abuse from a public health viewpoint.
Topics: Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Extinction, Psychological; Humans; Naltrexone; Narcotic Antagonists | 1998 |
Alcoholic patients' experience and attitudes on pharmacotherapy for alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Patient Acceptance of Health Care | 1998 |
Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Alcoholism; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Infusions, Intravenous; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Treatment Outcome | 1998 |
[Medical treatment of alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 1998 |
How is naltrexone used in the treatment of alcoholism?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 1998 |
The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Genotype; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains | 1998 |
Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat.
Topics: Alcoholism; Animals; Drug Tolerance; Humans; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid | 1998 |
New treatments for alcohol dependency better than old.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Taurine | 1999 |
Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification.
Topics: Adult; Alcoholism; Brain; Cerebrovascular Circulation; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Radiopharmaceuticals; Technetium Tc 99m Exametazime; Temperance; Tomography, Emission-Computed, Single-Photon | 1999 |
Drug reduces alcohol craving.
Topics: Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 1999 |
CSAT consensus panel supports expanded use of naltrexone for treatment of alcohol dependence. Center for Substance Abuse Treatment.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 1999 |
Rhabdomyolysis associated with naltrexone.
Topics: Adult; Alcoholism; Depression; Humans; Male; Naltrexone; Narcotic Antagonists; Rhabdomyolysis | 1999 |
[Interactions between naltrexone, an opioid antagonist, and opioids administered during general anesthesia].
Topics: Alcoholism; Analgesics, Opioid; Anesthesia, Intravenous; Anesthetics, Intravenous; Drug Interactions; Female; Humans; Hysterectomy; Middle Aged; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Sufentanil | 1999 |
Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alcohol Drinking; Alcoholism; Animals; Benzomorphans; Ethanol; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid; Reinforcement, Psychology; Self Administration; Sucrose | 1999 |
Prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Self-Help Groups; Taurine | 1999 |
Medical allies against alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 1999 |
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine | 1999 |
Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats.
Topics: Alcoholism; Animals; Ethanol; Male; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Self Administration | 1999 |
Psychometric properties of the Penn Alcohol Craving Scale.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Psychometrics; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires | 1999 |
[Acute delirium psychosis induced by naltrexone chlorhydrate].
Topics: Adult; Alcoholism; Delirium; Female; Hallucinations; Humans; Naltrexone; Psychoses, Alcoholic | 1999 |
Naltrexone: new preparation. Transient preventive efficacy on alcoholic relapse.
Topics: Alcohol Deterrents; Alcoholism; Controlled Clinical Trials as Topic; Drug Evaluation; Humans; Naltrexone; Narcotic Antagonists; Secondary Prevention; Temperance; Treatment Outcome | 1999 |
Alcoholics Anonymous and the use of medications to prevent relapse: an anonymous survey of member attitudes.
Topics: Adult; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Attitude to Health; Female; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Sampling Studies | 2000 |
Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects.
Topics: Adolescent; Adult; Age Factors; Aged; Alcoholism; Female; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Sex Factors; Temperance | 2000 |
Naltrexone for individuals with comorbid bipolar disorder and alcohol dependence.
Topics: Adult; Alcoholism; Bipolar Disorder; Diagnosis, Dual (Psychiatry); Female; Humans; Naltrexone; Narcotic Antagonists; Nausea | 2000 |
Nalmefene for alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2000 |
Pharmacological validation of a new animal model of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Reproducibility of Results; Secondary Prevention; Self Administration; Substance Withdrawal Syndrome; Taurine | 2000 |
Pharmacogenetics of alcohol: treatment implications.
Topics: Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Central Nervous System Depressants; Cytochrome P-450 CYP2E1; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics | 2000 |
Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness.
Topics: Adult; Alcoholism; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders; Naltrexone; Narcotic Antagonists; Prospective Studies; Psychiatric Status Rating Scales; Retrospective Studies | 2000 |
Can this pill stop you from hitting the bottle?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Humans; Motivation; Naltrexone; Narcotic Antagonists; Taurine; United States | 2001 |
Adherence with naltrexone prescription advice in hospital outpatient alcohol rehabilitation programme.
Topics: Adult; Aged; Alcoholism; Drug Prescriptions; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Patient Compliance | 2001 |
Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates.
Topics: Adult; Albumins; Alcoholism; Female; Humans; Liver Transplantation; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care | 2001 |
Combined behavioral and pharmacologic treatments of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine | 2001 |
Does the alcoholic's remedy come in a pill?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Excitatory Amino Acid Antagonists; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Patient Compliance; Serotonin Antagonists; Social Support; Taurine; United States | 2001 |
Outpatient cognitive behavioural therapy programme for alcohol dependence: impact of naltrexone use on outcome.
Topics: Adult; Alcoholism; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Naltrexone; Narcotics; Program Evaluation; Treatment Outcome | 2001 |
Research with rats germane to medication for alcoholism: consequences of noncompliance.
Topics: Alcohol Drinking; Alcoholism; Animals; Calcium Channel Blockers; Drinking; Drug Therapy, Combination; Isradipine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Temperance | 2001 |
Addiction medicine for the primary care physician.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Primary Health Care; Recurrence; Risk Factors; Severity of Illness Index; Substance-Related Disorders; Taurine; Treatment Outcome | 2001 |
Naltrexone treatment for alcohol dependence.
Topics: Alcoholism; Combined Modality Therapy; Counseling; Humans; Naltrexone; Narcotic Antagonists; Treatment Failure | 2001 |
Naltrexone for alcohol dependence: comments on Morris et al. (2001).
Topics: Alcoholism; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Naltrexone in the treatment of alcohol dependence: what clinicians need to know.
Topics: Alcoholism; Humans; Mental Disorders; Naltrexone; Narcotic Antagonists; Temperance | 2001 |
Naltrexone for drinking problems: useful further evidence on efficacy.
Topics: Alcoholism; Behavior Therapy; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Naltrexone for alcohol dependence: compliance is a key issue.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Patient Compliance; Treatment Outcome | 2001 |
Getting beyond the research clinic studies: comments on Morris et al. (2001).
Topics: Alcoholism; Humans; Male; Naltrexone; Narcotic Antagonists; Temperance; Treatment Outcome | 2001 |
Conservative management with naltrexone of an iatrogenic methadone overdose in an opiate-naive patient.
Topics: Alcoholism; Cocaine-Related Disorders; Diagnosis, Dual (Psychiatry); Drug Overdose; Humans; Male; Medication Errors; Methadone; Middle Aged; Naltrexone; Schizophrenia | 2002 |
Drug treatments for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2002 |
Naltrexone for alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Patient Selection; Recurrence; Time Factors | 2002 |
Naltrexone for alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Temperance | 2002 |
Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Adult; Alcoholism; Analysis of Variance; Biotransformation; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System | 2002 |
[The level of 8-iso-prostaglandin F2 alpha, 4-hydroxynonenal and malondialdehyde in alcohol dependent men during combined therapy].
Topics: Adult; Alcoholism; Aldehydes; Antidepressive Agents, Tricyclic; Dinoprost; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; F2-Isoprostanes; Humans; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Naltrexone; Narcotic Antagonists; Thiazepines; Time Factors | 2002 |
The clinical usefulness of narcotic antagonists: preliminary findings on the use of naltrexone.
Topics: Adult; Alcoholism; Boston; Cannabis; Depression; Emotions; Follow-Up Studies; Heroin Dependence; Humans; Internal-External Control; Male; Naloxone; Naltrexone; Patient Acceptance of Health Care; Patient Dropouts; Psychotherapy; Self Concept; Sleep | 1975 |
Drugs to decrease alcohol drinking.
Topics: Alcohol Drinking; Alcoholism; Animals; Extinction, Psychological; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Inbred Strains | 1990 |
False positive urine drug screens from quinine in tonic water.
Topics: Adult; Alcoholism; Heroin; Heroin Dependence; Humans; Male; Middle Aged; Mineral Waters; Naltrexone; Patient Compliance; Quinine | 1989 |
Does the blockade of opioid receptors influence the development of ethanol dependence?
Topics: Alcoholism; Animals; Diprenorphine; Female; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Seizures; Substance Withdrawal Syndrome | 1987 |
Role of pituitary and related neuropeptides in alcoholism and pharmacodependence.
Topics: Adrenocorticotropic Hormone; Alcoholism; Animals; Arginine Vasopressin; beta-Endorphin; Brain; Endorphins; Haplorhini; Heroin Dependence; Humans; Melanocyte-Stimulating Hormones; Naltrexone; Neurotransmitter Agents; Peptides; Pituitary Gland; Rats; Reinforcement, Psychology; Reward; Substance-Related Disorders | 1986 |
The role of drugs in the treatment of opioid addicts.
Topics: Alcoholism; Anxiety; Clonidine; Dextropropoxyphene; Heroin; Humans; Inactivation, Metabolic; Kinetics; Methadone; Mood Disorders; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1986 |